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STEC O157 is a bacteria that infects the gastro-intestinal tract of humans. Humans become 
infected when animal faeces contaminates food, water and the environment. Infection in 
humans is by the oral route, and human to human infection is also possible. Despite efforts to 
reduce STEC O157 transmission to humans through revisions in the food chain and 
improvements in critical care that reduce fatalities we are still seeing around 250 cases a year 
in Scotland. Often the exact source of many of these cases is unknown, however we known 
that the main reservoir for human infection is the intestinal tract of ruminants, especially 
cattle.   
Unlike humans, cattle can be infected and shed high levels of STEC O157 in their faeces 
without showing any signs of illness. Humans generally develop bloody diarrhoea, but 
because the bacteria produce toxins which can affect the blood vessels in the kidneys and 
brain some will go on to develop kidney failure and or neurological signs.  Unfortunately it 
is often children who go on to develop these more severe symptoms.  
Some strains of the bacteria are more able to transmit from one animal to another and also 
shed in animal’s faeces at higher levels and thus more likely to affect humans. Although 
STEC O157 does not cause any clinical signs of disease in cattle, it is believed that the shiga 
toxins produced by this bacteria are suppressing the cattle’s immune system enabling the 
bacteria to better colonise and survive in the cattle’s gastro-intestinal tract. Understanding 
how the cattle’s immune system responds to the bacteria, hopefully will enable better 
interventions to be developed to help reduce the levels of bacteria in cattle faeces and thus 
reduce the risk of human infection in the future. This PhD examines how cattle respond to 
STEC O157 infections in both the field and experimental challenges.   
We determined that in the field super shedding cattle (shedding high numbers of STEC O157 
in their faeces) had reduced antibody responses to a STEC O157 specific antigen (Tir) 
compared to cattle shedding at low levels or not shedding. We determined that toxoid 
vaccinated calves had increased STEC O157 flagella specific antibody responses compared 
to calves that were not toxoid vaccinated. These results indicate that shiga toxins in the field 
may be causing some immune suppression in cattle. However in the experimental trials, 






responses to STEC O157 both systemically and locally in the terminal rectum, which is the 
primary site of colonisation of the bacteria, the results did not consistently indicate 
significant STEC O157 specific immune suppression.  
Part of this PhD also aimed to determine if immune suppression by STEC O157 in cattle was 
more wide spread and if any suppression of the immune system might affects the cattle’s 
ability to respond to vaccinations routinely used in commercial farming practices. We 
determined that been colonised with STEC O157 could actually enhance cattle’s ability to 
mount an immune response to a concurrent vaccine under experimental conditions. However 
this response was very subtle and this affect was only seen with one of the three challenge 
strains used in these experimental challenges.  
In conclusion this study provides some further evidence of modulation of the host immune 
response by STEC O157, which is strain dependent, and variable. It seems unlikely from the 
data in this study that STEC O157 colonisation is having a major impact on the responses of 


















Shiga producing E. coli (STEC) O157 is a zoonotic pathogen. In humans STEC O157 causes 
bloody diarrhoea and potentially fatal renal failure. Cattle are the major reservoir, where 
bacteria are limited to the intestinal tract and do not cause clinical signs of disease. Previous 
studies indicate that shiga toxins produced by STEC O157, suppress STEC-specific cellular 
immune responses in vivo.  
This study aimed to initially examine the humoral immune response in cattle following 
natural challenge and the effects of a toxoid vaccination on this humoral STEC specific- 
immune response. We determined a statistically significant suppression in Tir specific IgA in 
STEC O157 positive cattle compared to O157 negative cattle but not in super shedding 
cattle. Following toxoid vaccination we determined a significant increase in flagellin specific 
IgG1 antibody levels in toxoid vaccinated animals despite lower numbers of positive faecal 
samples compared to placebo vaccinated controls. These results suggest that shiga toxins 
produced by STEC O157 are actively suppressing the STEC specific immune response in 
natural colonisation. To clarify this suppression further calves were orally challenged with 
STEC O157 (either a PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ strain) and 
their STEC specific immune responses monitored. STEC specific systemic antibody 
responses were variable and weak in some cases. STEC specific local antibody responses 
were only significantly increased following challenge with the PT21/28 Stx2a+Stx2c+ 
challenge. Transcripts for genes associated with immune responses, and in particular B cell 
activation, at the terminal rectum were analysed by reverse transcriptase quantitative PCR. 
Suppression of IL2RA transcripts was observed in calves challenged with PT21/28 
Stx2a+Stx2c+ compared to control calves but not with the other two STEC O157 strains 
tested. 
This study also aimed to determine the effects of cattle colonisation with STEC O157 on the 
immune response to a non-bacterial T-cell dependent antigen, ovalbumin (OVA). Cattle 
were orally challenged with either a PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 
Stx2a+Stx2c+ strain or unchallenged. Calves were subcutaneously immunised with OVA 
five days post challenge, on two separate occasions with a two week interval. Lymphocytes 
from lymph nodes local to the immunisation site demonstrated significantly increased OVA-






were challenged with the PT21/28 Stx2c+ strain (but not with the other two challenge 
strains), compared to unchallenged controls. These results indicate that colonisation with 
STEC O157 can alter local adaptive immune responses to non-bacterial antigens in a strain 
dependent manner, unexpectedly enhancing the immune response rather than suppressing it. 
Circulating T cell responses were unaffected. 
In conclusion this study provides some further evidence of adaption of the host immune 
response by STEC O157, which is strain dependent, and variable. It seems unlikely from the 
data in this study that STEC O157 colonisation is having a major impact on the responses of 






Chapter 1  
Introduction  
1.1  Shiga toxin producing E. coli (STEC) O157  
 
Escherichia coli are gram negative facultative anaerobic bacilli. There are many strains 
identified, some of which are pathogenic and can severely affect human health. 
Enterohaemorrhagic Escherichia coli (EHEC) are zoonotic pathogens and typically causes 
bloody diarrhoea in humans. Shiga toxigenic E. coli (STEC) produce cytotoxins called Shiga 
toxins (Stx) and a subset of these strains are EHECs which are also proven to be pathogenic 
in humans. Human infections can progress on to potentially fatal haemolytic uremic 
syndrome (HUS) characterised by capillary damage in the kidneys as a result of systemic Stx 
activity1-3. Stx target endothelial cells in humans, leading to the capillary damage in the 
kidneys. Stxs can also lead to central nervous system complications of STEC O157 
infections in humans. Many human cases are sporadic but occasionally large outbreaks do 
occur4.   
STEC O157 is the main serotype of STEC associated with serious human disease in the UK5. 
The first human infection of STEC O157 was traced back to a fast food restaurant serving 
hamburgers in the USA6. The first outbreak of STEC O157 in the UK was in 19837. The 
treatment for HUS is supportive as there is currently no specific suitable treatment available8. 
Patients are managed, with particular attention paid to fluid and electrolyte balance, 
nutritional support, treatment of anaemia, and control of hypertension, seizures and 
azotaemia9,10. STEC O157 is the leading cause of acute paediatric renal failure and patients 
may require life-long dialysis or a kidney transplant8. In Scotland (1984-2012 data) almost 
50 % of cases of detected STEC O157 infections are in children under 16 years of age. Rates 
of infection are highest in children under 5 years, at 15 cases per 100,000 population, 
compared with a population average of 4.5 per 100,000 population. In cases of HUS due to 






are substantial; for example in the USA, the costs of healthcare, social care, and lost 
productivity is estimated at $600 million per year12. The average cost for a person infected 
with STEC O157 varies greatly from $26 for an individual who does not receive medical 
care to $6.2 million for a person who died from HUS in the USA13. In 2011, the estimated 
annual total cost of STEC infections in Australia was (AUD) $2,633,18114. 
Cattle are the major reservoir of STEC O157, and reducing shedding levels in cattle is 
predicted to lower the risk of STEC O157 infection in humans5,15. Humans can become 
infected not only by consumption of contaminated food but also due to ruminant faecal 
contamination of the environment and water16-18. This latter observation is consistent with 
data indicating that incidences of human cases are positively associated with livestock 
density and the ratio of cattle to humans19,20. STEC O157 bacteria are capable of long term 
survival in manure, pasture and soil, potentially making control more difficult21. In contrast 
to humans, cattle are colonised with and shed STEC O157 without showing any clinical sign 
of disease22. The receptor for Stx cannot be detected histologically on cattle endothelial cells; 
in humans, endothelial cells are rich in Stx receptors, and binding of Stx to endothelial cells 
in the capillary of the kidneys leads to the potentially fatal HUS seen as a consequence of 
STEC O157 infections in humans (see Table 1). Other subclinical carriers of STEC O157 
including sheep21 and goats23 have also been implicated in human outbreaks. STEC O157 
has also been detected in other domestic species including pigs, dogs, cats and 
chickens24.Wildlife species including deer and rabbits, which often share common grazing 
ground with cattle, can also act as reservoirs of infection25,26.  
The principle site of STEC O157 colonisation in cattle is the terminal rectum27 (Figure 1) 
and shedding of STEC O157 is highly heterogeneous, with a small proportion of cattle (< 10 
%) excreting > 104 colony forming units per gram (CFU/g) faeces28.  These so-called “super 
shedders” are believed to have a significant role in the transmission and persistence of STEC 
O157 within cattle populations5. Other sites of the cattle intestinal tract can become 
colonised but it is believed that the colonisation of the terminal rectum is required for 
animals to shed STEC O157 at high levels29. Super shedding is influenced by the bacteria 
strain30, but it is also seems likely that other factors are involved such as host genotype, 
phenotype and / or environmental factors. The infective dose of STEC O157 cattle is 
unknown, but it is known that oral exposure to < 300 CFU can result in infection and that the 







Figure 1: Transmission electron micrographs of regions containing STEC O157-
positive microcolonies taken from Naylor et al. (2005)32. (A) R1 indicates a normal 
region of mucosa with microvilli. R2 indicates a region with attached bacteria and 
effaced microvilli on the terminal rectal mucosa of an experimentally colonised calf (× 
1000). (B) A higher magnification than (A), showing intimately attached bacteria within 
an E. coli O157 microcolony present on the terminal rectal mucosa of an 
experimentally colonised calf (× 5000). (C) A pedestal formed (R4) beneath an attached 
bacterium within an E. coli O157 microcolony on the terminal rectal mucosa of a 






The mechanisms of pathogenicity employed by STEC O157 are numerous. The STEC O157 
type III secretion system (T3SS) is one of the important virulence factors, and is involved in 
colonisation of the intestinal tract. It is used to deliver about 40 effector proteins such as 
translocated intimin receptor (Tir) into the host epithelial cells33. EspA forms a filamentous 
needle like structure and creates a physical bridge between the host cells and the bacteria. Tir 
is secreted from the tips of the EspA filaments34. Tir and intimin (a protein expressed on the 
bacterial cell surface) are central to the formation of intimate attaching and effacing lesions 
which facilitate binding of the bacteria to the cells in the gastrointestinal tract. Intimin 
negative strains have been shown to have an impaired ability to colonise calves which is 
believed to be due to their inability to form attaching and effacing lesions35. Other effector 
proteins are involved in subverting the host cell, including interfering with inflammatory 
signalling36, inhibiting apoptosis and disrupting tight junctions. A pathogenicity island on the 
bacterial chromosome, the locus of enterocyte effacement (LEE), encodes many of these 
effector proteins and also the secretion system37. The LEE necessitates other factors encoded 
in a separate part of the genome to form the attaching and effacing lesions. The LEE is 
arranged into several polycistronic operons termed LEE1 to LEE438, the LEE4 operon 
encodes several proteins required for the attaching and effacement phenotype. Given their 
key role in allowing efficient colonisation of the bovine intestinal tract, T3SS proteins have 
been used as antigens in vaccines39,40. 
1.2  Shiga Toxins 
 
Shiga toxins (Stx) are a family of related toxins with two major groups, Stx1 and Stx2. Stx1 
and Stx2 are immunologically distinct and share only 56 % amino acid sequence identity41. 
Stx2 are more commonly associated with human disease42 and have been found to be more 
potent in mice experimental challenges43. Stx1 is identical to the Shiga toxins of Shigella 
dysenteriae serotype 1. There are a number of variants of each Stx subtype; Stx1a, b, c and d 
have been identified and Stx2 a, b, c, d, e, f and g44. Some STEC strains produce only one 
type of Stx, while other strains express a combination of variants of one or both types45. 
Recent analysis of a large number of STEC O157:H7 genomes has indicated that a recent 
acquisition of Stx2a prophage was critical to the relatively recent emergence of STEC O157 






Stx consist of the enzymatic A subunit (32 kDa) and five binding B subunits (7.7 kDa)47,48 as 
shown in Figure 2. The genes for the A and B subunit of Stx are carried in the late region of 
lysogenic bacteriophages49. Stx transcription starts once the bacterial SOS stress response 
triggers viral lytic replication of the bacteriophage. Expression during the lytic cycle 
removes the need for a specific secretion system since Stx is released upon phage mediated 
host cell lysis. Several antibiotics can lead to activation of the bacterial SOS repair response 
and thus the subsequent release of Stx50,51. This has led to the policy of not treating human 
cases of STEC with antibiotics due to the increased risk of Stx release leading to potentially 
fatal HUS52. The eukaryotic cell surface receptor for the B subunit of Stx is 
globotriasosylceramide (Gb3/CD77)53. The B subunit binds to the CD77 receptor initiating 
endocytosis of the A subunit. The A subunit is composed of two fragments, A1 and A2, 
joined by a disulphide bond. A protease, furin cleaves the A subunit, releasing the A1 
peptide which inactivates protein synthesis, by cleaving a N-glyosidic bond in the 28S 

















Table 1: CD77 expression on cells in cattle and humans. 
Cell CD77 expression in human CD77 expression in cattle 
Endothelial 
cells 
Expressed55 (kidney, colon and 
brain endothelial cells) 
No expression on endothelial cells in 
vivo56 
Epithelial cells Colonic epithelial cells low 
level expression57 
Expressed on mesangial and 
tubular epithelial cells in the 
kidney55 
Expressed on some epithelial cells in 
the gastrointestinal tract58 
Expressed on tubular epithelial cells 
in the kidneys56 
T-cells No expression59 Expressed in early phase of 
activation60 
B-cells Expressed59 Expressed in early phase of 
activation60 
Granulocytes Expressed61 No expression62 
Macrophages Expressed63 Expressed64 
 
In humans Stx bind to CD77 on renal glomerular endothelial, mesangial and tubular 
epithelial cells leading to HUS55. In addition to inhibiting protein synthesis, Stx are also 
known to induce programmed cell death, or apoptosis, in many human cell types43. The 
induction of apoptosis seems to be related to the ribotoxic stress response (due to ribosomal 
damage) or induction of the unfolded protein response. Stx1 shows a higher affinity for 
trisaccharide on CD7765, but as previously stated Stx2 is more potent in mice and more 
commonly associated with disease in humans. Asymptomatic colonisation with STEC O157 
in ruminants appears to be due to the lack of receptor (CD77) on endothelial cells in cattle56 
and thus Stx are unable to cause the same clinical outcome in cattle as they do in humans. 









Figure 2: Diagram of Stx molecules. A is a ribbon diagram of Stx2 adapted from Fraser et al. (2004)66. The A subunit is red, whereas the B-
subunits are orange, cyan, green, yellow and blue. The active site in the A-subunit is marked by the magenta letter A. The side chains of the 
cysteine residues that link A1 and A2 are depicted in yellow. The sites equivalent to the Gb3 binding sites on the B-pentamer of Stx1 are 
shown by magenta numbers that distinguish the type of binding site. B is a schematic diagram of a generic Stx molecule, the A subunit is red 






1.3  The prevalence of STEC O157  
 
The UK has a relatively high rate of human with STEC O157 infections5 and Scotland is 
generally higher than the rest of the UK67 as shown in Figure 3. The potential for STEC 
O157 to lead to large outbreaks is exacerbated by its low infectious dose in humans, believed 
to be less than 10 viable bacteria68 and because some cases can be asymptomatic; however in 
Scotland most cases are sporadic infections. The rate of faecal culture positive cases per 
100,000 population for the whole of Scotland in 2015 was 3.2, compared to 4.9 in 2014, 3.1 
in 2013 and a five-year average (2010 – 2014) of 4.367.  
 
Figure 3: E. coli O157 rates per 100,000 population- culture positive cases, UK, 2006-
2015. Adapted from Health Protection Scotland, (2016). Data for Wales, N Ireland and 
England includes Stx positive cases only. All data for 2015 is provisional. 
 
Occupational, as well as recreational, exposures have been associated with infection. Health 
Protection Scotland (HPS) surveillance and research data show that 17 % of all E. coli O157 
outbreaks (1996-2012), involved farms and that contact with farm animal faeces was the risk 
factor most strongly associated with sporadic STEC O157 outbreaks8. Food contamination is 
also a major source of infection. The surface of meat can become contaminated during 






cooked properly. Unpasteurised or inadequately pasteurised milk, or raw vegetables, may 
also be contaminated. HPS data showed that in 28 % of all E. coli O157 outbreaks in 
Scotland (1996-2012), the main mode of transmission was foodborne67.  
The on farm prevalence of STEC O157 has been determined in two studies on Scottish 
farms; the Scottish Executive Environment and Rural Affairs Department study (SERAD, 
1998-2000) indicated a mean farm-level prevalence of 0.218 and the Welcome Foundation 
International Partnership Research Award In Veterinary Epidemiology study (IPRAVE, 
2002-2004) a mean farm-level prevalence of 0.20569. The distribution of prevalence is highly 
skewed, with shedding not detected in the majority of cattle groups at any time point, but a 
small proportion of groups contain a high number of individuals shedding bacteria in their 
feces70. A study by Omisakin et al. (2003) in Scotland, enumerating bacterial shedding in 
cattle at slaughter determined that super shedding (≥ 104 CFU/g of faeces) cattle were 
responsible for > 96 % of all STEC O157 bacteria shed but only made up 9 % of cattle 
sampled71. 
In the UK the strains of STEC O157 are subtyped by determining their sensitivity to a 
specific panel of 16 typing phages. In Scotland the phage type (PT) 21/28 has been most 
commonly associated with human disease and also more likely to be associated with super 
shedding in cattle5. PT21/28 is also a concern as it is more likely to lead to severe morbidity 
in human cases72. In Scotland between 1997 and 2001, 61 % of HUS cases in children were 
caused by PT21/2872. In one study of 88 Scottish farms in 2006, approximately half of STEC 
O157 isolated were PT21/2873. PT32 is another commonly found strain isolated in bovine 
faecal samples in Scotland. PT21/28 is more likely to contain both Shiga toxin 2a (Stx2a) 
and Shiga toxin 2c (Stx2c) encoding prophages, whereas PT32 strains mainly contain 
prophages encoding Stx2c alone74. PT32 is also less likely to be associated with high 
shedding levels. PT21/28 is also more likely to be identified with human disease within 








Figure 4: The worldwide human burden of STEC O157, adapted from Chase-Topping 
et al. (2008)5. Map of the worldwide relative burden of STEC O157 in humans in 2005 
per 100,000 individuals in the population. Crude rates are presented from countries 
where there are surveillance programmes, although surveillance and detection methods 
differ between countries and therefore direct comparisons of burden are problematic.  
 
Figure 4 demonstrates the worldwide human burden of STEC O157 in 2005. Human 
infections have been noted in more than 50 countries and in every continent except 
Antarctica5. The highest annual incidences are reported in the USA, Canada, Japan and 
Scotland10,75. There have been numerous studies determining prevalence of STEC O157 on 
farms worldwide, these studies vary in study design and laboratory methods making accurate 
comparisons between countries difficult. A total of 140 studies consisting of 220,427 cattle 
were included in a meta-analysis which estimated the prevalence of STEC O157 in 
individual cattle at the global level at 5.68 % (95 % confidence intervals [CI], 5.16–6.20)76. 
They also determined that world region, type of cattle, specimens and laboratory methods 
contributed to the variation in prevalence estimated76. There was a wide regional variation in 
the prevalence of STEC O157 in individual cattle, ranging from 1.65 % (95 % CI, 0.77–






1.4  Prevalence of non-O157 serotypes 
 
STEC O157 serotypes are the most common strains associated with Stx positive E. coli 
infections. However recent large outbreaks in the USA and Germany77 of non-O157 strains 
show the potential importance of these non-O157 strains. Figure 5 demonstrates data from 
HPS showing a gradual increase in the number of non-O157 STEC detected in humans; and 
they are now identified as approximately one quarter of all laboratory confirmed infections. 
They have also reported that non-O157 cases can be associated with significant morbidity 
and include HUS cases78. An outbreak in Scotland in 2011, found that cases of STEC O26 
were significantly more likely to develop neurological complications, diabetes mellitus and 
require admission to the intensive care unit than HUS cases in children due to STEC O15778. 
Although STEC O26 is still relatively uncommon in human cases in Scotland, it is a major 
cause of HUS in continental Europe. A Scottish study recently found a farm and pat level 
prevalence similar to that of STEC O157; however the prevalence of STEC O26 was 
reduced if the carriage of genes for virulence factors such as intimin and Stx were taken into 
account79. The outbreak of STEC O104:H4 in Germany highlights the potential for Stx 
prophage acquisition into different EHEC genetic backgrounds and the potential for large 
scale, severe outbreaks80.  
In the USA an estimated 265,000 STEC infections occur each year, O157 is the most 
common serotype seen in human infection (0.75 per 100,000 in 2013) but non-O157 
serotypes are becoming increasingly important81. The big six non-O157 STEC in the USA 
are O26, O45, O103, O121, O111 and O145; these strains are routinely tested for in the 
USA82. In the EU in 2014, STEC was the fourth most commonly reported zoonosis, with 
O157 representing about half of the cases83. Unlike the rest of Europe, in Italy STEC O26 is 
the most common serotype (40 %) detected in humans, with O157 the second (33 %) and 







Figure 5: Faecal culture positive O157 and non-O157 isolates 2011-2015 taken from 
Health Protection Scotland (2016). Total number of Scottish cases in the human 
population. 
1.5  Control of STEC O157 in cattle 
 
Controlling STEC O157 shedding in cattle is predicted to reduce the risk of human 
disease15,71. Control methods can be broken down into pre-harvest (on farm control methods) 
and post- harvest (abattoir and food processing control methods). 
 
1.5.1  Pre-harvest control of STEC O157 in cattle 
 
The level of control of STEC O157 shedding in cattle required to protect public health is an 
area of debate. It has been hypothesised that controlling super shedding cattle will 
significantly reduce the risk to humans15,70. A number of control methods have been 
evaluated which aim to reduce STEC O157 colonisation and faecal shedding in cattle. The 
idea behind reducing STEC O157 in live animals (pre-harvest), is that it will reduce the 






more effective and thus reducing the risk to human health from infected meat products. The 
risk to humans from Campylobacter, another zoonotic bacterial infection has been shown to 
be reduced by pre-harvest on poultry farm interventions84. It is hypothesised that super-
shedding cattle are a particular risk of allowing contamination to occur at meat processing 
plants85. Reducing STEC O157 shedding in cattle will also reduce horizontal STEC O157 
spread from infected animals, reduce the STEC O157 burden in the environment and waste 
water streams, and it will reduce the risk to those in direct contact with animals. 
A number of pre harvest interventions specifically aimed at reducing STEC O157 shedding 
have been considered. Antibiotics have been shown to have some level of control, and 
neomycin has been shown to reduce STEC O157 populations in the gastrointestinal tract86. 
However antimicrobial resistance dictates that long term use of antibiotics to control STEC 
O157 is an unsustainable control measure. Probiotics have also been considered as a possible 
control method; because competition for nutrients with endogenous or exogenous bacteria 
may cause inhibition of STEC O157 proliferation in the gastrointestinal tract. This is 
supported by evidence that faecal shedding of STEC O157 can be reduced in experimentally 
challenged calves when probiotic bacteria are administered87. In the USA a number of 
probiotics are routinely used including Bovamine Defend (Chr.Hansen, USA) which claim to 
aid in increasing production but also reducing pathogens including E. coli in the digestive 
tract88.  
Manipulation of cattle diet and feeding regimes can also reduce the carriage and shedding of 
STEC O157, although the effects of diet on STEC O157 shedding often appears to be 
inconsistent. For example some studies have found that grain fed cattle have an increased 
risk of shedding STEC O15789-91 whereas another study found no significant difference 
between feeding a grain or forage based diet on the duration or level of STEC O157 
shedding92. Feeding distillers grains to cattle has been shown to have a positive correlation 
with an increased prevalence of STEC O15793. Diet and probiotics could be evaluated further 
but changes in diet maybe unreliable and difficult to change in the modern beef industry. 
Probiotics although already in use have to be administered on a regular (daily) basis, which 
again can be difficult to deliver and even with regular delivery the effect is often variable.  
Bacteriophages can be used to specifically target STEC O157 in cattle. Phages have been 
approved and marketed for use as a hide spray in the USA to reduce the entry of STEC O157 
on the hides of cattle entering the food chain. One product Finalyse (Elanco, USA) is 






facilities, it is used to spray the hides of cattle just prior to slaughter. It works in 5 minutes 
and its affects are reported to work for up to 4 hours. Finalyse contains a mixture of naturally 
occurring phages which specifically target STEC O157 and other STECs94. 
Vaccination against STEC O157 may prove to be a more reliable and deliverable control 
method in cattle95. A recent systematic review of ruminant STEC O157 vaccines concluded 
that vaccines targeting either epithelial adherence or iron regulation are currently the most 
effective96. Two commercial vaccines have been developed to date, both of which obtained 
conditional licenses for sale in North America97. One vaccine licensed in the USA, Epitopix 
SRP (Zoetis) targets siderophore proteins which the bacteria excrete in an effort to obtain 
iron from the intestinal tract of cattle. Targeting these proteins is thought to disrupt iron 
transport into the bacterium, resulting in bacterial cell death. A vaccine produced from STEC 
O157 extracts (type III secreted proteins, T3SPs) has been produced as Econiche (Bioniche 
Life Sciences Inc.) in the USA which is thought to interfere with T3SS-mediated adherence 
to the intestinal epithelium. However, Econiche is no longer commercially available as 
Bioniche Life Sciences Inc. divested its animal health division in 2014. The Econiche 
vaccine has been shown to have protective effects against experimental STEC O157 
challenge39,98; however the efficacy of the vaccine in field studies has been variable96. A 
number of vaccine trials have been performed looking at the effectiveness of the Bioniche 
vaccine. In a small scale field trial, when three doses of vaccine were given, significant 
reductions in faecal shedding of STEC O157 were observed39. However, a subsequent large 
scale field trial published in 2005 failed to demonstrate any significant effect on faecal 
shedding of STEC O157, either at the time of the second vaccination (2 vaccines were 
administered 73-103 days apart) or at slaughter (2.5-5 months after the second vaccine)99. In 
a field trial using the Epitopix vaccine there was a reduction in STEC O157 shedding 
compared to control placebo vaccination cattle100. In experimental challenge trials, the 
Epitopix vaccine was given twice, 3 weeks apart, the calves were then orally challenged 2 
weeks after the second vaccine with a 5 strain mixture of STEC O157101. They determined a 
significant reduction in the number of calves that were faecal culture positive for STEC 
O157 in vaccine versus control calves101.  
McNeilly et al. (2015) have demonstrated reduced bacterial shedding following subunit 
vaccination with EspA, intimin and flagellin (H7) with calves experimentally orally 
challenged with Stx negative E. coli O15740. This has not been demonstrated in a more 






more costly to manufacture and produce, but may lead to more consistent and better 
protection against STEC O157 in the future. 
Toxoid vaccination is another alternative proposed mode of vaccination. A toxoid 
vaccination, is when the protein based toxin (in this case Stx) is rendered harmless and used 
as the antigen in the vaccine to elicit immunity, and has been shown to be a highly successful 
approach to control disease caused by other Shiga-toxigenic E. coli. For example, previous 
studies have demonstrated that vaccination of piglets with either chemically inactivated or 
genetically modified Stx2e is protective against Stx2e-induced oedema disease102. Kerner et 
al. (2015) have evaluated the biological safety in vitro of recombinant STEC shiga-toxoids 
as candidates for vaccines for use in cattle103. The group hypothesised that the toxoid 
vaccines against Stx1 and Stx2 will lead to protection against the immunosuppressive effects 
of the toxins, thus allowing cattle to develop a more rapid immune response to natural 
challenge STEC strains. Furthermore, as a shiga-toxoid based vaccine targets shared Stx 
across STEC strains it may be able to offer protection across different serotypes, it may be 
more commercially viable than a vaccine only offering protection against specific STEC 
serotypes. The Epitopix patent submission suggests that sequence conservation between the 
siderophore receptor genes provides the opportunity for vaccines manufactured from a single 
serotype of a bacteria to induce protective immunity against a range of serotypes and broad 
range of related organisms. However, these claims have not been demonstrated and 
importantly a field trial with Epitopix vaccine failed to demonstrate any impact of the 
vaccine on STEC O26 prevalence104.  
With any intervention there are potential negative consequences. One study has 
demonstrated a reduction in weight gain in cattle vaccinated with the Epitopix STEC O157 
vaccine compared to unvaccinated control animals105, presumably as a result of additional 
handling and stress on animals as a result of the vaccination regime. This is highly 
significant as there is little incentive for farmers to vaccinate due to the lack of clinical signs 
of STEC O157 colonisation in the cattle population. Any loss of productivity due to 
vaccination will have a further negative impact on uptake of the vaccine. Interestingly, a 
survey of UK farmers concluded that vaccines may be a viable option to control STEC O157 
provided there was good evidence that the intervention was effective106. Given the issues 
with the lack of field efficacy of current STEC O157 vaccines, improved vaccine efficacy is 
required. Cattle can clear STEC O157 from the intestinal tract naturally, and therefore a 
greater understanding of the role of the host immune response in the clearance of the 






1.5.2  Post- Harvest control 
 
It can be argued that post- harvest control measures for STEC O157 may be the most logical 
and effective. Pre-harvest interventions are specific for particular pathogens and they all 
have limits in their effectiveness. Post-harvest interventions are often non-specific and may 
help to reduce other pathogenic bacteria as well. Cases associated with the consumption of 
contaminated meat, and not through environmental routes, will be most impacted by abattoir 
(post-harvest) interventions. Since the emergence of STEC in the USA, the beef industry has 
invested in STEC control in meat processing plants107. Although in-plant strategies have 
significantly reduced contamination of meat products by STEC, these processing 
interventions have not been perfect108,109.  
Effective prevention and control of contamination in abattoirs requires the application of 
good hygiene practices, the application of Hazard Analysis and Critical Control Point based 
management practices and risk based meat inspection practices to reduce faecal 
contamination of carcasses. Because none of the interventions are 100 % effective, all beef 
processors use a multiple hurdle intervention system of sequential interventions at different 
processing steps. Hides are the main source of contamination by STEC O157 of beef 
carcases in commercial meat processing plants110,111. Contamination of the carcases through 
faecal contamination can occur when the hides are removed and during removal of the 
gastro-intestinal tract. A pre-harvest treatment of the hides as discussed previously is now 
licenced in the USA. Washing, chemical de-hairing and treatments with antimicrobial 
products have all been researched and generally show some reductions in the levels of 
contamination107. Simple hygiene and good practices such as good removal of hides, keeping 
them separate from the carcase all help to reduce carcase contamination in the plant.  
Among the numerous retail meat cuts available, ground beef possesses more risk than other 
intact muscle cuts, because it can also be contaminated during the grinding operation. The 
Food Standard Agency (FSA) in the UK provides guidelines for businesses dealing with 
food to help reduce the risk of cross contamination, they provide advice on keeping 
equipment used for raw meat and cooked meat separate, handwashing and use of 
disinfectants112. Education of the consumer in home cooking practices play a role in helping 
to reduce the risk of infection; again the FSA provides advice on cooking at home with a 






In practice a combination of pre and post-harvest interventions will both be important in the 
control of STEC O157. 
1.6  Adaptive immune responses to STEC O157 
in cattle 
 
Most animals are able to clear STEC O157 infections successfully without showing clinical 
signs of disease. Although STEC O157 is often thought of as a normal resident of the 
bovine, cattle have been shown to develop an active immune response to the bacteria97,114. 
1.6.1  Systemic antibody responses 
 
Systemic antibody responses against STEC antigens have been demonstrated to be 
inconsistent and are not always correlated with bacterial shedding or associated with 
clearance of the bacteria (Table 2). A number of studies have demonstrated systemic 
antibody responses to STEC antigens following oral challenge. In one study Bretschneider et 
al. (2007) demonstrated a significant increase in serum IgG specific to STEC O157 intimin, 
Tir, EspA, EspB and O157 LPS (lipopolysaccharide) in adult cattle following oral challenge 
with STEC O157 (stx-positive) strain. This indicates that cattle can respond serologically to 
STEC O157 T3SS proteins and LPS following STEC O157 colonisation. Furthermore, in 
this study serum IgG responses to Tir, intimin or O157 LPS were highly correlated with 
faecal shedding of STEC O157115. However a similar challenge study in calves found no 
correlation between anti-O157 LPS or IgG specific to Stx1 and STEC O157 shedding in oral 
experimentally (STEC O157, stx-positive) challenged calves116,117. The study by 
Bretschneider et al. (2007) also demonstrated a decrease in serum specific IgA to Tir, 
intimin and EspB following oral challenge with a STEC O157 stx-positive strain. The 
authors suggested that this may be due to sequestration of IgA from the serum by binding to 
the bacteria in the gastro intestinal tract of cattle. However this may also have been due to a 
down regulation of mucosal IgA producing cells. Antibody responses to Stx1 and Stx2 have 
been found in sera and colostrum in other STEC O157 oral challenge studies but the 






O157 challenge116. Stx1 seropositivity has been demonstrated to be higher than that for 
Stx2118. It is unclear if this is due to Stx1 being expressed at higher levels than Stx2 in the 
gastrointestinal tract of colonised calves, or if Stx1 is more immunogenic or less 
immunosuppressive than Stx2. Finally, Wray et al. (2007) demonstrated no serological 
response to STEC O157 LPS following oral challenge with STEC O157 in adult cattle and 





















Table 2: Studies determining antibody responses in cattle either experimentally 
challenged or naturally colonised with STEC O157. 





STEC O157 stx 
positive oral 
challenge 
Serum IgG specific for 
intimin, Tir, EspA, 










et al. (2007) 
Experimental 
STEC O157 stx 
positive oral 
challenge 
Serum IgA specific for Tir, 
intimin and EspB 
decreased after oral 
challenge 
Not calculated Bretschneider 
et al. (2007) 
Experimental 
STEC O157 stx 
positive oral 
challenge 
Faecal IgG or IgA specific 
for intimin, Tir, 
EspA, EspB or O157 
LPS not detected pre 
or post challenge 
Not calculated Bretschneider 
et al. (2007) 
Experimental 
STEC O157 stx 
positive oral 
challenge 
Serum Antibodies (IgG and 
IgM) specific for 
O157 LPS and Stx1 
detected following 
challenge (but not 
Stx2) 
No correlation 
and did not 
prevent re-
infection 







Serum IgG and IgM for 
O157 LPS: no 
response in adult 
cattle and variable in 
calves (increased 
IgG in 3 calves and 
decreased IgM post 
challenge) 









Table 2 continued: Studies determining antibody responses in cattle either 
experimentally challenged or naturally colonised with STEC O157. 





STEC O157 stx 
positive oral 
challenge 
Serum IgG and IgA for O157 










(both stx+ and 
stx- strains) oral 
challenge 
Serum Antibodies to O157 
LPS following 
challenge (no Stx2 
antibodies following 
challenge) 
Not calculated  Hoffman et 
al. (2006) 
Experimental 






IgA and IgG specific 
to H7 flagellin 
increase detected 
following challenge 
Not calculated McNeilly et 
al. (2009) 
Experimental 
E.coli O157 stx 
negative oral 
challenge 
Serum IgA and IgG specific 
to H7 flagellin 
increase detected 
following challenge 
Not calculated McNeilly et 
al. (2009) 
Experimental 






IgA specific to H7 
flagellin detected 
following challenge 
(but not IgG) 




Serum IgG and IgM specific 
to O157 LPS detection 














Under conditions of natural exposure and presumptive infections STEC O157 specific 
antibodies are even more variable and there is often poor seroconversion. Cristancho et al. 
(2008) demonstrated variable seroconversion to O157 LPS in veal calves following shedding 
after natural exposure, with some calves seroconverting to O157 LPS even when no STEC 
O157 was isolated. This may have been due to poor detection of the bacteria or exposure of 
the calves to bacteria with cross reactive LPS antigenic determinants119. It has also been 
demonstrated that there is transfer of STEC specific antibodies in colostrum from dam to 
calves, which plays an important role in elevating serum antibodies against STEC in 
neonatal calves120. 
1.6.2  Mucosal antibody responses 
 
Mucosal antibodies are believed to act as the first line of defence against many bacteria and 
viruses. Strong rectal mucosal IgA antibody responses have been detected to EspA, EspD, 
EspB, Tir, H7, OmpC and O157:H7 LPS in calves experimentally challenged with a stx-
negative E. coli O157 strain114. Another study has examined mucosal IgA antibody responses 
in the rectal mucosa of calves following challenge with a stx-positive STEC O157 strain. The 
authors showed that the titres can be low and inconsistent between animals121. It is unclear 
how much protection mucosal antibodies afford in STEC O157 challenges and what the 
precise mechanism of this protection is. There is evidence in mice that rectal mucosa 
antibody levels do also reflect the responses at other sites of the intestinal tract122123. 
However in cattle and sheep there is evidence that most serum IgA is locally produced, and 
mucosal IgA levels are often not consistent with circulating IgA levels124,125. 
1.6.3  Cellular immune responses 
 
Studies on the cellular immune response in cattle to STEC O157 are limited and therefore 
the role of cellular immunity during colonisation is largely unknown. A study demonstrated 
that cattle colonised with STEC O157 generate lymphoproliferative responses in peripheral 
blood mononuclear cells (PBMC) to heat killed Stx negative E. coli O157126. In a more 
recent study, oral challenge of calves with two different strains of STEC O157 (a PT32 and a 
PT21/28 STEC O157 strain) resulted in an increase in transcripts (IFN-γ and T-bet) 






whilst expression of IFN-γ and T-bet peaked at 7 days post challenge in calves challenged 
with the PT32 strain there was a delay in the peak expression of both transcripts in the 
PT21/28 challenged calves, suggesting a difference in cellular immune response kinetics 
between the two strains. Furthermore, ex vivo stimulation of rectal lymph node cells from the 
same calves with T3SS proteins resulted in proliferation of CD4, CD8 and γδ T cells from 
PT21/28 challenged calves whereas with cells from the PT32 challenged calves there was an 
increase in proliferation of natural killer (NK), CD8 and γδ T cells97. These findings support 
the hypothesis that cattle develop a cellular response during colonisation and that this 
response appears to vary depending on the STEC O157 strain. A study with sheep orally 
inoculated with a stx-negative E. coli O157 strain, also demonstrated that the animals mount 
a lymphocyte proliferative response to intimin, EspA and EspB127.  
1.7  Immune modulation  
 
STEC O157 is able to persist in the bovine intestinal system, in some cases for prolonged 
periods of time. It has been demonstrated that some cattle can continue to shed STEC O157 
in their faeces for up to 11 months after infection128. Also some cattle were found to shed 
multiple strains of STEC O157 when studied in a longitudinal study128. It is hypothesised 
that this may be in part due to the Stx produced by STEC O157 modulating the hosts 
immune system and thus enabling persistent colonisation. This is consistent with the weak 
and variable immune responses generated following STEC O157 colonisation. 
Reduced innate and adaptive immune function has also recently been demonstrated in STEC 
O157 super shedding cattle at the terminal rectum129. The study performed transcriptomic 
analysis of rectal tissue collected from naturally colonised adult cattle which were either 
super shedding STEC O157 (> 104 CFU/g faeces) within the previous 10 days prior to 
sampling or negative for STEC O157. Out of a total of 58 differentially expressed genes, 
most (47/58) were downregulated in super-shedding cattle, of which the majority (31/47) 
were associated with adaptive immune responses. The authors hypothesised that this could 
either be due to innate and adaptive immune responses in rectal tissue of super-shedders 
being inherently less effective in super-shedding cattle, thus allowing high levels of shedding 
to occur, or immune responses being down regulated due to factors produced by the bacteria 
which results in less adaptive immune cells and therefore less transcripts129. Another 






stimulatory factors in the ileal peyers patches and the terminal rectum from calves 
experimentally orally challenged130. This work was carried out with a stx-negative strain of 
E. coli O157, meaning the effects on the immune response were Stx independent. 
Furthermore, the E. coli O157 negative control animals used for comparison with the 
challenged calves were not the same age or weaning stage as the challenged animals, 
therefore the direct effect of the bacteria on the intestinal immune system is unclear.  
Stxs have been hypothesised to be adapting the host immune system and there are a number 
of studies supporting this hypothesis. It has been demonstrated in previous studies that 
peripheral blood mononuclear cells (PBMC) from E. coli O157 stx-negative challenged 
calves developed proliferative responses to heat killed STEC O157 which also increased 
after re- challenge with an isogenic stx2 positive strain126. The same study also showed that 
PBMC from STEC O157 (stx positive) challenged calves did not develop consistent 
proliferative responses to heat killed STEC O157126.  This suggests that Stx can block 
induction of cellular immune responses. Since calves initially challenged with a stx-negative 
strain generated proliferative responses to heat killed STEC O157 following stx-positive re-
challenge it was also hypothesised that the effects of Stx are limited to priming of cellular 
immune responses and do not block the recall of existing antigen specific cellular 
responses126. Hoffman et al. (2006) also hypothesised that the effect of STEC O157 infection 
on the bovine immune system was not a generalised one, as they demonstrated that PBMC 
from calves challenged with stx-positive or stx-negative isogenic strains of STEC O157 were 
equally capable of proliferating in response to the T-cell mitogen, Concanavalin A 
(ConA)126. The same study also found that the STEC O157 (stx-positive) challenge did not 
hinder the development of a humoral response to O157 LPS126. As LPS can act as T-cell 
independent B-cell antigen this suggests that Stx may be suppressing T-cell responses but are 
not able to suppress T-cell independent immune responses in the same manner. 
As previously discussed following challenge with phage type PT21/28 and PT32 STEC 
O157 the cellular immune responses can differ97. In the same study cells were examined 
from both a lymph node (rectal) local to the site of infection and also a lymph node (pre-
scapular) distant to the site of colonisation; cells from both sites differed in their response to 
the two STEC O157 strains. The cells from the PT32 challenged animals had reduced IFN-γ 
response compared to uninfected controls and  also PT21/28 challenged calves, in both the 
local and distant lymph node cells following either mitogenic (ConA) or antigenic 
stimulation, suggesting that challenge with the PT32 strain can result in widespread effects 






the same as the PT32 strain, so the differences seen between the two strains are not 
associated with differences in active Stx types. Another study looking at sheep infected with 
Bovine Leukaemia (BLV) virus found that oral challenge with a stx2a-positive STEC O157 
strain resulted in reduced BLV viremia when compared to sheep challenged with an isogenic 
mutant Stx negative strain131. As BLV exhibits a major tropism for B lymphocytes both in 
the circulation and in lymph nodes local to the site of infection132, this suggests that Stx2a 
from intestinal STEC O157 is capable of interacting with circulating immune cells as well as 
those in secondary lymphoid organs. These two studies suggest that in addition to 
modulating STEC-specific immunity, STEC O157 may have more generalised effects on 
ruminant immune cells throughout the body, so called bystander immune modulation. While 
multiple studies have evaluated the general immunomodulatory effects of helminth parasites, 
potent immune modulators, on their ruminant hosts133, there is little or no information 
available on how STEC O157 (stx-positive) bacteria modulate non-STEC immunity in cattle.  
The distribution of CD77, the Stx receptor on cells, as shown in Table 1 varies between 
human and bovine cells. In humans only a few cells express CD77 receptors; the endothelial 
lining of the intestine, brain, and kidney express CD77, which are the main organs targeted 
by Stx in humans134. Although human neutrophils do not express CD77, Stx can bind to 
surface expressed TLR4 on these cells. Unlike the CD77 receptor which binds the B subunit 
of Stx which results in internalisation of the toxin 3,135, TLR4 on human neutrophils interacts 
with A subunit of Stx and the toxin is not internalised.  
Stx1 targets peripheral blood and intraepithelial lymphocytes within the gastrointestinal tract 
of cattle136137. In humans the CD77 receptor is lacking on T cells but is present on B and 
endothelial cells59138. In cattle CD77 is expressed on both B and T-cells, but it has been 
shown that B and T-cells only transiently express CD77 on their cell surface in an early 
phase of activation60. Granulocytes in bovines fail to express CD77 and thus seem to be 
resistant to the impact of Stx62. Stx1 has been shown to significantly reduce CD8α+ T-cell 
and B-cell proliferation in vitro in cattle60,139. In gastrointestinal (GIT) loop experiments it 
was shown that Stx1 producing STEC O157 significantly reduced the percentage of CD8α+ 
T-cells in the intraepithelial lymphocyte population compared to loops inoculated with a stx1 
negative mutant E. coli O157140. 
In addition to Stx, the bacteria also produce many other proteins that have the potential to 
affect the host animal’s immune system. For example, STEC injects the non-LEE encoded 






shown in Enteropathogenic Escherichia coli (EPEC) strains to lead to disruption of the NF-
κB pathway. The NF-κB family proteins are key regulators of inflammatory genes: following 
immune receptor activation the NF-κB kinase complex is stimulated, resulting in NF-κB 
dimers (p50 and p65) entering the nucleus and promoting the transcription of genes encoding 
inflammatory proteins such as IL-8, IL-1β and TNF-α141. N1eE inhibits IκB phosphyloration 
which maintains the NF-κB dimers in an inhibited state and prevents NF-κB signalling142. 
N1eB enhances the activity of N1eE142 and N1eC a zinc protease digests p65 which also 
prevents NF-κB signalling143 (Figure 6). Thus these proteins can down regulate 
inflammatory responses at the initial site of colonisation of the bacteria. Another effector 
protein EspJ produced by STEC O157 is inserted into the host epithelial cell by the T3SS 










Figure 6: Schematic of NF-κB pathway adapted from Zhang et al. (2014)145. Upon 
stimulation, cell surface receptors activate IKK complex, which then phosphorylate 
IκB. These phosphorylations lead to its degradation by the proteasome and the entry of 
NF-κB in the nucleus, which turns on target genes. N1eE prevents the phosphorylation 
of IκB thus preventing NF-κB signalling, N1eB enhances the activity of N1eE. N1eC 
digest p65 thus also preventing NF-κB signalling.  
 
Lymphostatin, encoded by lifA, is another protein which is involved in modulating host 
immune cells and is expressed by EPECs and many non-O157 STEC strains146. 
Lymphostatin has been shown to inhibit bovine T-cell proliferation in response to ConA147. 
STEC O157 strains lack lymphostatin, but a homologue is encoded on the pO157 plasmid, 
known as ToxB148,149. ToxB is a 365 kDa protein thought to be secreted by the T3SS, and 
exhibits 29.2 % identity at the amino acid level to LifA150. Recombinant ToxB has been 
shown to have lymphostatin like activity, being able to inhibit proliferation of ConA 
stimulated bovine T-cells147 and IL-4 mediated activation of bovine B-cells147. ToxB and 
other effector proteins could certainly be contributing factors in immunomodulation seen by 






1.8  Conclusion 
 
Previous studies indicate that Stx produced by STEC O157 are capable of suppressing the 
bovine immune system, potentially enhancing its ability to colonise the bovine intestinal 
tract for prolonged periods and allow super shedding in some cattle. Much of the data on 
antibody responses to STEC O157 infections in cattle is conflicting and studying both 
systemic and local antibody responses in controlled animal experiments should help to 
clarify this. Other pathogens that suppress host immunity to enable their longer term survival 
are also able to suppress host immune responses to unrelated antigens, so-called bystander 
immune suppression. There is a currently a lack of information in the literature about the 
impact of immunosuppression by STEC O157 on bystander immune responses such as those 
induced by concurrent infections or vaccinations.  
1.9  Aims and objectives 
 
The overall aim of this PhD is to further characterise humoral and cellular responses to 
STEC O157, with a focus on how stx positive STEC O157 modulate adaptive immune 
responses.  
Specific aims are: 
1) To characterise antibody responses to STEC O157 antigens in naturally colonised 
cattle including cattle that have been immunised with a Shiga-toxoid vaccine. 
2) To quantify STEC-specific cellular and humoral responses following experimental 
challenge with STEC O157 strains expressing either Stx2a and Stx2c, or Stx2c 
alone. 
3) To determine the effects of STEC O157 colonisation on cellular and humoral 
immune responses to a non-STEC O157 T-cell dependent antigen. 
4) To quantify transcripts of specific genes involved in immunity at the terminal rectum 







Chapter 2  
Natural STEC colonisation and 
toxoid vaccination 
2.1  Introduction  
 
In cattle, in vitro and in vivo evidence suggests that Stx play a prominent role in STEC O157 
colonisation of the intestinal tract by down regulating adaptive immune responses to the 
bacteria126,129,137. Stx can suppress activation of bovine lymphocytes, in particular CD8 T-
cells and B-cells, in vitro126,136,137,139. Using isogenic stx positive and negative strains of       
E. coli O157, Hoffman et al. (2006) demonstrated that challenge of calves with stx positive 
E. coli O157 resulted in impaired priming of circulating STEC-specific cellular immune 
responses, as determined by antigen-specific proliferation of peripheral blood mononuclear 
cells, compared to challenge with an isogenic stx negative E. coli O157 strain126. The 
duration and level of bacterial shedding was greater for calves challenged with the stx 
positive strain, demonstrating a negative association between STEC-specific cellular 
responses and colonisation. 
The influence of Stx on humoral immunity is not as clear, Hoffman et al. (2006) 
demonstrated that challenges with stx positive or stx negative E. coli O157 strains induced 
similar levels of antibody to O157 LPS126. LPS is a T-cell independent antigen151, which 
directly activates B-cells via engagement with Toll-like receptor 4 (TLR4) leading to 
proliferation and differentiation of the mature B-cells and production of antibodies. It is 
possible that antigens not requiring CD4+ T-cell help are less sensitive to the suppressive 
effects of Stx. STEC protein antigens are likely to lead to T-cell dependent antibody 
responses; however these responses are generally weak, highly variable and often short 
lived, which may suggest a degree of modulation of the responses by STEC115,121. 






(Tir, EspA and EspB) following experimental STEC challenge but the responses to Tir and 
EspA were short lived115. The same study found a reduction in IgA serum antibody levels 
specific to Tir, intimin and EspB following experimental STEC challenge115 which they 
speculated was a result of sequestration of STEC-specific IgA into the gut lumen and 
binding to STEC and its secreted proteins. Finally a recently published transcriptomic study 
in cattle has demonstrated that in cattle naturally colonised with STEC O157, at the terminal 
rectum had 31 genes associated with innate and adaptive immunity down regulated in super 
shedding compared to non-shedding cattle. Of these 31 down regulated genes 19 genes are 
directly associated with B-cell function129. Collectively this data suggests that STEC can 
actively modulate humoral immune responses. Although a role for Stx in this modulation has 
yet to be proven, mechanisms exist in which both T-cell dependent and independent immune 
responses may be modulated by Stx: either by direct interaction of Stx with B-cells129 to 
modulate T-cell independent or dependent antigens, or indirectly via suppression of T-cell 
help126,136 to modulate T-cell dependent responses.  
Human disease can be caused by a large number of different serotypes of STEC (O157, O26, 
O45, O103, O121, O111 and O145) and it is believed that reducing the shedding levels of 
STEC in cattle by vaccination will reduce the risk of human infection96. To date the most 
promising STEC vaccines for cattle have targeted either the Type three secretion system39,96 
or bacterial iron up take mechanisms100,101. Evidence suggests that these vaccines may be 
poorly cross protective against different STEC serotypes, presumably due to serotype-
dependent variation in the antigens targeted by the vaccines152. In order to improve cross- 
reactivity, a toxoid-based vaccine targeting Stx has been developed for use in cattle103. 
Kerner et al. (2015) generated recombinant Shiga toxoids through site-directed mutagenesis 
of stx1 and stx2a which were devoid of immunomodulatory activity on bovine immune cells 
compared to recombinant wild-type toxins but retained their immunogenicity as determined 
by inducing antibodies following immunisation of cattle which are capable of neutralising 
Stx1 and Stx2 activity103. The group hypothesised that neutralising the immunosuppressive 
activities of Stx1 and Stx2 through vaccination would prevent the persistent infection with 
STEC in cattle103. 
This approach is predicted to cross-protect against different STEC serotypes by generating 
antibodies which neutralise colonisation-promoting activities of Stx such as 
immunomodulation126,136,153 and enhanced epithelial colonisation154. By targeting the Stx 






hybrid strains of STEC such as E. coli O104:H4 which led to nearly 900 cases of HUS and 
54 deaths in 2011155. The E. coli O104:H4 strain possessed a combination of virulence 
factors from both STEC and enteroaggregative (EAEC) strains155. 
The hypotheses for the research presented in this chapter is that STEC colonisation 
modulates STEC-specific antibody responses primarily via Stx activity, and that 
neutralisation of Stx activity through Shiga toxoid vaccination may enhance this antibody 
response. To address these two hypotheses, we first determined STEC-specific antibody 
responses in a cohort of cattle naturally colonised with STEC O157 to determine the 
relationship between STEC O157 shedding and STEC-specific antibodies in the field; 
secondly, we determined the effects of vaccination with an experimental Stx toxoid vaccine 
on levels of STEC-specific antibodies in calves naturally exposed to STEC. 
Aim of chapter 
 To characterise antibody responses to STEC O157 antigens in naturally colonised 







2.2  Material and Methods 
2.2.1  Ethics statement 
 
The faecal sample collection during the field trial in Nebraska, USA was reviewed and 
approved by U.S. Meat Animal Research Centre and University of Nebraska-Lincoln Animal 
Care and Use Committees. 
The Shiga toxoid vaccination study was carried out in strict accordance with European and 
German law for the care and use of experimental animals. Experiments were approved by the 
Lower Saxony State Office for Consumer Protection and Food Safety (LAVES), Oldenburg, 
Germany (Reg number 33.9-42502.04.12/0933). 
 
2.2.2  Sample collection from cattle naturally colonised with 
STEC O157  
 
The field samples were collected in 2011 (June to October), from an ongoing field study 
performed by Dr. Jim Bono (U.S. Meat Animal Research Centre, USDA, Nebraska, USA). 
Faecal and serum samples were collected at the same time point for each individual animal. 
Levels of STEC O157 shedding in the faeces were determined as described below. Shedding 
levels and sampling dates for individual animals are shown in Table 3. In total serum 
samples were available for 5 animals shedding > 104 CFU/g faeces STEC O157 (super 
shedders, O157-SS), 15 animals shedding > 0 but < 104 CFU/g faeces STEC O157 (positive 
but not super shedding, O157-NSS) and 16 STEC O157 negative animals (O157-NEG). 







Table 3: STEC O157 shed in faeces from cattle in the USA field trial 
Sample Cow 
ID 
Date STEC O157 
Status 
CFU/plate CFU/g of faeces 
1 #67 11/07/2011 O157-SS 102 20400 
2 #15 01/08/2011 O157-SS 130 26000 
3 #41 01/08/2011 O157-SS 118 23600 
4 #173 04/10/2011 O157-SS 1744 348800 
5 #189 04/10/2011 O157-SS 1248 249600 
6 #9 28/06/2011 O157-NSS 1 200 
7 #30 28/06/2011 O157-NSS 1 200 
8 #38 28/06/2011 O157-NSS 3 600 
9 #78 28/06/2011 O157-NSS 13 2600 
10 #80 28/06/2011 O157-NSS 3 600 
11 #29 11/07/2011 O157-NSS 10 2000 
12 #31 11/07/2011 O157-NSS 2 400 
13 #48 11/07/2011 O157-NSS 2 400 
14 #60 11/07/2011 O157-NSS 1 200 







Table 3 continued: STEC O157 shed in faeces from cattle in the USA field trial 
Sample Cow 
ID 
Date STEC O157 
status 
CFU/plate CFU/g of faeces 
16 #165 04/10/2011 O157-NSS 10 2000 
17 #175 04/10/2011 O157-NSS 4 800 
18 #178 04/10/2011 O157-NSS 11 2200 
19 #187 04/10/2011 O157-NSS 5 1000 
20 #214 10/04/2011 O157-NSS 28 5600 
21 #2 07/11/2011 O157-NEG 0 0 
22 #3 07/11/2011 O157-NEG 0 0 
23 #4 07/11/2011 O157-NEG 0 0 
24 #5 07/11/2011 O157-NEG 0 0 
25 #6 04/10/2011 O157-NEG 0 0 
26 #7 04/10/2011 O157-NEG 0 0 
27 #8 04/10/2011 O157-NEG 0 0 
28 #9 04/10/2011 O157-NEG 0 0 
29 #10 04/10/2011 O157-NEG 0 0 






Table 3 continued: STEC O157 shed in faeces from cattle in the USA field trial 
Sample Cow 
ID 
Date STEC O157 
status 
CFU/plate CFU/g of faeces 
31 #1001 06/10/2011 O157-NEG 0 0 
32 #1002 06/10/2011 O157-NEG 0 0 
33 #1003 06/10/2011 O157-NEG 0 0 
34 #1172 06/10/2011 O157-NEG 0 0 
35 #1173 06/10/2011 O157-NEG 0 0 
36 #1174 06/10/2011 O157-NEG 0 0 
 
2.2.3  Sample collection from cattle immunised with 
recombinant Shiga toxoids 
 
The toxoid vaccination preparation and animal trial was performed by Nadine Schmidt at the 
Friedrich-Loeffler-Institut, Germany, under the supervision of Prof. Dr. Christian Menge, 
Institute of Molecular Pathogenesis, Jena site of FLI, and of Dr. Sven Dänicke, Institute of 
Animal Nutrition, Brunswig, respectively. The toxoids used for vaccination were prepared as 
described previously103; briefly recombinant Stx from the E. coli  reference strain EDL 933 
(ATCC 43895) were PCR amplified, the products were ligated into a compatible plasmid 
vector and a QuickChange Site-Directed Mutagenesis Kit (Stratagene, Amsterdam, The 
Netherlands) was used to replace E167 and R170 with glutamine and leucine respectively. 
rStxMUT were expressed in E. coli BLR (DE3) and control preparations were obtained from 
E. coli BLR (DE3) transformed with an empty vector. After incubation of the bacterial pellet 
with Polymixin B, expressed toxin was collected from the periplasmic space and depleted of 






E. coli BLR (DE3) is reportedly non-motile156 which was confirmed upon re-testing for 
motility using Hitchens agar. The recombinant Shiga toxoids rStx1MUT and rStx2MUT (0.75 
Mio CD50-equivalent/1.4 ml/dose) was injected intramuscularly into cattle with 0.6 ml 
Aluminium hydroxide (Al[OH]3). 
The animal trial was performed as follows. Colostrum was collected from five 
rStx1MUT/rStx2MUT vaccinated dams (at 9 and 6 weeks before their calving dates) and nine 
unvaccinated dams, stored (-20 oC) and pooled according to anti-Stx titres. The following 
year 24 calves were passively (colostrum from vaccinated cows) and actively (intra-
muscularly at the 5th and 8th week of life) vaccinated. A further 24 calves served as placebo 
vaccinated controls (fed with low anti-Stx colostrum, placebo injected [NaCl solution and 
adjuvant]). During the first year of life faecal samples were collected at 3, 16, 26 and 55 
weeks of age. Blood samples were collected from each animal pre and between 6 to 24 hours 
after initial colostrum intake, 9-12, 15-16, 15-26 and 55 weeks of age by jugular 
venepuncture and centrifuged; serum was subsequently collected. The serum and colostrum 
was stored at -20 oC and an aliquot was sent from FLI-Jena to be analysed at MRI. Figure 7 
shows the time course of the vaccination and sampling schedule. 
 






2.2.4  Bacteriological analysis of STEC isolates 
  
Bacteriology was performed at U.S. Meat Animal Research Centre, USDA, Nebraska, USA 
for the USDA field study, and at FLI, Jena, Germany, for the toxoid immunisation study as 
described below.  
USDA field study:  
For the faecal samples collected during the study, STEC O157:H7 was detected by 
immunomagnetic separation (IMS) performed according to the manufacturer’s instructions 
using anti-EHEC O157 Dynabeads (Invitrogen, Carlsbad, USA). The number of bacteria in 
positive samples was enumerated by diluting faecal samples in phosphate buffered saline 
(PBS) and plating the dilutions onto sorbitol MacConkey agar with 2.5 mg/L potassium 
tellurite and 0.05 mg/L cefixime (CT-SMAC; Dalynn Biologicals, Calgary, Canada), and 
incubated at 37 oC for 18 to 24 hours. Colonies were counted and expressed as CFU/g of 
faeces. 
Shiga toxoid immunisation study:  
Faecal samples were analysed for the presence of STEC by plating diluted faeces (1:10 in 
PBS) on Gassner agar (SIFIN diagnostics GmbH, Berlin, Germany) and incubating at 37 oC 
for 18 hours. After incubation colonies were washed off with 1 ml LB broth supplemented 
with 30 % glycerine, boiled for 10 minutes, put on ice for 5 minutes and then used as PCR 
template. PCR primer pairs for detection for stx1 and stx2 were designed with reference to 
published sequence data157. Colonies from stx-positive samples were isolated by DNA-DNA 
colony hybridization158, with the following variations. DNA probes were labelled with 
digoxigenin with MP4/MP3 primers157 using the PCR DIG Probe Synthesis Kit (Roche, 
Basel, Switzerland). The number of total stx-positive colonies on each blot was counted and 
STEC CFU/g faeces calculated.  
Up to 10 stx-positive colonies per blot were individually cultured in 200 µl LB broth, 
incubated (18 hours, 37 oC), 30 % glycerin added, and stored at -80 oC. H-typing of 95 STEC 
isolates which were collected from the 3rd week (28 isolates) and 15th week (67 isolates) of 






Positive PCR products were digested with Rsal (New England Biolabs GmbH, Frankfurt, 
Germany) and RFLP (restriction fragment length polymorphism) analysis of the resulting 
restriction fragment patterns was performed using Bionumerics software (Version 6.6, 
Applied Maths, Sint-Martens-Latem, Belgium). Isolates representing each restriction pattern 
and one F-fliC-1-/R-fliC2-PCR-negative isolate were sub-cultured and DNA subsequently 
extracted from each using a Qiagen DNeasy kit (Qiagen, Hilden, Germany) prior to 
microarray analysis using an E. coli H/O Serogenotyping AT-1 kit (Alere Technologies 
GmbH, Jena, Germany).  
 
2.2.5  Vero cell cytotoxicity assay (VCA) and 
Verocytotoxicity neutralisation assay (VNA) 
 
The VCA and VNA was performed by Nadine Schmidt as previously described160 to 
determine the neutralising antibodies (nAb titre) against wild-type Stx1 (Sigma-Aldrich 
Chemie GmbH, Taufkirchen, Germany) in serum from rStxMUT immunised and control 
calves. Briefly serum samples were tested at dilutions of 1:30 and 1:90, colostrum samples at 
1:300 and 1:900. Neutralising antibody tires were determined by multiplying the relative cell 
activity with the dilution factor when the relative cell activity was > 30 % (rStx1WT). 
 
2.2.6  Generation and characterisation of STEC antigens 
 
STEC antigens were produced as follows, the flagellins were produced by acid dissociation 
as previously described161; H21 flagellin was generated from strain ZAP0115 (O111:H21), 
H2 flagellin from ZAP0269 and H7 from strain ZAP984 (O157:H7). To generate H2 and 
H21, single colonies were used to spike motility agar and grown over night at 37 oC, the 
most motile colonies were picked and cultured overnight in 20 ml of LB at 37 oC (200 rpm). 
This was added to 1.2 L LB and cultured at 30 oC (180 rpm) until reaching optical density 
(OD) 600 of 1.2. The bacteria were pelleted by centrifugation at 4 oC, 10,000 g for 15 
minutes. The pellet was re-suspended in 0.9 % NaCl with added protease inhibitor (Protease 






HCL was added with constant stirring until the pH reached 2, and stirring continued for 30 
minutes. The solution was then centrifuged at 5,000 g for 30 minutes at room temperature. 
The pellet was discarded and 1 M NaOH was added to the supernatant with constant stirring 
until the pH reached 7. (NH4)2SO4 was added with vigorous stirring to each 2.67 M solution, 
gentle stirring continued overnight at 4 oC. The solution was then centrifuges at 4 oC, 15,000 
g for 15 minutes. The supernatant was removed and the pellet gently re-suspended in PBS 
and protease inhibitor (Sigma-Aldrich, Dorset, UK). The solution was dialysed overnight at 
4 oC with PBS using cellulose tubing (Sigma-Aldrich, Dorset, UK) with a molecular weight 
cut off of 14,000 Daltons. H7 preparations were prepared in a similar manner by Sean 
McAteer (The Roslin Institute). Recombinant EspA and Tir proteins generated as previously 
described40 were provided by Sean McAteer (The Roslin Institute). All proteins were 
analysed by One-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(1D SDS-PAGE) using a NuPAGE 4-12 % Bis-Tris Protein Gel (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions and subsequent staining with SimplyBlue™ 
SafeStain (Invitrogen, Paisley, UK). The presence of LPS in each flagellin preparation was 
determined in a parallel gel using a Pro-Q Emerald 300 Lipopolysaccharide gel stain kit 
(Thermo-Fisher Scientific, Loughborough, UK) as per manufactures instructions. A trans-
illuminator was used to view and image the stained gel. A bicinchoninic acid (BCA) protein 
assay kit (Pierce, Rockford, USA) was used to estimate the protein concentration in the final 
protein preparations.  
The identities of H2 and H21 proteins were confirmed by MALDI-TOF analysis (performed 
by Kevin McLean, MRI) as follows: analysis was performed on protein bands of the 
expected molecular weight (52 and 51 kDa for H2 and H21, respectively). Selected bands 
were excised from the stained gels (Figure 19 A) and washed in 50mM ammonium 
bicarbonate in 50 % acetonitrile three times for 15 minutes each at room temperature on a 
vortex mixer. The solution was removed and the respective gel piece covered with 100 % 
acetonitrile to dehydrate for 5 minutes. Supernatant was removed and the gel piece vacuum-
dried for 10 minutes. A volume of 10 mM DTT in 100 mM ammonium bicarbonate 
sufficient to cover the gel pieces was added and samples were placed in a 56 oC water bath 
for 1 hour. The DTT solution was replaced with the same volume of 55 mM iodoacetamide 
in 100 mM ammonium bicarbonate and placed in the dark for 30 minutes. The 
iodoacetamide solution was removed and samples were given 2 ×15 minute washes with 100 
µl 50 mM ammonium bicarbonate/ 50 % acetonitrile. Supernatant was removed and the gel 






trypsin, Promega, Southampton, UK) digest solution (10 ng/µl trypsin in 25 mM ammonium 
bicarbonate) at 37 oC overnight. Digests were analysed on a Bruker Ultraflex II MALDI-
ToF-ToF mass spectrometer (Bruker Daltronics, Bremen, Germany), scanning the 600 to 
5000 Dalton region in reflectron mode producing monoisotopic resolution. The instrument 
was calibrated using known peptide standards (PepMix 2, Bruker Daltronics, Bremen, 
Germany). Each spectrum was produced by accumulating data from 10 ×100 consecutive 
laser shots. Peptides were identified by matching the measured monoisotopic masses to 
theoretical monoisoptic masses generated using MASCOT (version 2.5.1, Matrix Science, 
London, UK) search engine (peptide mass fingerprinting, PMF). The search parameters 
were: maximum of one missed cleavage, variable modification of cysteines by 
propionamidation and carbamidomethylation, variable modification of methionines by 
oxidation, and a peptide tolerance of ± 50 ppm. Using these parameters and searching the 
NCBI (taxonomy E. coli) database, Mascot scores greater than 77 were considered 
significant (p < 0.05). See Figure 8 and 9. 











Figure 8: Results shown in ProteinScape software (Version 3.0, Bruker Daltronics, Bremen, Germany) of MALDI analysis of the excised 52 
kDa band from lane 1 in figure 19 A; confirming the protein identity as H2. Amino acids in red lettering denote sequence homology between 
the known H2 sequence and the peptides obtained by mass spectrometry. Shades of grey boxes denote the level of intensity coverage during 
the mass spectrometry process from weak (pale grey) to strong (black). The sequence coverage was 68.4 %. Highlighted in yellow is the 
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Figure 9: Results shown in ProteinScape software (version 3.0, Bruker Daltronics, Bremen, Germany) of MALDI analysis of the excised 51 
kDa band from lane 3 in figure 19 A; confirming the protein identity as H21. Amino acids in red lettering denote sequence homology 
between the known H21 sequence and the peptides obtained by mass spectrometry. Shades of grey boxes denote the level of intensity 
coverage during the mass spectrometry process from weak (pale grey) to strong (black). The sequence coverage was 67.6 %. Highlighted in 
yellow is the potential sites of N-glycosylation. 
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2.2.7  Quantification of antigen-specific antibody responses 
 
Levels of antigen-specific IgA, IgG1 and IgG2 in bovine serum were quantified by indirect 
ELISA as previously described161 except samples were added at a set dilution (Table 4) in 
duplicate wells. All washes were performed using a plate washer, 5 washes with 200 µl wash 
buffer (PBS with 0.05 % Tween 20) per well. All incubation steps were for one hour at 37 oC 
unless stated otherwise. Immulon 2HB 96-well flat bottom MicroTitre® ELISA plates 
(ThermoElectron Corporation, Milford, USA) were coated with antigen (H7, H2, H21, EspA 
or Tir) at 1 µg/ml diluted in 0.05 M carbonate buffer (1.59 g Na2C03, 2.93 g NaHCO3 made 
up to 1 L in dH2O, pH 9.6), 50 µl per well and incubated overnight at 4 oC. Plates were 
washed and then incubated with 100 µl per well of blocking buffer (PBS with 3 % fish 
gelatine; Sigma-Aldrich, Dorset, UK) to prevent non-specific binding. Plates were washed 
again and 50 µl of diluted samples were added to each well in duplicate wells (sample 
dilutions, Table 2). The optimum sample dilutions were determined following serial dilution 
of representative samples from each group to ensure that the colour reaction at an optical 
density (OD) at 492 nm for the sample was on the linear part of the curve. Plates were 
incubated for 1 hour and then washed again; secondary antibodies (mouse anti-bovine IgA 
monoclonal antibody [mAb K84.2F9], anti-bovine IgG1 [mAb K37.2G6] or anti-bovine IgG2 
[mAb K192.4F10; all AdDSerotec, Oxford, UK]) were added 50 µl per well and again the 
plates were incubated for 1 hour. Plates were washed again and rat anti-mouse IgG1 
conjugated to HRP (LO-MG1-2, AbDSerotec, Oxford, UK) was added 50 µl per well and 
the plates incubated for 1 hour. Plates were washed again and developed using o-
phenylenediamine dihydrochloride (OPD [Sigma-Aldrich, Dorset, UK]) 100 µl per well and 
stopped after 12 minutes with stop solution (2.5 M sulphuric acid) 25 µl per well. The plates 
were read at 492 nm using a Tecan plate reader (Dynex Technologies, Worthing, UK). The 
final OD was calculated by normalising the OD to the average plate blank control OD, and 
inter plate variation was normalised to the OD of a positive control sample. 
Colostrum samples were centrifuged at 4 oC, 3,000 rpm for 30 minutes to separate liquid 
(skimmed milk) and fat. The fat layer was removed and the skimmed milk sample used for 





Table 4: Dilution of serum samples for STEC response ELISAs 
 Dilution of serum and colostrum samples 
Antigen IgA IgG1 IgG2 
H7 1 in 10 1 in 100 1 in 50 
Tir 1 in 10 1 in 250 1 in 25 
EspA 1 in 3 1 in 25 1 in 10 
 
2.2.8  Total Immunoglobulin levels 
 
Total immunoglobulin levels were detected in serum samples using commercially available 
kits; bovine IgA, IgG1 and IgG2 ELISA quantitation kit (Bethyl laboratories Inc, 
Montgomery, USA). The manufacturer’s instructions were followed except the plates were 
developed using 100 μl OPD for 10 minutes at room temperature and stopped with 25 μl stop 
solution (2.5 M sulphuric acid). OD was measured at 492 nm using a Tecan microplate 
reader (Dynex Technologies, Worthing, UK).  
 
2.2.9  Western Blots  
 
For the western blots, H2, H7 and H21 preparations (from the same batches as used in the 
ELISAs described above) were separated by 1D SDS-PAGE as previously described. The 
proteins were then transferred to a nitrocellulose membrane using an iBlot® - Western 
Blotting System (Invitrogen, Paisley, UK) following the manufactures instructions. The 





for 1 hour with 20 ml of PBS, Tween 80 (Sigma-Aldrich, Dorset, UK) and 0.5 M NaCl 
(PBS-T80-NaCl) with gentle rotation. All subsequent washes and dilutions were with 20 ml 
of PBS-T80-NaCl. The membrane was then incubated with 10 ml of pooled serum samples 
from animals with high (OD values of 0.8 or greater; n = 5) or low (OD values of 0.3 or 
lower; n = 5) levels of anti-flagellin IgG1 (as determined by ELISA) diluted 1 in 100, for 1 
hour with gentle rotation. The membranes were washed; incubated for 1 hour with 10ml 
mouse anti-bovine IgG1 (diluted 1:1000 in PBS-T80-NaCl; clone K37.2G6, AbDSerotec, 
Oxford, UK). The membrane was washed and incubated with 10 ml of rabbit anti-mouse IgG 
HRP (diluted 1:1000 in PBS-T80-NaCl, P0260, Dako, Ely, UK) for 1 hour with gentle 
rotation. The membrane was washed again, with a final overnight wash. Bound IgG was 
visualised using anAmersham ECL Western Blotting Detection Kit (GE Health care life 
Sciences, Little Chalfont, UK) following the manufactures instructions. Images captured 
using an ImageQuant LAS 4000 (GE Health care life Sciences, Little Chalfont, UK).  
 
2.2.10 Statistical analysis 
 
A Kruskal-Wallis H non-parametric statistical test was used to compare antibody levels 
between cattle shedding different levels of STEC O157 in the USDA field study followed by 
Dunn’s multiple comparisons test. Differences in STEC antigen specific antibody levels 
between toxoid vaccinated and placebo control calves at each time-point were determined by 
a Mann-Whitney U test. Correlations between Stx nAb titre and STEC antigen-specific 
antibody measures and between different H-type specific antibody levels were determined by 
Spearman’s rank correlation test. All analyses were performed using GraphPad Prism 
(version 7.0, La Jolla, USA) except the Fishers exact tests which were performed on the 
faecal shedding data from the toxoid trial, and they were performed by Nadine Schmidt 
using “IBM SPSS statistics” (version 19, IBM Corporation, New York, USA).  






2.3  Results 
2.3.1  Serum antibody responses in cattle naturally 
colonised with STEC O157 
 
Serum antibody responses to selected STEC O157 antigens from cattle shedding > 104 
CFU/g faeces STEC O157 (O157-SS), > 0 but < 104 CFU/g faeces STEC O157 (O157-NSS) 
or no detectable STEC O157 (O157-NEG) are shown in Figure 10. O157-SS cattle had 
significantly higher H7-specific IgA and IgG1 compared to O157-NEG cattle. In contrast, 
O157-NSS cattle had lower Tir-specific IgA compared to O157-NEG cattle. No statistically 
significant differences in total levels of IgA, IgG1 or IgG2 were determined between O157-







Figure 10: Antigen-specific antibody responses in cattle naturally colonised with STEC 
O157. Serum antibody levels were determined by ELISA. Each symbol represents the 
mean optical density (OD) of duplicate wells of diluted serum from one animal. The 
error bars represent median and interquartile range (IQR). The animals are grouped 
into O157-SS > 104 CFU/g faeces STEC O157 (n = 5), O157-NSS animals shedding > 0 
but < 104 CFU/g faeces STEC O157 (n = 15) and STEC O157-NEG animals (n = 16). 
The p-value was determined using a Kruskal-Wallis H test followed by Dunn’s multiple 
comparisons test. The overall p-value of the Kruskal-Wallis H test is shown. 







Figure 11: Total antibody levels in serum collected from cattle naturally colonised with STEC O157 determined by a commercial ELISA. 
Each symbol represents the mean total antibody level determined by taking the mean OD of duplicate wells of diluted serum from one 
animal and extrapolated the quantity from a standard curve on the same plate; (A) total IgA levels, (B) total IgG1 and (C) total IgG2 levels. 
The error bars represent median and interquartile range. The animals are grouped into O157-SS > 104 CFU/g faeces STEC O157 (n = 5), 
O157-NSS animals shedding > 0 but < 104 CFU/g faeces STEC O157 (n = 15) and STEC O157-NEG animals (n = 16). The overall p-value 





2.3.2  Effects of Shiga toxoid vaccination on STEC 
prevalence  
 
Figure 12 shows stx1/stx2-PCR results from faecal cultures for calves in the toxoid 
vaccination trial. Stx1/stx2-PCR results were positive in 34 % of faecal cultures from 
vaccinated calves and 49 % of faecal cultures from placebo injected control calves of all 
samples for each group taken over the entire observation period. A Fisher’s exact test 
indicated a significant difference (p = 0.040) in the proportion of stx positive versus stx 
negative faecal samples between the toxoid vaccinated group and placebo vaccinated group 
over the whole observation period. 
 
Figure 12: Assessment of the proportion of faecal samples positive for stx1/stx2 by PCR 
obtained from Shiga toxoid vaccinated calves and placebo control calves. Results were 
positive in 34 % of overnight solid cultures of faecal samples from toxoid-vaccinated 
animals (red bars), 49 % control animals (blue bars) of samples (191 samples in total) 
taken over the entire observation period, which indicated a significantly lower 
proportion of stx positive faecal samples in the toxoid vaccinated cattle compared to the 
unvaccinated controls (Fisher’s exact test, p = 0.040). Data, statistical analysis and 








2.3.3  Neutralising antibody levels from calves in the toxoid 
vaccination trial 
 
Stx1 neutralising antibody titres for all calves in the toxoid vaccination were determined, 
post colostrum (24 hours), 3, 9-12, 15-16, 25-26 weeks and 1 year of age. There were 
statistically significant differences between the vaccinated and placebo control calves for 
anti-Stx1 antibodies at 24 hours, 3 weeks, 9-12 weeks and 15-16 weeks with the vaccinated 
group having significantly higher titres than the placebo group (Figure 13). 
 
Figure 13: Temporal pattern of neutralising anti-Stx1 antibodies determined by 
Verocytotoxicity Neutralisation Assay (VNA). Each symbol represents an individual 
animal, red solid circles Stx toxoid vaccinated calves and blue clear circles placebo 
controls. The middle line represent median and the error bars IQR of the group. 
Neutralising antibody titres were compared at each time-point by Mann-Whitney U 
test; Significance level * p < 0.05, ** p < 0.01; *** p < 0.001. Data courtesy of Nadine 









2.3.4  Effects of Shiga toxoid vaccination on levels of STEC 
O157-antigen specific antibody responses 
 
STEC O157-antigen specific antibody responses in the serum of vaccinated and placebo 
control cattle are shown in Figure 14. Following colostrum administration at 24 hours, all 
calves had detectable levels of H7 specific IgA. By 3 weeks the H7 specific IgA levels had 
rapidly decreased and remained low for the remainder of the study. The H7 specific IgA 
antibody levels showed statistically significant differences between the vaccinated and 
placebo control calves at 24 hours (p = 0.008), with the toxoid vaccinated group being 
significantly higher than the placebo control group. H7 specific IgA antibody responses were 
not significantly different between vaccinated and placebo control calves at any other time 
points. Again following colostrum administration at 24 hours, all calves had detectable levels 
of H7 specific IgG1 with no difference between the groups. The H7 specific IgG1 levels 
decreased to a low at 9-12 week, but they increased again at the later time points. There was 
a significant increase in H7 specific IgG1 antibody levels in toxoid vaccinated calves 
compared to the placebo controls at 9-12 weeks (p = 0.0021) and 15-16 weeks (p = 0.0191). 
H7 specific IgG2 antibody levels were low at the early time points and remained low until 
25-26 weeks, at which stage some calves started to show increasing H7 specific IgG2 
antibody levels. There were statistically significant differences between control and toxoid 
vaccinated calf groups at 24 hours and 3 weeks in H7 specific IgG2 antibody levels (p < 
0.0001), with the vaccinated calves having lower levels of H7 specific IgG2. The H7 specific 
IgG2 antibody responses were no statistically significant differences between vaccinated and 
placebo control calves at any other time point. 
Following colostrum administration at 24 hours, all calves had detectable Tir specific IgA. 
There were statistically significant differences in Tir specific IgA responses between 
vaccinated and placebo control calves at 24 hours (p < 0.0001) and also at 9-12 weeks (p < 
0.05); at both time points the placebo control group was significantly higher than the toxoid 
vaccinated group. The Tir specific IgA responses declined after 24 hours and remained lower 
for the rest of the trial. The Tir specific IgA responses were not statistically significantly 
different between vaccinated and placebo control calves at any other time points. At 24 hours 
all calves had detectable Tir specific IgG1 responses this declined until 9-12 weeks and then 
increased again until 25-26 weeks and then declined again by 1 year. The Tir specific IgG1 





control calves at any time points. Tir specific IgG2 responses were low at 24 hours, some 
calves started to show responses at 15-16 weeks and the level remained similar until the end 
of the study. The Tir specific IgG2 responses were not statistically significantly different 
between vaccinated and placebo control calves at any time points. 
All calves had low EspA specific IgA responses throughout the trial. There was a statistically 
significant difference between vaccinated and placebo calves at 24 hours (p = 0.0033), being 
higher in the placebo control group. EspA specific IgA responses were not statistically 
significantly different between vaccinated and placebo calves at any other time points. All 
calves had detectable EspA specific IgG1 responses at 24 hours post colostrum, the levels 
then decreased to a low at 9-12 weeks, increased to peak again at 25-26 weeks but had 
declined again by 1 year. There was a statistically significant difference in EspA specific 
IgG1 responses between vaccinated and placebo control calves at 24 hours (p = 0.023) and 3 
weeks (p = 0.008), with EspA-specific IgG1 being higher in the toxoid vaccinated group. 
EspA specific IgG1 responses were not statistically significantly different between vaccinated 
and placebo calves at any other time points. EspA specific IgG2 responses were low until 15-
16 weeks, there was no statistically significant differences between vaccinated and placebo 
calves at any time points. 
The significant differences identified between toxoid vaccinated and placebo control calves 
at 24 hours generally mirrored the differences shown in the colostrum fed to the two groups, 
in that H7 specific IgA in the colostrum of toxoid vaccinated dams was higher than in the 
colostrum of control dams, H7 specific IgG1 were similar in both colostrum groups and H7 
specific IgG2 were higher in the colostrum samples from the control dams compared to the 
vaccinated dams. Tir specific IgA in the control colostrum were higher than in the colostrum 
of vaccinated dams, Tir specific IgG1 were very similar and Tir specific IgG2 were higher in 
the control colostrum compared to the colostrum of vaccinated dams. The Tir specific 
antibody responses in colostrum were again mirrored in the early time points serum samples, 
except the IgG2 responses which were very low in the early time point serum samples and 
showed no difference between the toxoid vaccinated and placebo control groups. EspA 
specific IgA in colostrum were higher in the control colostrum compared to that of 
vaccinated dams, EspA specific IgG1 in colostrum were higher in the toxoid vaccinated 
group compared to controls and EspA specific IgG2 were similar in the toxoid vaccinated 
group and the controls. Again these EspA specific antibody levels in colostrum correlated 





point serum samples. However, no statistical analysis was performed on the colostrum data 








Figure 14: Colostrum and serum levels of H7, Tir and EspA antibodies in toxoid vaccinated and placebo vaccinated control calves. Each 
symbol represents the mean OD of duplicate wells of diluted serum from one animal. Designation “colostrum” below x-axis indicates values 
obtained for the colostrum pools (2 samples from each pool) used to feed the new-born calves of the respective group, time indicates calf age. 
The red solid symbols are the Stx toxoid vaccinated calves and the blue clear circles the control placebo vaccinated calves. The middle line 
represents the median and the line above and below the interquartile range. Statistical significance was determined using a Mann-Whitney 






2.3.5  H-typing of STEC isolates from Shiga toxoid 
vaccinated and non-vaccinated calves 
 
As shown in the previous section, statistically significant differences in H7 specific IgG1 
antibody were seen in the toxoid vaccinated verse control calves at 9-15 weeks, with the 
toxoid vaccinated calves having significantly higher H7 specific IgG1. However, as IgG1 
responses to H7 are known to target N- and C-terminal domains which are highly conserved 
between different E. coli flagellins161, differences in H7 specific IgG1 between vaccinated 
and control calves may have reflected a general difference in antibody response to many 
different H-types of STEC. To determine the range of H-types of STEC that the calves may 
have been exposed to, H-typing was performed on a subset of STEC isolates by RFLP 
analysis of PCR products amplified using pan-fliC primers (F-fliC-1-/R-fliC2-PCR) and 
subsequent microarray analysis. Of 95 isolates collected during the vaccine trial, 3 were 
unavailable, so 92 were analysed; 58 isolates were positive and 34 negative by F-fliC-1-/R-
fliC2-PCR. From the positive PCR products 17 different RsaI- restriction digest patterns 
were identified. A selection of 16 “pattern” representatives and 8 “negative” representatives 
were used for microarray analysis. The results in Table 5 indicated that the pre-dominant H-
types detected at 3 weeks were H9 and H18. At 15 weeks (closest to the time points when 
the differences in H7-specific IgG1 levels were detected) the pre-dominant H-types were H2, 







Table 5: H-typing of STEC isolated from Shiga toxoid immunisation study by RFLP 







Detected H antigen types  






H1, H4, H18 
H9,  
H18, H19 






















H21, H28, H33, H2/H19* H1/H12*  
H19, H21 












H7, H2/H19*  
H7 
H2, H49, H1/H12*  
H21 
H2 






2.3.6  Effects of Shiga toxoid vaccination on levels of STEC-
O157 antigen specific antibody responses 
 
As the predominant H types in the study population were determined as H7, H2 and H21, 
antibody levels specific to H2 and H21 were also quantified to determine if the differences 
(between vaccinated and placebo control calves) seen in H7 specific IgG1 antibody levels 
between 9-16 weeks were specific for H7 or were similar for other STEC flagellins.  
H2 and H21 specific IgG1 levels were significantly higher in the toxoid vaccinated calves at 
week 9-12 compared to the placebo injected controls (p < 0.0001 for both antigens). There 
were also significantly higher levels of H21 specific IgG1 at week 15-16 (p < 0.0001). These 
results largely mirrored those seen with the H7 specific IgG1 (Figure 15). 
 
Figure 15: Flagellar specific IgG1 responses in vaccinated and control calves in the 
toxoid study. ELISA plates were coated with H2, H21 or H7 corresponding to the 
STEC strains most commonly circulating in the group of calves during study. Each 
symbol represents the mean OD of duplicate determinations of diluted serum from one 
animal. The red solid symbols are the Stx toxoid vaccinated calves and the blue clear 
circles the control placebo vaccinated calves. The middle line represents the median 
and the error bars above and below the interquartile range. (A) Represents serum 
samples taken at 9-12 weeks; and (B) week 15-16. Statistical significance was 
determined using a Mann-Whitney U test. * p < 0.05; ** p < 0.01, ***p < 0.001.  
Given the similar impact of Shiga toxoid vaccination on the IgG1 response to the three 
different flagellins, correlation analysis was performed on H2, H21 and H7 responses 
(Figure 16). Significant positive correlations were found between H2 and H7 IgG1 specific 
antibody levels at week 9-12 (p < 0.0001, rs = 0.6161) but not at week 15-16 (p = 0.1892, rs = 






antibody levels at both week 9-12 and week 15-16 (p < 0.0001, rs = 0.6390 and p = 0.0035, rs 
= 0.4132 respectively) and between H21 and H2 IgG1 specific antibody levels at week 9-12 
(p < 0.0001, rs = 0.6761) and week 15-16 (p = 0.0005, rs = 0.4846). 
Sequence alignments of H2, H27 and H21 are shown in Figure 17 and 18. There was 48.96 
% similarity between the H21 and H7 amino acid sequence and 46.97 % similarity between 
the H2 and H7 amino acid sequence. When comparing the conserved domains there was 78.8 
% similarity between the H2 and H7 amino acid sequences, 77 % similarity between H21 










Figure 16: Correlations between H2, H7 and H7 specific IgG1 antibody responses in serum from the toxoid vaccination trial. Serum 
samples from 9-12 week and 15-16 week, ELISA results expressed as mean OD of duplicate wells, coats plated with H2, H7 or H21 protein 
preparations and antibodies used to determine IgG1 antibody levels in serum samples. Each symbol represents an individual animal. P- 











Figure 17: Aligned amino acid sequences of H2 and H7 flagellin, using Jalview (version 2.10.2)162 to formulate the figure and compare the 













Figure 18: Aligned amino acid sequences of H21 and H7 flagellin using Jalview (version 2.10.2)162, to formulate the figure and compare the 








2.3.7  Western blot analysis of flagellin-specific IgG1 
responses 
 
Western blots were performed to investigate the specificity of serum IgG1 antibodies for 
flagellin protein within the H2, H7 and H21 flagellin preparations. Serum samples were 
pooled from 5 animals that had high serum IgG1 specific flagellin responses and another 
pool from 5 animals that had low serum IgG1 specific flagellin responses. The western blot 
shown in Figure 19 demonstrate that IgG1 antibodies bound to molecules of the predicted 
molecular weights for H2, H7 and H21 within the flagellin preparations (52 kDa, 60 kDa and 
52 kDa for H2, H7 and H21, respectively). However, serum IgG1 also bound to molecules of 
low molecular weight (approximately 6 kDa), particularly for H7 and H21 preparations. A 
stain for lipopolysaccharide (LPS) was performed on a SDS- PAGE gel of the three flagellin 
preparations to determine if the antibody-reactive low molecular weight molecule could be 
LPS. The results of the LPS staining indicate that all three flagellin preparations contained 
LPS, either at the same molecular weight as the flagellin protein or present at low molecular 
weights between 3 and 14 kDa. This suggests that some of the serum IgG1 were binding LPS 










Figure 19: Characterisation of flagellin preparations by SDS-PAGE gel, western blotting and LPS staining. (A) Simply Blue™ (Invitrogen, 
Paisley, UK) stained SDS-PAGE gel of H2, H7 and H21 flagellin preparations together with a SeeBlue Plus2 (Invitrogen, Paisley, UK) 
protein standard (left-hand lane). (B) Western blot of H2, H7 and H21 preparations with pooled serum from calves with high or low levels 
of flagellin specific IgG1 determined by ELISA to determine the specificity of the IgG1 response. Following incubation with serum samples, 
the blot was incubated with a secondary antibody a mouse anti-bovine IgG1 and then a tertiary rabbit anti-mouse IgG polyclonal antibody 
conjugated to HRP. (C) Staining of H2, H7 and H21 preparations separated by 1D SDS-PAGE using Pro-Q Emerald 300 






2.3.8  Correlation between Stx neutralising antibody (nAb) 
titre and flagellin-specific antibodies 
 
As we had hypothesised that neutralisation of Stx activity may enhance STEC-specific 
immunity upon natural STEC exposure, correlations between levels of Stx1 nAb titres and 
anti-flagellin IgG1 responses were determined at the two time-points where Stx toxoid 
vaccination status coincided with increased flagellin-specific IgG1. There were significant 
positive correlations between H7 specific IgG1 and rStx1 nAb titres in vaccinated (rs = 0.497, 
p = 0.014) but not control calves at 9-12 weeks (rs = 0.368, p = 0.077; Figure 20) and also 
15-16 weeks (vaccinated, rs = 0.519, p = 0.009; control calves rs = 0.084, p = 0.697). There 
were significant positive correlations between H2 specific IgG1 and rStx1 neutralising 
antibody titres in vaccinated (rs = 0.752, p < 0.001) but not control calves at 9-12 weeks (rs = 
0.286, p = 0.176). There were significant positive correlation between H2 specific IgG1 and 
rStx1 neutralising antibody titres in control calves (rs = 0.406, p = 0.022) but not in the 
vaccinated calves (rs = 0.308, p = 0.1434) at 15-16 weeks. There were no significant 
correlations between H21 specific IgG1 and rStx1 neutralising antibody titres (week 9-12, 
vaccinated calves rs = 0.225, p = 0.290 and controls rs = 0.116, p = 0.599; week 15-16, 













Toxoid vaccinated  
rs = 0.497, p = 0.014  
 
Toxoid vaccinated 
rs = 0.752, p < 0.001 
Toxoid vaccinated 
rs = 0.225, p = 0.290 
Placebo controls 
rs = 0.368, p = 0.077 
 
Placebo controls 
rs = 0.286, p = 0.176 
Placebo controls 




rs = 0.519, p = 0.009 
 
Toxoid vaccinated 
rs = 0.308, p = 0.143 
Toxoid vaccinated 
rs = 0.351, p = 0.092 
Placebo controls 
rs = 0.084, p = 0.697 
 
Placebo controls 
rs = 0.406, p = 0.022 
Placebo controls 
rs = -0.001, p = 0.999 
Figure 20: rStx1 neutralizing titres compared to H7, H2 and H21 specific IgG1 levels in 
serum in calves from the toxoid trial. H7, H2 and H21 specific IgG1 antibody levels are 
expressed as the mean OD of duplicate determinations per animal normalised to a 
positive control sample. Red circles are toxoid vaccinated calves and blue open circles 
placebo vaccinated calves. P-values were determined by Spearman’s rank correlation 
coefficient analysis and indicated in the table (correlation between rStx1 nAb titre 






2.4  Discussion 
Shiga toxins are known immune modulators62,136,139,153,163. In the first part of this chapter we 
determined STEC antigen specific antibody levels in cattle naturally infected and shedding 
STEC O157. We showed that under field conditions, shedding of STEC O157 is associated 
with increased levels of H7-specific IgA and IgG1 but levels of Tir-specific IgA are lower in 
cattle shedding moderate levels of STEC O157, suggesting at lower levels of colonisation 
the bacteria may be suppressing induction of Tir-specific humoral immunity. In the case of 
the other STEC O157 antigens investigated (Intimin and EspA) there was no evidence of an 
increase in antibody response to these antigens suggesting that these antigens are either 
poorly immunogenic or that the antibody response to these antigens was also suppressed. 
Although in this field study we do not know when the cattle were infected, for how long they 
were infected and if this was a primary or secondary infection. All of these factors may be 
contributing to the antibody responses seen. An alternative hypothesis that has been 
proposed is that colonisation with STEC sequesters IgA into the gut lumen, and this results 
in a reduction in levels of circulating STEC specific IgA115. However other studies have 
shown with gastrointestinal nematode infections (Teladorsagia circumcincta) that there is a 
good positive correlation between circulating and mucosal antigen-specific IgA164, which 
does not support this alternative hypothesis. 
Previous studies have shown that STEC O157 antigen antibody responses can be variable in 
field situations165. A study examining serum antibody levels found no significant difference 
between intimin and Tir antibody levels in STEC O157 negative compared to STEC O157 
positive cattle farms. They also demonstrated that faecal secretion of STEC strains did not 
correlate with serum antibody responses to EspA, intimin or Tir165. The apparently different 
immunogenicity of H7 and other STEC antigens is potentially due to the T-cell dependency 
of the antigens, with H7 capable of acting as a T- cell independent antigen166,167. Thus, 
antibody responses to this antigen may be less sensitive to the effects of Stx, which is known 
to interfere with T-cell function both in vitro136 and in vivo126. We are seeing H7 specific 
IgG1 antibody production, so although H7 may be acting in a T-cell independent manner we 
are still seeing class switching of the antibodies which can occur with T-cell independent 
antigens168,169. A recent transcriptomic analyses of super shedding vs non-shedding cattle 
identified a suite of down-regulated transcripts in the terminal rectum of O157 colonised 
cattle associated with B-cell development129 as discussed further in chapter 5. Interestingly at 






actually shedding at low levels of STEC O157, and it may be that low levels of colonisation 
may be better at modulating host immunity as immune-modulators would be able to function 
in conditions of relatively low antigenic exposure. This may explain why suppression of Tir-
specific antibody responses was only seen in cattle shedding moderate but not high levels of 
STEC O157. It is unlikely that the reduced levels of Tir-specific IgA are due to a general 
reduction in antibody levels rather than a specific regulation of Tir-specific B-cell response 
because we determined there was no statistically significant difference between total IgA, 
IgG1 or IgG2 antibody levels between animals in the cohorts in this study.  
Based on these observations, and those of others which identify only weak and variable 
responses to STEC O157, we hypothesised that a significant component of this 
immunomodulatory effect was mediated by Stx, and that vaccination with a Stx toxoid 
would induce Stx neutralising antibodies which could interfere with this immune modulation 
and enhance antibody responses to STEC-specific antigens. Consistent with this hypothesis, 
our results indicate that Stx toxoid vaccines induce neutralising antibodies to Stx which 
correlate with significant reductions in STEC shedding but increased levels of flagellin-
specific IgG1. The strains of STEC found to be naturally circulating from calves in this study 
were H typed and the most common H types were found to be H21, H2 and H7 at week 15. 
Thus H7, H2 and H21 specific IgG1 antibody levels were determined, and all showed to be 
significantly increased in calves that were vaccinated with the Stx toxoid at 9-12 weeks 
compared to control placebo vaccinated calves at the same time point. The flagellin-specific 
IgG1 antibody levels were also found to highly correlate between the three H-types tested. 
This can be explained by the previous observation that anti-flagellin IgG1 antibodies in cattle 
recognise epitopes in the N and C terminal domains of the protein which are conserved 
between different H-types170,171.  
One possible explanation for these results is that the toxoid vaccine preparation contained 
flagellin and/or LPS resulting in the induction of IgG1 antibodies which bound to the 
flagellin preparations used for the ELISA tests which were shown to also contain LPS. 
Western blots confirm that the antibodies in the serum samples were binding to molecules of 
the same size as the flagellin proteins in the flagellin preparations; however, staining an 
equivalent gel also indicated that some of the antibody response may have been directed 
towards LPS within the flagellin preparations, particularly for H7 and H21. However the 
increased levels of H2, H7 and H21 specific IgG1 seen in toxoid vaccinated calves compared 






within the vaccine preparation for the following reasons: (i) FliC gene was absent from the 
parental strain used to generate the recombinant toxoid vaccine, and the strain was non-
motile confirming a lack of flagellar expression156, (ii) LPS was removed from the toxoid 
vaccine and (iii) the colostrum pools used as well as 24 hour serum samples from calves 
receiving colostrum from vaccinated dams contained significantly higher levels of Stx 
neutralising antibodies but similar levels of flagellin-specific IgG1 compared to calves 
receiving colostrum from control dams. As post-colostral serum IgG1 antibodies are 
reflective of the dam’s IgG1 response to the toxoid vaccine, there is no evidence to support 
the notion that the toxoid vaccine may have induced flagellin-specific IgG1 antibodies itself. 
Instead, H-specific humoral immune responses detected in the groups of calves are most 
likely to result from natural exposure and development of an active immune response by the 
animals, with calves with high anti-Stx antibody titres better able to respond to antibody-
mediated neutralisation of Stx mediated immune suppression.   
Interestingly, while differences were seen between vaccinated and control calves in flagellin-
specific antibodies, we saw no difference in response to the other antigens except at earlier 
time points (≤ 3 weeks post-colostrum) and Tir-specific IgA at 9-12 weeks. Differences in 
earlier time points reflect differences in colostral antibody levels rather than differences in 
the ability of the calves to respond immunologically to the antigens. The Tir-specific IgA 
responses were low for all calves in the trial and the significant difference between the 
groups marginal, being slightly higher in the control group at 9-12 weeks, possibly due to 
increased STEC exposure. The lack of observable differences in response to the other 
antigens may have been due to a lack of sensitivity to detect the differences: antibody 
responses were higher to flagellin preparations than to the other antigens, potentially making 
differences in flagellin-specific responses easier to detect. Whether this is due to the higher 
inherent immunogenicity of flagellins or higher exposure of the calves to flagellins, is 
unclear, although flagellin is a highly immunogenic molecule due to its ability to activate 
Toll-like receptor 5172.  
A toxoid vaccination that is able to lower STEC shedding in cattle to multiple serotypes of 
STEC could be of great economic and social consequence. Further work needs to be done to 
determine the use of this vaccine within the cattle population. If the vaccine leads to 
enhanced immune responses to STEC antigens, it could lead to enhanced immunogenicity of 
other non-O157 STEC strains. In conclusion, we provide evidence that STEC may modulate 






O157. Furthermore, vaccination with Stx toxoids results in reduced STEC shedding but 
enhanced flagellin-specific antibody levels, suggesting that Stx may be involved in delaying 








Chapter 3  
Immunity to STEC O157 
following experimental challenge 
3.1  Introduction 
 
Following on from the natural colonisation chapter, we wanted to further define the immune 
responses in calves experimentally challenged with STEC O157. The group has previously 
developed an effective oral challenge protocol enabling successful STEC O157 colonisation 
of pre-weaned calves97. Using an oral experimental challenge protocol would allow us to use 
aged matched calves, challenged at the same time point with defined STEC O157 strains 
with known Stx repertoires. 
Two different wild type strains were used for the STEC O157 calf challenges: a PT21/28 and 
a PT32 strain, both of which were stx2c positive. These strains were selected as they were 
representative of clinically relevant strains within the UK. A study in Scotland in 2003 
investigating faecal pat samples from cattle found three main phage types of STEC O157; 
PT21/28 (46 %), PT32 (19 %) and PT8 (12 %)30. PT21/28 strains were more likely to be 
associated with high levels of shedding in cattle30 compared to the other two PTs as indicated 
in Figure 21. Furthermore, PT21/28 stains were more likely to possess both stx2a and stx2c 
toxin subtypes3, in contrast to PT32 strains which were predominately stx2c–positive alone74. 
The two strains used in this study were selected as they were representative of the PT21/28 
and PT32 clusters determined by core-genome SNP analysis173, had been isolated from 
faecal pats with relatively high (PT21/28) and low (PT32) bacterial counts, and possessed 
both Stx2a and Stx2c encoding prophages (PT21/28 strain) or Stx2c-encoding prophages 
alone (PT32 strain). The two strains had also been shown in a previous study to efficiently 







Figure 21: Comparison of proportions of the three major phage types (and others) for 
low-level and high-level shedders using the point estimate of the high-level threshold (≥ 
3,135). Samples from Scottish farms taken March 2002 to February 2004; figure taken 
from Chase-Topping30 with permission. 
 
Through further sequence analysis it was found that the wild-type PT21/28 had an insertion 
sequence (ISec8) within the coding region of the A subunit of the Stx2a gene (Figure 22)173, 
meaning that this strain was incapable of producing functional Stx2a toxin. The ISec8 was 
removed genetically enabling us to compare the effect on immune responses of two isogenic 
PT21/28 strains which differ only in the expression of a functional A subunit of the Stx2a 











Figure 22: PT21/28 strain 9000 with the ISec8 insertion sequence (9000) compared to repaired isogenic PT21/28 strain (9000 R). The figure 
and sequencing information was generated by Sharif Shaaban (University of Edinburgh) using Easyfig alignment (version 2.2.2,  company, 





A recent study from within our group has provided evidence of cellular and humoral immune 
responses to type three secretion system (T3SS) proteins from STEC O157 in the rectal 
lymph nodes of calves colonised with the wild-type PT21/28 and PT32 strains174. Within the 
current study we wanted to investigate the systemic cellular and humoral immune responses 
in STEC O157 challenged calves to determine any strain-dependent differences in magnitude 
or timing of the response. Antibody responses as discussed in the previous chapter have been 
determined in a number of experimental challenge studies115,175, but to our knowledge this is 
the first study that compares STEC O157 antigen specific antibodies in calves challenged 
with two strains differing only in their ability to produce functional Stx2a. The previous 
chapter demonstrated that a neutralisation of Stx activity (by toxoid vaccination) can lead to 
an increase in STEC specific antibody responses in a natural colonisation situation. We 
hypothesised that a challenge with STEC O157 (stx positive) strains would suppress the 
hosts STEC specific antibody responses, with the strain expressing both Stx2a+ and Stx2c+ 
been the most suppressive. 
Main Aim 
To quantify STEC-specific cellular and humoral responses following experimental 







3.2  Material and Methods 
3.2.1  Type three secretion protein preparation 
 
Type three secretion protein (T3SP) preparation was generated from E. coli O157 strain ZAP 
193 (a stx negative strain). A single colony was used to inoculate 10 ml of LB (Luria broth) 
and incubated overnight at 37 oC (200 rpm). The 10 ml overnight culture was then added to 1 
L of MEM-HEPES (Sigma-Aldrich, Dorset, UK) supplemented with 20 % (1 g/l) glucose, 
which was cultured at 37 oC (200 rpm) until reaching an OD 600 of 0.8. The bacteria were 
pelleted by centrifugation 5,000 g for 30 minutes and the supernatant subsequently filter 
sterilised using a 0.2 μm low protein binding filter (Milipore, Watford, UK). Trichloroacetic 
acid (TCA) at a final concentration of 10 % v/v was used to precipitate the protein overnight 
at 4 oC. The proteins were pelleted at 4 oC, 5,000 × g for 30 minutes. The pellet was re-
suspended in 1.5 M Tris HCl pH 8.8. The preparation was than dialysed in phosphate 
buffered saline across a regenerated cellulose membrane which has a molecular weight cut-
off rating of 3.5 kDa (Spectrum, labs, Breda, The Netherlands). Two batches of the above 
preparation were pooled at this stage and the protein content checked by separation using a 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently 
stained with SimplyBlue™ SafeStain (Invitrogen, Paisley, UK; Figure 23). 
A bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, USA) was used to estimate 
the protein concentration in the final T3SP preparation. A EndoLISA kit (Hyglos, GmbH, 
Bernried, Germany) was used to estimate the lipopolysaccharide (LPS) concentration of the 
preparation, the plate was read using a Tecan microplate reader (Dynex Technologies, 






Figure 23: A 4-12 % w/v SDS-PAGE gel showing T3SP preparations used to determine 
antigen-specific recall responses in peripheral blood mononuclear cells (PBMC) and 
rectal lymph node cells. Migration of the SeeBlue Plus2 Pre-Stained standard ladder is 
indicated by tick and numbers on the left-hand side of the gel. 
 
3.2.2  Experimental challenge trials 
 
All animal work was carried out at the Moredun Research Institute (MRI) and ethical 
approval was obtained from the MRI animal experiments committee. All work was done 
under Home Office license. The animal trials were carried out as part of a larger scale STEC 
O157 shedding and transmission study (Fitzgerald et al. in preparation). 
Conventionally reared male Holstein-Friesian dairy calves entered MRI at 3 weeks old and 
were pre-screened on a weekly basis 5 times before the oral challenge. Pre-screening 
involved obtaining faecal samples directly from the rectum from each calf and using IMS 





Invitrogen, Paisley, UK) and subsequent culture confirming the calves to be STEC O157 
negative when entering the trials and also by RT-qPCR (SERL protocol, performed by Dr 
Jason Morgan or Dr Stephen Fitzgerald) confirming the calves to be STEC O157 and stx1 
and stx2 negative when entering the trials (Fitzgerald et al. in preparation).  
The calves were randomly assigned into groups as detailed in Table 6. At this stage all of the 
calves were weaned. Calves were housed in rooms in the high security unit at MRI for 
challenge studies with the exception of no-challenge control calves which were 
conventionally housed (the group was housed separately from other animals on the farm) on 
the MRI farm.  
Table 6: Details of STEC O157 experimental oral challenge trial protocol 




PT21/28 Stx2c+ challenged  Strain 9000  PT21/28 6 
PT21/28 Stx2c+ controls  None n/a 5 
PT32 Stx2c+ challenged Strain 10671 PT32 6 
PT32 Stx2c+ controls None n/a 4 
PT21/28 Stx2a+Stx2c+ 
challenged 
Strain 9000R PT21/28 7 
PT21/28 Stx2a+Stx2c+ controls None n/a 5 
  
Calves were orally challenged by orogastric intubation with ~109 CFU of each strain within 
10 ml of Lysogeny broth. For strain 9000, two of the six calves were challenged twice at a 7 
day interval as the first challenge did not result in efficient colonisation. For the other strains, 






3.2.3  Collection of faecal samples and bacterial counts 
 
For orally challenged calves, faecal samples were collected by digital manipulation directly 
from the rectum daily for the first 18 days post oral challenge and then every other day. For 
control calves faecal samples were taken every other day. Ten gram of faeces were placed 
into 90 ml of sterile PBS. Ten-fold serial dilutions of the faecal samples were then prepared 
in PBS and 100 μl from three dilutions across a 1,000 fold range of dilutions were plated out 
in triplicate onto sorbitol MacConkey agar plates containing 15 μg nalidixic acid (NAL-
SMAC). Plates were incubated at 37 oC overnight and colonies counted on the most suitable 
dilution plates. Randomly selected colonies from each plate were confirmed as O157 
positive by using a latex agglutination kit (Oxoid, Basingstoke, United Kingdom) following 
the manufacturer’s instructions. If no colonies were observed then overnight broth 
enrichment (tryptone soya broth [TSB; Oxoid, Basingstoke, USA]) from the undiluted faecal 
suspension was performed and then plated out on NAL-SMAC plates. Samples which were 
positive by broth enrichment were assigned a value of 10 CFU/g. Samples from the control 
animals were plated out directly onto cefixime –tellurite (CT)-SMAC plates containing 0.05 
mg/L cefixime, 2.5 mg/L tellurite; incubated overnight at 37 oC and then enumerated the 
next day.  
3.2.4  PBMC and serum preparations 
 
Blood was collected weekly by jugular venepuncture for subsequent isolation of peripheral 
blood mononuclear cells (PBMC) and serum.  
Serum was prepared by centrifugation of the blood at 330 g for 10 minutes and then the 
serum was aliquoted into 1.5 ml reaction tubes and stored at –20 oC prior to analysis. 
PBMC were purified from heparinised blood samples by density gradient centrifugation 
using Ficoll-Paque (GE Health care life sciences, Little Chalfont, UK) in SepMate™ 
isolation tubes (STEMCELL Technologies, Inc., Vancouver, Canada) according to the 
manufacturer’s instructions. Viable cells were counted using Trypan Blue viability stain 





3.2.5  Post Mortem and lymph node cell preparation 
 
On day 25 or 26 of the trial calves were euthanized using intravenous pentobarbital. Rectal 
lymph nodes (draining the site of colonisation of STEC O157) were collected and placed in 
35 ml transport medium (Hanks buffered saline solution [HBSS] without calcium and 
magnesium, 2 % heat-inactivated calf serum [HI-FCS], 10 mg/ml gentamicin [Sigma-
Aldrich, Dorset, UK], 200 IU/ml penicillin, and 200 μg/ml streptomycin) prior to processing. 
Lymph nodes were washed twice in transport medium then placed into 15 ml preparation 
medium (transport medium without HI-FCS) and cut into small pieces using a scalpel blade. 
The lymph node and media was then transferred to a stomacher bag and placed in a 
stomacher (Colworth Stomacher 80, Seward Ltd, Worthing, UK) for 30 seconds. The content 
was then filtered through a 70 μm filter (Thermo-Fisher Scientific, Loughborough, UK) and 
the volume made up to 20 ml with transport medium. The suspension was then underlaid 
with 10 ml Ficoll-paque Plus (GE Health care Life Sciences, Little Chalfont, UK) and 
centrifuged for 30 minutes at 800 g. The mononuclear layer was harvested from the top of 
the Ficoll layer, washed twice with PBS and then re-suspended in complete culture medium 
(RPMI1640 [Gibco, Invitrogen, Paisley, UK], 10 % HI-FCS, 200 mM L-glutamine 
[Invitrogen, Paisley, UK], 0.004 % β-mercaptoethanol [Sigma-Aldrich, Dorset, UK], 100 
IU/ml penicillin and 100 μg/ml streptomycin [Invitrogen, Paisley, UK]). Cells were either 
used for the generation of antibody secreting cell probes (see section below) or in 
lymphocyte stimulation assays. 
3.2.6  Antibody Secreting Cell probe (ASC) generation 
 
Antibody secreting cell probes were generated as previously described176. Briefly, lymph 
nodes cells (prepared as above) in complete culture medium were plated out (4 wells per 
lymph node) at 5 ×106 cells per well in 24 well plates to generate antibody secreting cell 
probes (ASC). The plates were incubated for 5 days at 37 oC and 5 % CO2. For negative 
controls, complete culture medium without cells was incubated in parallel. After 5 days the 
cells were harvested from the plates into 15 ml conical centrifugation tubes (Falcon™, 
Thermo Fisher Scientific, Loughborough, UK), centrifuged at 330 g for 5 minutes and then 
the supernatant containing the secreted antibodies was collected and stored at -20 oC for 





3.2.7  Lymphocyte stimulation assays (LSA) 
 
Cells (PBMC or lymph node cells) were seeded at 2 ×105 cells per well into 96 well round 
bottom plates. Triplicate wells for each animal were stimulated with complete culture media 
(RPMI 1640 [Invitrogen, Paisley, UK] containing 10% Hi-FCS, 2 mM L-glutamine, 100 
U/mL penicillin, 100 µg/mL streptomycin and 50 μM 2-mercaptoethanol) containing either 
PBS, T3SP preparation (10 μg/ml), media containing a matched concentration of commercial 
STEC O111:B4 LPS (Sigma-Aldrich, Dorset, UK) to that present in the T3SP preparation or 
Concanavalin A (ConA; 10 μg/ml, Sigma-Aldrich, Dorset, UK) as a positive control. Plates 
were incubated for 4 days at 37 oC at 5 % CO2. At day 4, 50 μl of supernatant was removed 
from each well and stored for at -20 oC for subsequent cytokine analysis. Fifty microliters of 
complete culture medium containing 0.5 μCi/well [3H] thymidine (PerkinElmer, Cambridge, 
UK) was then added per well and the cells incubated for a further 18 hours. Cells were 
harvested onto glassfiber filters (PerkinElmer, Cambridge, UK) and [3H] thymidine 
incorporation was quantified using an automated scintillation counter (PerkinElmer, 
Cambridge, UK). Stimulation indices were calculated by dividing the mean of the triplicate 
counts per minute by the mean of the relevant LPS stimulated controls. 
3.2.8  Bovine IFN-γ ELISpot 
 
A commercially available kit was used (ELISpot for Bovine IFN-γ; 3119-2HW-plus; 
MabTech, Nacka strand, Sweden) with hydrophobic polyvinylidene difluoride (PVDF) 
membrane ELISpot plates (Merck Millipore, Nottingham, UK) following the manufactures 
instructions. PBMC were stimulated with complete culture media containing either PBS, 
T3SP preparation (10 μg/ml), media containing a matched concentration of commercial 
STEC O111:B4 LPS (Sigma-Aldrich, Dorset, UK) or ConA (10 μg/ml) (Sigma-Aldrich, 
Dorset, UK) for 18 hours before addition to the plate in duplicate wells at 2 ×105 cells per 
well. Reactive spots were developed using ELISpot TMB substrate and the number of spots 
was quantified automatically using an ELISpot reader (AID ELISpot reader version 4, 
Autoimmun Diagnostika GmbH, Strasberg, Germany). Responses of LPS-stimulated 
cultures were subtracted from responses by parallel T3SP stimulated cultures prior to data 





3.2.9  Quantification of antigen-specific antibody responses 
 
Antigen specific IgA, IgG1 and IgG2 responses to H7, Tir, EspA and Intimin were quantified 
by indirect ELISA as described in Chapter 2. The optimum serum sample dilutions are 
shown in Table 7 and were determined following serial dilution of representative samples 
from each group to ensure that the colour reaction at an optical density (OD) at 492 nm for 
the sample was on the linear part of the curve. ASC probe samples were analysed neat for all 
antibody isotypes. 
Table 7: Dilutions of serum samples for STEC antigen specific antibody ELISAs 
 Dilution of serum samples 
Antigen IgA IgG1 IgG2 
H7 1 in 10 1 in 100 1 in 50 
Tir 1 in 10 1 in 250 1 in 50 
EspA 1 in 10 1 in 50 1 in 50 
Intimin 1 in 10 1 in 100 1 in 50 
 
3.2.10 Statistical Analysis 
 
Non-parametric Mann-Whitney U tests were used to compare rectal lymph node cells 
responses to ex vivo stimulation by T3SP between challenged and unchallenged control 
calves. STEC-antigen specific antibody responses in ASC probes between challenged and 
unchallenged calves were also compared using Mann-Whitney U tests. GraphPad prism 
(version 7.0, La Jolla, USA) was used for the statistical analysis above.  
Mixed models were used to analyse temporal immune response data. All mixed model 
statistical analysis was performed using R (version 10) by Javier Palarea (Biomathematics 





strain. The T3SP-specific lymphocyte stimulation index data from PBMC was analysed by 
log transforming the T3SP-specific simulation index, then a generalised additive model with 
identity link function and Gaussian errors was fitted by restriction maximum likelihood 
(REML) to allow investigation of the effects of treatment (STEC O157 challenge vs. no 
challenge) on simulation index over the duration of the experiment. It included treatment 
group as fixed effect and spline-based smooth terms (one per treatment) to account for 
potential non-linear relationship of the response with time. Animal was added as a random 
effect and heterogeneous variances by treatment was allowed. 
ELISpot (T3SP-specifc IFN-γ releasing cells) data was analysed by log transformation of the 
T3SP-specific spot forming units per 106 +1. A random interaction mixed model including 
treatment, time and their interaction as fixed effect and animal as random effect was fitted 
using restricted maximum likelihood (REML). An exponential within group variance 
structure over time was considered to model non-homogenous variances. 
Generalised additive mixed models with identity link function and Gaussian errors were 
fitted by REML to investigate the effect of treatment on the STEC antigen specific antibody 
responses over time. The antibody responses were (log +1) transformed to normalise the 
data. The models included treatment group as fixed effect and spline-based smooth terms 
(one per treatment) to account for potential non-linear relationships of the response with 
time. Animal was added as random effect. Heterogeneous variances by group were allowed.  






3.3  Results 
3.3.1  Faecal shedding 
 
Figure 24 represents the individual shedding curves for animals orally challenged with STEC 
O157. The unchallenged control calves were negative for STEC O157 for the duration of the 
trial (data not shown). The shedding data confirms that all orally challenged calves were 
successfully colonised following their oral bolus challenge. 
 
Figure 24: Faecal shedding curves of STEC O157 by experimental challenge of weaned 
calves. Six or seven calves in each trial were orally challenged with STEC O157 
(PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+) indicated by the black arrow. 
For strain 9000 (PT21/28 Stx2c+), two of the six calves were challenged twice at a 7 day 
interval as the first challenge did not result in efficient colonisation. Curves represent 
shedding after successful challenge and were aligned relative to the challenge day. The 
shedding data is expressed as log10 of colony forming units per gram of faeces + 1. 






3.3.2  Cellular immune responses 
 
Figure 25 demonstrates T3SP-specific systemic cellular immune responses in calves 
challenged with either PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+. PBMC 
from calves challenged with PT21/28 Stx2c+ showed no statistically significant difference in 
T3SP-specific lymphocyte proliferation (p = 0.2592) or in the number of T3SP-specific IFN-
γ releasing cells (p = 0.428) to PBMC of unchallenged control calves. PBMC from calves 
challenged with PT32 Stx2c+ showed no statistically significant difference in T3SP-specific 
lymphocyte proliferation (p = 0.8655) or in T3SP-specific IFN-γ releasing cells between 
challenged and unchallenged control (p = 0.469). PBMC from calves challenged with 
PT21/28 Stx2a+Stx2c+ showed no statistically significant difference in T3SP-specific 
lymphocyte proliferation between challenged and unchallenged controls (p = 0.895). 
Numbers of T3SP-specific IFN-γ releasing cells were not determined for calves challenged 
with this strain as there were no statistically significant differences seen following challenge 
with the other two STEC O157 strains. The results suggest that oral challenge with all three 
STEC O157 strains induces a limited systemic cellular immune response to the T3SP 









Figure 25: T3SP-specific lymphocyte proliferation and bovine IFN-γ spot  forming  units  in  PBMC  prepared  at  weekly  time  points  and 
stimulated  ex vivo  with  T3SP  preparation or  LPS controls  throughout  the  PT21/28 Stx2c+,  PT32 Stx2c+  and  PT21/28  Stx2a+Stx2c+ 
trials. Proliferation (A) determined by a lymphocyte stimulation assay is expressed as indices, representing fold changes in the response to 
T3SP from levels with the relevant LPS control. Bovine IFN-γ releasing cells were determined by Elispot (B) and expressed as spot forming 
units per 106 cells in response to T3SP, responses of cultures stimulated with an equivalent amount of LPS to that present in the T3SP were 





Antigen specific responses to a mucosal pathogen may be difficult to detect within PBMC 
unless samples are taken that coincide with recirculation of lymphocyte populations induced 
at the mucosal site of infection177,178. Thus the rectal lymph nodes were removed at post 
mortem from calves challenged with the two PT21/28 strains to capture the immune 
response in the draining lymph nodes to the primary site of colonisation of STEC O157 in 
bovines27, as the lymph nodes would be expected to be enriched for STEC O157-antigen 
specific T-cells. However unlike PBMC the rectal lymph nodes cannot be used to study the 
temporal nature of the immune response as they are only accessible at post mortem (one time 
point). Rectal lymph node cells were re-stimulated ex vivo with the T3SP preparation and the 
lymphoproliferative response determined. The results are shown in Figure 26. For the 
PT21/28 Stx2c+ strain there was no statistically significant difference in rectal lymph node 
cell proliferation between the challenged and unchallenged control calves (p = 0.8030). 
Similarly for the PT21/28 Stx2a+Stx2c+ strain no significant difference in proliferation was 
observed between the challenged and unchallenged control calves (p = 0.6389).  
 
 
Figure 26: T3SP-specific proliferation of bovine lymph node cells isolated post-mortem 
from the rectal lymph node and re-stimulated ex vivo for 5 days with T3SP. Calves 
were orally challenged with either the PT21/28 Stx2c+ strain or the PT21/28 
Stx2a+Stx2c+ strain. T3SP-specific proliferation was determined by a lymphocyte 
stimulation assay and is expressed as indices, representing fold changes in the response 
to T3SP relative to those from LPS stimulated control cultures. Circles represent 
individual calves and error bars represent median and interquartile range (IQR) of the 
group. The p-value is determined from a Mann-Whitney U test for differences between 





3.3.3  Rectal STEC-specific antibody responses 
 
Rectal lymph node ASC probes were generated to enable antibody responses local to the site 
of colonisation to be analysed. The results are shown in Figures 27 and 28. Levels of H7-
specific IgA and IgG1 were significantly higher in rectal ASC probes from calves challenged 
with the PT21/28 Stx2a+Stx2c+ strain compared to their unchallenged controls (Figure 27, p 
= 0.025 and p = 0.025 for IgA and IgG1, respectively). In contrast, levels of H7-specific IgA 
or IgG1 within ASC probes from PT21/28 Stx2c+ or PT32 Stx2c+ challenged calves were 
not significantly different from their unchallenged controls. There were no statistically 
significant differences in the levels of H7-specific IgG2 between challenged and 
unchallenged calves with any of the three STEC O157 strains.  
Levels of Tir- specific IgA were significantly higher in rectal ASC probes from calves 
challenged with the PT21/28 Stx2a+Stx2c+ strain (p = 0.018), but not the  PT21/28 Stx2c+ 
or PT32 Stx2c+ strains, compared to their respective unchallenged controls (Figure 27). No 
statistically significant differences in the levels of Tir-specific IgG1 or IgG2 were observed 
between challenged and unchallenged calves for any of the three STEC O157 strains. 
Levels of EspA-specific IgA were significantly higher in rectal ASC probes from calves 
challenged with the PT21/28 Stx2a+Stx2c+ strain (p = 0.012), but not the PT21/28 Stx2c+ or 
PT32 Stx2c+ strains, compared to their respective unchallenged controls (Figure 28). No 
statistically significant differences in the levels of EspA-specific IgG1 or IgG2 were observed 
between challenged and unchallenged calves for any of the three STEC O157 strains. 
Levels of intimin- specific IgA were significantly higher in rectal ASC probes from calves 
challenged with the PT21/28 Stx2a+Stx2c+ strain (p = 0.018), but not the PT21/28 Stx2c+ or 
PT32 Stx2c+ strains, compared to their respective unchallenged controls (Figure 28). No 
statistically significant differences in the levels of intimin-specific IgG1 or IgG2 were 






Figure 27: Levels of H7-and Tir-specific antibodies within rectal lymph node antibody 
secreting cell probes (ASC) generated from STEC O157 challenged and unchallenged 
calves. ASC probes were generated from rectal lymph nodes of calves challenged with 
PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2c+Stx2a+ and their relevant 
unchallenged controls. Levels of H7- and Tir-specific antibodies were determined by 
ELISA. The error bars represent medians and interquartile ranges. Each symbol 
represents an individual animal. Mann Whitney U-tests were used to compare antibody 
levels between challenged and unchallenged control calves for each strain and 






Figure 28: Levels of EspA- and intimin-specific antibodies within rectal lymph node 
ASC probes generated from STEC O157 challenged and unchallenged calves. ASC 
probes were generated from rectal lymph nodes of calves challenged with PT21/28 
Stx2c+, PT32 Stx2c+ or PT21/28 Stx2c+Stx2a+ and their relevant unchallenged 
controls. Levels of EspA- and intimin-specific antibodies were determined by ELISA. 
The error bars represent medians and interquartile ranges. Each symbol represents an 
individual animal. Mann Whitney U-tests were used to compare antibody levels 






3.3.4  Systemic STEC-specific antibody responses 
 
The systemic antibody responses to H7, Tir, EspA and intimin were assessed by quantifying 
levels of antigen-specific antibodies within serum samples collected at multiple time points 
throughout the trial. Levels were compared between challenged and their respective 
unchallenged control calves for each of the three STEC O157 strains. Serum levels of H7-
specific antibodies are shown in Figure 29. Circulating levels of H7-specific IgA were 
significantly higher in calves challenged with all three STEC O157 strains compared to their 
unchallenged controls (p = 0.002, p < 0.001 and p < 0.001 for P21/28 Stx2c+, PT32 Stx2c+ 
and PT21/28 Stx2a+Stx2c+, respectively). Serum H7-specific IgG1 responses were 
significantly higher in calves challenged with the PT21/28 Stx2a+Stx2c+ strain (p = 0.029), 
but not the PT21/28 Stx2c+ (p = 0.075) or PT32 Stx2c+ strains (p = 0.060), compared to 
their unchallenged controls. No significant differences in serum H7-specific IgG2 responses 
were found for any of the three strains (p = 0.967, p = 0.128 and p = 0.056 for P21/28 
Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+, respectively).  
Serum levels of Tir-specific antibodies are shown in Figure 30. No significant differences in 
serum Tir-specific IgA responses were found for any of the three strains (p = 0.517, p = 
0.440 and p = 0.299 for P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+, 
respectively). Serum Tir-specific IgG1 responses were significantly higher in calves 
challenged with the PT32 Stx2c+ strain (p = 0.045), but not the PT21/28 Stx2c+ (p = 0.599) 
or PT21/28 Stx2a+Stx2c+ (p = 0.419) strains, compared to their unchallenged controls. No 
significant differences in serum H7-specific IgG2 responses were found for any of the three 
strains (p = 0.639, p = 0.909 and p = 0.321 for P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 
Stx2a+Stx2c+, respectively).  
Serum levels of EspA-specific antibodies are shown in Figure 31. No significant differences 
in serum EspA-specific IgA responses were found for any of the three strains (p = 0.143, p = 
0.585 and p = 0.988 for P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+, 
respectively). Serum EspA-specific IgG1 responses were significantly higher in calves 
challenged with the PT32 Stx2c+ strain (p = 0.023), but not the PT21/28 Stx2c+ (p = 0.501) 
or PT21/28 Stx2a+Stx2c+ (p = 0.056) strains, compared to their unchallenged controls. No 
significant differences in serum H7-specific IgG2 responses were found for any of the three 
strains (p = 0.173, p = 0.328 and p = 0.367 for P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 





Serum levels of intimin-specific antibodies are shown in Figure 32. No significant 
differences in serum intimin-specific IgA responses were found for any of the three strains (p 
= 0.089, p = 0.882 and p = 0.563 for P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 
Stx2a+Stx2c+, respectively). No significant differences in serum intimin-specific IgG1 
responses were found for any of the three strains (p = 0.074, p = 0.555 and p = 0.981 for 
P21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+, respectively). Finally, no 
significant differences in serum intimin-specific IgG2 responses were found for any of the 
three strains (p = 0.430, p = 0.266 and p = 0.978 for P21/28 Stx2c+, PT32 Stx2c+ and 







Figure 29: Serum levels of H7-specific antibodies in STEC challenged and unchallenged 
calves. IgA, IgG1 and IgG2 antibody levels in serum were determined using an ELISA 
from serum collected at weekly time points from calves challenged with either PT21/28 
Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ and their unchallenged controls calves. 
Each symbol represents the mean of each groups and the error bars the SEM. The H7-
specific antibody levels are expressed as the mean OD of duplicate wells normalised to 






Figure 30: Serum levels of Tir-specific antibodies in STEC challenged and 
unchallenged calves. IgA, IgG1 and IgG2 antibody levels in serum were determined 
using an ELISA from serum collected at weekly time points from calves challenged 
with either PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ and unchallenged 
controls calves. Each symbol represents the mean of each groups and the error bars the 
SEM. The Tir-specific antibody levels are expressed as the mean OD of duplicate wells 







Figure 31: Serum levels of EspA-specific antibodies in STEC challenged and 
unchallenged calves. IgA, IgG1 and IgG2 antibody levels in serum were determined 
using an ELISA from serum collected at weekly time points from calves challenged 
with either PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ and unchallenged 
controls calves. Each symbol represents the mean of each groups and the error bars the 
SEM. The EspA-specific antibody levels are expressed as the mean OD of duplicate 







Figure 32: Serum levels of Intimin-specific antibodies in STEC challenged and 
unchallenged calves. IgA, IgG1 and IgG2 antibody levels in serum were determined 
using an ELISA from serum collected at weekly time points from calves challenged 
with either PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ and unchallenged 
controls calves. Each symbol represents the mean of each groups and the error bars the 
SEM. The Intimin-specific antibody levels are expressed as the mean OD of duplicate 






3.4  Discussion 
 
To understand the field study results described in Chapter 2 in more detail experimental 
animal trials were performed to assess STEC O157-specific responses in more defined STEC 
O157 orally challenged animals. The experimental animal trials were performed as part of a 
larger experiment studying the shedding and transmission dynamics of three STEC O157 
strains PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+ in cattle (Fitzgerald et al. 
in preparation) and this enabled variation in host cellular immune responses and antibody 
responses between the three strains to be analysed.  
To identify the presence of circulating adaptive immune responses following STEC O157 
colonisation PBMC preparations were prepared, pre-challenge and then weekly following 
oral STEC O157 challenge and stimulated ex vivo with an STEC O157 T3SP preparation 
which had previously been shown to contain epitopes recognised by mucosal helper (CD4+) 
T-cells from STEC O157 challenged calves179. Lymphocyte activation was determined by 
assessing antigen-specific proliferation and as a previous study in the group had determined 
that STEC O157 colonisation was associated with a local T-helper (TH)  Type 1 response174, 
ELISpot assays were used to determine the number of antigen-specific IFN-γ producing cells 
within the PBMC population. The effects of contaminating LPS within the T3SP preparation 
was controlled for by using parallel LPS stimulated cultures in these experiments. In addition 
to analysing circulating cellular immune responses, for the two PT21/28 strains 
lymphoproliferative responses to the T3SP preparation within the rectal lymph node, which 
drains the site of STEC O157 colonisation27, were also analysed. However, no significant 
differences in either local or systemic T-cell specific lymphoproliferative responses, or 
numbers of antigen-specific IFN-γ producing cells, were found between challenged and 
unchallenged control groups for any of the three strains tested. All the calves included in the 
study were found not to shed STEC O157 when screened during the 5 weeks immediately 
prior to challenge. However, calves may have been previously exposed to some of the T3SP 
antigens as calves may start shedding STEC strains even in the first weeks of life when 
raised on a conventional farm160. It is also possible that the frequency of antigen-specific T-
cells within the circulation may have been too low to detect any differences between 
challenged and control calves, although this would not explain the failure of rectal lymph 
node cells to respond to the T3SP preparation as it would be expected that a higher 





that STEC O157 colonisation induces a limited cellular immune response, which would be 
consistent with work done previously within the group which also failed to detect differences 
in rectal lymphoproliferative responses to T3SP between challenged and control calves174.  
Comparative levels of IgA, IgG1 and IgG2 specific to the STEC antigens (H7 flagellin, Tir, 
EspA and intimin) were determined in serum samples from calves orally challenged with 
PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+ STEC O157 strains. As 
determined with serum samples from naturally infected cattle, cattle challenged with STEC 
O157 (and shedding high levels of STEC O157) showed a statistically significant increase in 
systemic H7-specific IgA levels compared to negative control animals. All three challenge 
strains lead to a significant increase in systemic H7-specific IgA.  
Systemic H7-specific IgA antibody levels increased 7 days post challenge and peaked for 
PT21/28 Stx2a+Stx2c+ challenged calves although staying relatively high until the end of 
the trial. H7-IgA peaked at 21 days for PT21/28 Stx2c+ challenged calves and 14 days for 
PT32 Stx2c+ challenged calves. The fairly rapid decline in systemic H7-specific IgA may be 
explained by the relatively short half-life of IgA180. Bretschneider et al. (2007) also showed a 
similar decline in STEC antigen specific IgA shortly after challenge and proposed this may 
be evidence of their use in response to challenge through binding of STEC O157 and its 
secretory proteins115. As stated previously there was significant difference in mean bacterial 
shedding counts due to the distinct behaviour of the PT32 Stx2c+ strain challenged calves, 
there was a more rapid decline in their mean shedding over time; so by the end of the trial 
there were lower levels of PT32 Stx2c+ shed in the faeces (Fitzgerald et al. in preparation). 
This would fit in with the more rapid decline in H7-specific IgA in the PT32 Stx2c+ 
challenged calves. 
The systemic H7-specific IgG1 and IgG2 responses were more variable and two challenged 
calves had high H7-specific IgG1 responses pre-challenge. There was a significant difference 
in the H7-specific IgG1 response with both the PT32 Stx2c+ and PT21/28 Stx2a+ Stx2c+ 
challenge strains. Tir-, EspA- and intimin-specific antibody levels in serum were more 
variable within the groups. Some animals had relatively high levels of Tir-specific IgA, IgG1 
and IgG2 levels prior to challenge with STEC O157. EspA- and intimin-specific antibody 
levels were lower in all animals compared to Tir and H7. Asper et al. (2011) have previously 
determined significant levels of EspA-specific antibody levels in serum in two 
experimentally challenged animals175. STEC-specific IgG2 systemic antibody levels were 





STEC O157 in cattle infects a mucosal surface and peripheral immune responses in sera do 
not always reflect the local immune responses182. Antibody secreting cells (ASC) probes 
have been used previously to study the local immune response to a number of pathogens 
resident at mucosal surfaces176,183,184. ASC probes were used to allow assessment of the local 
antibody response to STEC O157 colonisation (rectal lymph node probes). The H7-specific 
IgA in the rectal lymph node ASC probes were only statistically significantly different with 
the PT21/28 Stx2a+Stx2c+ strain challenge calves compared to their controls, unlike the 
systemic responses (statistically significant difference with all three strains). The only 
difference between the PT21/28 Stx2c+ and PT21/28 Stx2a+Stx2c+ strains is the removal of 
the ISec8 insertion sequence and thus the ability of the strains to produce an active A subunit 
of Stx2a. Given the hypothesis that Stx suppress bovine immune responses is true and that 
the latter strain produces both Stx2a and Stx2c it may be expected that the toxins act in an 
additive manner and PT21/28 Stx2a+Stx2c+ challenged calves would have lower H7-
specific IgA responses rather than higher ones as observed in this study. The data presented 
does not support this assumption. This however may not reflect what is occurring in natural 
exposure in the field. The experimental challenge is a single large bolus of bacteria, we only 
challenged with two wild type strains and also the calves were all young with developing 
immune systems. These factors and others maybe effecting the immune responses seen in 
this study. 
The magnitude of the antibody response may partly reflect the level of antigen challenge185. 
A different group has previously demonstrated differences in systemic EspA-specific IgA 
responses between calves orally challenged with 1010 compared to 108 CFU of bacteria181. 
Statistical analysis of the STEC O157 faecal shedding data (Fitzgerald et al. in preparation) 
has determined that there was a statistically significant difference in mean counts over time 
between the three strains (p = 0.006). Further pairwise tests of mean differences between 
strains support that the statistically significant difference in mean counts is mostly explained 
by the distinct behaviour of the PT32 strain and not between PT21/28 Stx2c+ and PT21/28 
Stx2a+Stx2c+ (Fitzgerald et al. in preparation). Thus it is less likely that the amount of 
antigen could be affecting the H7-specific IgA responses, unless the strains differ in their 
surface expression of flagellin or the flagellin in the different strains differ in their 
immunogenicity. 
There were significant differences in local H7-specific IgG1, Tir-specific IgA and EspA-
specific IgA responses between PT21/28 Stx2a+Stx2c+ challenged calves and their 





other STEC antigens because flagellin is more immunogenic (of the STEC antigens tested it 
is the only one which can directly activate an innate immune receptor) or because it is less 
affected by any immunosuppressive effects of Stx. In this study the PT21/28 Stx2a+Stx2c+ 
challenged calves had significantly higher H7-specific IgA and IgG1 local antibody 
responses, whereas the PT21/28 Stx2c+ and PT32 Stx2c+ challenged calves did not, so it 
seems unlikely that Stx are having a significant suppressive effect on H7 responses in these 
calves. Again with the Tir-specific IgA responses there were significantly higher Tir-specific 
IgA responses in the PT21/28 Stx2a+Stx2c+ challenged calves but not in the PT21/28 
Stx2c+ or PT32 Stx2c+ challenged calves. The PT21/28 Stx2a+Stx2c+ strain produces an 
active Stx2a+ as well as Stx2c+ unlike the other two challenge strains used which just 
produce Stx2c+. Data from within our group has shown that in vivo the PT21/28 
Stx2a+Stx2c+ produces more Stx than the other two challenge strains (Dr Stephen 
Fitzgerald, personal communication). Also in Vero cell assays Stx2a has been shown to be 
more than 25 times more potent than Stx2c and also in vivo studies in mice showed Stx2a to 
be more potent than Stxc186. 
All IgG2 antibody levels in the rectal lymph node generated ASC probes were lower than 
IgA or IgG1. Intimin- and EspA-specific IgA and IgG1 were also lower than against Tir and 
H7. This data concurs with previous data from within the group and other studies indicating 
that colonisation with a Stx positive STEC O157 often leads to only a poor mucosal antibody 
response174. The detection of sporadic local IgA levels again agrees with previous studies121. 
This may reflect immune modulation by Stx at this local site, however one may have 
expected lower antibody responses in calves challenged with the PT21/28 Stx2a+Stx2c+ 
strain possessing active Stx2a and Stx2c genes compared to the other two strains just 
possessing active Stx2c+ genes, and the PT21/28 Stx2a+Stx2c+ strain has been shown to 
produce higher levels of Stx2 in vitro (Dr Stephen Fitzgerald, personal communication).  
The data from these experimental oral challenge animal trials indicate that oral challenge 
with STEC O157 lead to limited cellular immune responses to T3SP but some induction of 
humoral responses, both systemically and local to the site of STEC O157 colonisation. The 
PT21/28 Stx2a+Stx2c+ strain generally leads to more significant STEC antigen specific 
antibody responses. This indicates that although there is weak cellular responses there is no 
evidence that a functional Stx2a+ leads to an increased level of immune suppression. It has 
been previously shown in a mouse model that Stx can lead to upregulation of nucleolin154. 
Nucleolin is a eukaryotic protein, recognised by intimin and associated with sites of STEC 





E. coli O157 colonised at a higher level than a stx2 isogenic mutant E. coli O157 strain and 
also adhered better to epithelial cells in tissue culture154. This mouse study indicates that Stx 
may be able to promote colonisation in the short term, this would lead to enhanced T-cell 
independent and B-cell immunity perhaps before T-cell inhibition can become apparent. In 
this experimental study, if the calves were pre-immune to T3SP as indicated in the cellular 
assays, then they may be less sensitive to Stx immune suppression. The colonisation 
promoting effect may have outpaced the immunosuppressive effect at this stage and in this 
experimental setting. 
The major limitation of this study is that we were not able to compare the results with calves 
that were challenged with a Stx negative strain. As discussed in the introduction chapter, 
STEC O157 produce a number of effector proteins with the potential to modulate the host 
immune response. The direct comparison between an isogenic stx negative strain and stx 
positive strain would have allowed us to make more definite conclusions regarding the 

















Chapter 4  
STEC O157 effect on a bystander 
immunisation 
4.1  Introduction 
 
Vaccinations are an important tool in livestock production. In many vaccine studies evidence 
of variation in host response have been reported188-190, with a varying proportion of non-
responders even after several vaccinations191,192. Much of this variation is believed to be 
related to the genotype of the host, with particular emphasis on the major histocompatibility 
complex (MHC) which plays a central role in antigen presentation to T-cells193. Other non-
genetic factors could influence an animal’s ability to respond to vaccinations such as on-
going malnutrition and co-infections. Helminths have developed complex mechanisms to 
suppress and/ or avoid the mammalian immune response98,194-196 and to enable long-term 
survival within these hosts. Helminth mediated immune modulation can affect responses to 
parasite specific but also to non-parasite specific antigens (so called ‘bystander’ immune 
suppression). As a consequence, helminth co-infections have been associated with poor 
vaccine efficacy196-200. Other studies in cattle have demonstrated that although concurrent 
helminth infections can reduce cytokine responses to respiratory vaccinations there was no 
significant effect of helminth infections on the antibody responses to respiratory 
vaccinations201,202. However in other livestock species including pigs and chickens, helminth 
infections have been shown to suppress antibody levels to concurrent vaccinations200,203. A 
study has shown that malaria infections in mice can compromise established adaptive 
immunity to a live, attenuated vaccine against Salmonella Typhimurium204. The malaria 
infection had no effect on antibody responses to the vaccine but did suppress CD4 and CD8 
T-cell effector responses and lead to an increase in IL-10 expression204.  
There is little information in the literature about concurrent bacterial infections and vaccine 
performance. One study showed that the quantity of campylobacter and enterovirus at the 
time of administration of primary oral polio vaccination in children in Bangladesh has been 
associated with reduced polio neutralizing titers205. As previously described in the 





number of genes involved in adaptive immune responses within the intestinal mucosa97, and 
can produce a number of proteins with in vitro immunosuppressive 
activity64,126,136,137,139,140,206, presumably with the main objective of enabling more efficient 
colonisation of the bovine intestinal epithelium. Stx are likely to circulate throughout the 
body and thus Stx has the potential to modulate immune responses systemically as well as 
locally. Whether ‘bystander’ immune suppression occurs with STEC O157 infections in 
cattle is currently unknown. STEC O157 is prevalent in many cattle populations. Therefore if 
STEC O157 colonisation has a negative impact on the ability to respond to vaccinations or 
concurrent infections, this could have far-reaching effects on cattle health and welfare. 
The aim of this chapter was to determine if STEC O157 colonisation affects the ability of 
cattle to respond to a concurrent immunisation. Ovalbumin (OVA), a T-cell dependent 
antigen, it was selected as the antigen for immunisation as it has been widely used as a 
model antigen in cattle due to its ability to elicit robust antibody and cellular immune 
responses, and that it is not encountered in the natural environment of cattle207-209. 
Furthermore, OVA is antigenically distinct from STEC O157 antigens, being the main 
protein found in chicken eggs207, and can be obtained in a highly pure form210. Therefore the 
immune response to OVA would be highly tractable. OVA immunisations were administered 
on two occasions, two weeks apart together with the saponin adjuvant Quil A. Saponins have 
been used in a variety of veterinary vaccines211,212 and induce mixed TH1/TH2 immune 
responses213,214, meaning that the effects of STEC O157 on modulating both TH1 and TH2 
immunity could be assessed. The timing of the first immunisation was designed to coincide 
with peak STEC O157 shedding (five days post-challenge) as it has previously been shown 
that when evaluating STEC O157-specific immune responses, T-cell priming rather than 
recall of memory T-cells is most affected by Stx activity126. Cellular, cytokine and humoral 
responses to OVA were monitored and compared between STEC O157 challenged calves 
and calves which were not STEC O157 challenged. 
Main Aim: 
To determine the effects of STEC O157 colonisation on cellular and humoral 
immune responses to a non-STEC O157 T- cell dependent antigen and if any affect 





4.2  Material and Methods 
4.2.1  Animal trials 
 
Two calf trials were performed (Tables 8 and 9, also see chapter 3). Briefly calves were 
orally challenged with ~109 colony forming units (CFU) of the following STEC O157 
strains: PT21/28 Stx2c+ strain 9000, PT32 Stx2c+ strain 10671 or PT21/28 Stx2a+Stx2c+ 
strain 9000R in Trial 1, and PT21/28 Stx2a+Stx2c+ strain 9000 only in Trial 2. Calves were 
immunised on two separate occasions (5 days and 19 days post-challenge) in the left hand 
side of the neck via the subcutaneous route with 60 μg low-endotoxin ovalbumin 
(EndoGrade® Ovalbumin, Hyglos GmbH, Bernried am Starnberger See, Germany) plus 5 
mg Quil A (Brenntag Biosector, Frederikssund, Denmark). In Trial 1, two calves challenged 
























PT21/28 Stx2c+ challenged and 
immunised (C-I) 
Strain 9000 4 4 
PT21/28 Stx2c+ challenged only (C) Strain 9000 2 0 
PT21/28 Stx2c+ controls (immunised 
only [I]) 
None 5 5 
PT32 Stx2c+ challenged and immunised 
(C-I) 
Strain 10671 4 4 
PT32 Stx2c+ challenged only (C) Strain 10671 2 0 
PT32 Stx2c+ controls (immunised only 
[I]) 
None 4 4 
PT21/28 Stx2a+Stx2c+ challenged and 
immunised (C-I) 
Strain 9000R 5 5 
PT21/28 Stx2a+Stx2c+ challenged only 
(C) 
Strain 9000R 2 0 
PT21/28 Stx2a+Stx2c+ controls 
(immunised only [I]) 
None 5 5 
 







PT21/28 Stx2a+Stx2c+ challenged and 
immunised (C-I) 
Strain 9000 6 6 
PT21/28 Stx2a+Stx2c+ controls 
(immunised only [I]) 





4.2.2  Bacterial faecal shedding counts 
 
Data was collected as described in chapter 3 and expressed as colony forming units per gram 
of faeces (CFU/g). 
4.2.3  PBMC and serum preparations 
 
Blood was collected by jugular venepuncture on days -3, 7, 13, 21, and 25/26 for subsequent 
isolation of peripheral blood mononuclear cells (PBMC) and serum. PBMC and serum was 
prepared as described in chapter 3. 
4.2.4  Lymph node cell preparation 
 
At post mortem pre-scapular lymph nodes (PsLN) from the left hand side (i.e. draining the 
site of immunisation) were removed and placed into 35 ml of preparation medium (Hank’s 
balanced salt solution (HBSS) without calcium or magnesium, 2 % heat inactivated FCS, 10 
mg/ml gentamicin (Sigma Aldrich, Dorset, UK), 200 IU/ml penicillin and 200 µg/ml 
streptomycin). Single cell suspensions were then prepared as detailed in Chapter 3. 
Cells were then either used immediately for ELISpot and Lymphocyte stimulation assays, or 
cryopreserved by re-suspending in Hi-FCS containing 10 % (vol/vol) dimethylsulfoxide 
(DMSO; Sigma-Aldrich) and freezing in a CoolCell® FTS30 (BioCision, California, USA) 
before longer-term storage in liquid nitrogen. 
4.2.5  Lymphocyte stimulation assays (LSA) 
 
Assays were performed as described in chapter 3 except cells were stimulated with OVA (10 
μg/ml), Concanavalin A (Con A; 10 μg/ml [Sigma-Aldrich]) or an equivalent volume of PBS 
(unstimulated control) in RPMI 1640 (Invitrogen) containing 10 % Hi-FCS, 2 mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 50 μM 2-mercaptoethanol for 





the triplicate CPM for each stimulant by the mean of the corresponding unstimulated (PBS) 
controls. 
4.2.6  Antibody Secreting Cell probe (ASC) generation 
 
Probes were generated as described in Chapter 3. 
4.2.7  Quantification of OVA-specific antibody responses by 
Enzyme Linked Immunosorbent assay (ELISA) 
 
Responses were determined following a protocol described previously161 using antibodies 
listed in Table 10. All wash steps were 5 washes with wash buffer (PBS with 0.05 % 
Tween20) and all incubation steps were 1 hour at 37 oC unless stated otherwise. Immulon 
2HB 96 well MicroTitre plates (Thermo Electron Corporation, Milford, USA) were coated 
with 50 µl low-endotoxin ovalbumin (EndoGrade® Ovalbumin, Hyglos GmbH, Bernried am 
Starnberger See, Germany) at 1 µg/ml diluted in 0.05 M carbonate buffer (1.59 g Na2C03, 
2.93 g NaHCO3 made up to 1 L in dH2O, pH 9.6) and incubated overnight at 4 oC. Plates 
were washed and then incubated with 100 µl of blocking buffer (PBS with 3 % fish gelatine 
[Sigma-Aldrich]) to reduce non-specific antibody binding. Plates were washed again and 50 
µl of the samples were added to each well in the plate in duplicate as follows; ASC probes 
generated from PsLN cells were added to the plate undiluted; serum samples were added 
1:100 for OVA- specific IgG1 and 1:4 for OVA-specific IgG2. The optimum sample dilutions 
were determined following serial dilution of representative samples from each group to 
ensure that the colour reaction at an optical density (OD) at 492 nm for the sample was on 
the linear part of the curve. Plates were incubated for 1 hour and then washed again; 50 µl of 
secondary antibodies (mouse anti-bovine IgA monoclonal antibody (mAb) (clone K84.2F9), 
anti-bovine IgG1 mab (clone K37.2G6) or anti-bovine IgG2 mab (clone K192.4F10) (all 
mabs from AbD Serotec, Oxford, UK) were added and again the plates were incubated for 1 
hour. Plates were washed again, 50 µl of monoclonal rat anti-mouse IgG1 conjugated to HRP 
(LO-MG1-2, AbD Serotec) was added and the plates incubated for 1 hour. Plates were 
washed and developed using 100 µl per a well of o-phenylenediamine dihydrochloride 
(OPD) and stopped after 12 minutes with 25 µl per well of stop solution (2.5M H2SO4). The 





The final OD was calculated by normalising the OD to the average plate blank control OD, 
and inter-plate variation was normalised to the OD of a positive control sample. 
4.2.8  Cytokine ELISAs 
 
Levels of OVA specific IFN-γ and IL-10 in supernatants collected from LSAs after 4 days of 
stimulation were quantified by ELISAs. All ELISAs were performed using Immulon 2HB 96 
well MicroTitre plates (Thermo Electron Corporation, Milford, USA). All plates were read at 
450 nm using the Tecan plate reader (Dynex Technology, Worthing, UK) and OVA specific 
response determined by removing background levels of cytokines determined in cells 
cultured in medium supplemented with PBS only. All samples were run in duplicate wells 
and a standard curve run on every plate. The details of the antibodies used in the cytokines 
ELISAs and their dilutions are in Table 10.  
IFN-γ ELISAs 
A commercially available kit was used (Bovine IFN-γ ELISA kit [HRP], 3119-1H-6, 
MabTech, Nacka strand, Sweden) following the manufacturer’s instructions. Briefly, plates 
were coated with 50 µl of primary antibody (mouse anti-bovine IFN-γ; clone MT17.1) and 
incubated overnight at 4 oC. Plates were then washed, and incubated with 100 µl of wash 
buffer with 0.1 % BSA (incubation buffer) for 1 hour to reduce non-specific binding. Plates 
were washed again; samples (diluted 1 in 4, with incubation buffer) and standards (50 µl) 
were added to the plate and incubated for 2 hours. Plates were washed and 50 µl mouse anti-
bovine IFN-γ (clone MT307b) was added to the plate and incubated for 1 hour. Plates were 
washed and then incubated with 50 µl of Streptavidin-HRP (MabTech, Nacka strand, 
Sweden) for 1 hour. Plates were washed and developed with 100 µl of 3,3',5,5'-
tetramethylbenzidine (TMB) substrate (KPL SureBlue TMB peroxidase substrate, Insight 
technologies, London, UK); the reaction was stopped with 50 µl of TMB stop solution.  
IL-10 ELISAs 
Plates were coated with 50 µl of primary antibody (mouse anti-bovine IL-10; clone CC318) 
diluted in 0.05 M carbonate coating buffer and incubated overnight at 4 oC. All wash steps 
were 6 washes with 200 µl of wash buffer and incubation steps 1 hour at room temperature 





(PBS with 1 % BSA). Plates were washed just twice with wash buffer. A standard curve of 
recombinant bovine IL-10 (kindly provided by Mr Sean Wattegedera, Moredun Research 
Institute) was added to each plate, with all samples diluted 1 in 4 (50 µl per well). After 
incubation, wells were washed and then incubated with 50 µl of secondary antibody (mouse 
anti-bovine IL-10 biotinylated; clone CC320). Plates were washed and then incubated with 
50 µl per well of streptavidin-HRP (P0397, Dako, Ely, UK) at room temperature for 45 
minutes. Plates were washed and then developed with 100 µl per well of TMB substrate; the 
reaction was stopped with 50 µl per well of TMB stop solution.  
4.2.9  Bovine IFN-γ ELISpot 
 
A commercially available kit was used (ELISpot for Bovine IFN-γ; 3119-2HW-plus; 
MabTech, Nacka strand, Sweden) following the manufacturer’s instructions. Briefly, PBMC 
were stimulated with complete culture media containing either PBS, OVA (10 μg/ml) or 
ConA (10 μg/ml) for 18 hours at 37 oC and 5% CO2 before addition to hydrophobic PVDF 
membrane ELISpot plates (Merck Millipore, Nottingham, UK) in duplicate wells at either 2 
×105 cells per well or 2 ×104 cells per well. Following a further 24 hours incubation at 37  oC 
and 5 % CO2, cells were washed off and spots developed by addition of ELISpot TMB 
substrate; spots per well were quantified automatically using an ELISpot reader (AID 
ELISpot reader version 4, Autoimmun Diagnostika Gmbh, Strasberg, Germany). To 
determine numbers of OVA-specific IFN-γ producing cells, the mean number of spots per 
well from unstimulated duplicate cultures were subtracted from those obtained from OVA-









Table 10: Monoclonal antibodies used in ELISAs to detect cytokines and OVA specific 
antibodies. 
Reactivity Host/Clone Isotype Conjugate Supplier Dilution 
Bovine IgA Mouse/ 
K84.2F9 
IgG1 None AbD Serotec 
(MCA628) 
1 in 1000 
Bovine IgG1 Mouse/ 
K37.2G6 
IgG1 None AbD Serotec 
(MCA627) 
1 in 1000 
Bovine IgG2 Mouse/ 
K192.4F10 
IgG1 None AbD Serotec 
(MCA626) 
1 in 1000 
Mouse IgG1 Rat/ 
LO-MG1-2 
IgG HRP AbD Serotec 
(MCA336P) 


























IgG2a Biotin MabTech (3119-
6) 








4.2.10 Flow cytometry to detect OVA-specific 
CD25+CD4+ and CD25+CD8+ T-cells in PsLN 
 
For flow cytometric analysis of leukocyte population, PsLN cells were seeded at 2 × 105 
cells per well into 96 well round bottom plates. Triplicate wells for each animal were 
stimulated with OVA (10 μg/ml), Con A (10 μg/ml [Sigma-Aldrich]) or an equivalent 
volume of PBS (unstimulated control) in RPMI 1640 (Invitrogen, Paisley, UK) containing 
10 % Hi-FCS, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 50 μM 
2-mercaptoethanol. Plates were incubated for 5 days at 37 oC at 5 % CO2. Cell were 
harvested and antibody labelling was performed in 96-well round bottomed plates as 
follows: cells were washed once with flow cytometry buffer (PBS + 5 % Hi FCS + 0.02 % 
sodium azide) before incubation for 30 minutes at 4 oC  with the following pairs of 
monoclonal antibodies: anti-bovine CD4 plus anti-bovine CD25 or anti-bovine CD8 plus 
anti-bovine CD25. Additional cells were also incubated in parallel with each antibody 
separately to act as Fluorescence Minus One (FMO) controls, or with appropriate isotype 
controls. Cells were pelleted by centrifugation at 1,200 rpm for 1 minute and washed twice 
with flow cytometry buffer. Cells were then incubated with both anti-mouse IgG1 conjugated 
to Alexa Fluor® 647 and anti-mouse IgG2a conjugated to Alexa Fluor® 488 for 30 minutes 
at 4 oC. Cells were pelleted and washed twice with flow cytometry buffer and finally re-
suspended in PBS. Immediately prior to analysis, SYTOXTM Blue Nucleic acid stain 
(ThermoFisher Scientific, Loughborough, UK) was added to cells to discriminate live and 











Table 11: Antibodies used in flow cytometry to detect cellular responses. 
Reactivity Clone/ 
Host 
Isotype Conjugate Supplier Dilution 
Bovine CD8 IL-A105 IgG2a None Tim Connelley215  1:4000 
Bovine CD4 Il-A12 IgG2a None Tim Connelley216  1:4 
Bovine 
CD25 
IL-A111 IgG1 None AbD Serotec 1:200 
Mouse IgG1 Goat N/A AlexaFlour®647 AbD Serotec 1:2000 
Mouse IgG2a Goat N/A AlexaFlour®488 AbD Serotec  1:2000 
Isotype 
control 
Mouse IgG1 None AbD Serotec 1:50 
Isotype  
control 
Mouse IgG2a None AbD Serotec 1:50 
 
Cells were analysed on a MACS Quant flow cytometer (Miltenyi Biotec, Surrey, UK) and 
the data was analysed using Flow Jo software version 10 (FlowJo, Ashland, USA). Figure 33 
panel A demonstrates lymphocyte gating by side and forward scatter, doublets were 
discriminated as in Figure 33 panel B and dead cells were discriminated by fluorescence in 
the VioBlue channel by SYTOXTM Blue staining as in Figure 33, panel C. Gating for 
antibody labelling of bovine CD4, CD8 and CD25 was set using fluorescence minus one 
(FMO) stained cells as detailed in Figure 34. OVA-specific activation was expressed as the 
fold change in the percentage of CD4+CD25+ and CD8+CD25+ cells in OVA-stimulated cells 






Figure 33: The gating strategy used to determine single live lymphocytes for the 
quantitation of activated (i.e. CD25+) CD4+ and CD8+ pre-scapular lymph node cells by 
flow cytometry. A, is pulse area and H, is maximum pulse amplitude (height). Numbers 
represent the percentage of events in each gate. Figure A is all the events captured by 
the flow cytometer, the gate is lymphocytes captures, B is the events sitting in the 
lymphocyte gate in panel A and the gate captures single lymphocytes and allows 
discrimination against doublets; and C is the events sitting in the single cells gate in 
panel B, the gate represents live cells discriminated versus dead cells by SYTOX™ Blue 






Figure 34: Fluorescence minus one controls of stained pre-scapular lymph node cells. A 
is pulse area. Events are pre-gated for lymphocytes, singles and live cells (except C). 
Numbers represent the percentage of events in each gate. Cytometer channels are FITC 






4.2.11  Statistical analyses 
 
Mixed model statistical analysis and the combined analysis of Trial 1 and Trial 2 data was 
performed using R version 10 by Dr Javier Palarea (Biomathematics and Statistics Scotland; 
BioSS). For each STEC O157 strain (PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 
Stx2a+Stx2c+) the data was analysed separately, comparing OVA immune responses from 
challenged and immunised animals (C-I) with the appropriate unchallenged and immunised 
(I-only) or challenged only animals (C-only). The OVA-specific lymphocyte stimulation 
index data from PBMC was analysed by log transforming the OVA-specific stimulation 
index and then a generalised additive model (GAM) with identity link function and Gaussian 
errors was fitted by restricted maximum likelihood (REML) to allow investigation of the 
effect of treatment (STEC challenge and/ or OVA-immunisation) on stimulation index over 
the duration of the experiment. It included treatment as fixed effect and spline-based smooth 
terms (one per treatment) to fit the non-linear relationships of the response with time. 
Heterogeneous variances by treatment were allowed. Pair-wise linear hypotheses tests were 
subsequently used to compare between treatments and FDR corrections.  
ELISpot (OVA specific IFN-γ releasing cells) data was analysed by log transformation of the 
OVA-specific spot forming units per 106 +1. A random intercept mixed model including 
treatment, time and their interaction as fixed effect and animal as random effect was fitted 
using REML. An exponential within group variance structure over time was considered to 
model non-homogenous variances between treatment groups. Again pair-wise linear 
hypotheses tests were subsequently used to compare between treatments and FDR 
corrections. 
A GAM with identity link function and Gaussian errors was fitted by REML to investigate 
the effect of treatment on the OVA-specific IgG1 and IgG2 antibody levels in serum over 
time and the systemic OVA-specific IL-10 responses over time. It included treatment as 
fixed effect an spline-based smooth terms to fit the non-linear relationships of the response 
with time. Heterogeneous variances by group were allowed. 
Data originating from PsLN cells and ASC probes were analysed with each trial using non-
parametric tests using GraphPad prism (Version 7, La Jolla, USA). For Trial 1 where > 2 





comparisons tests if the overall p-value was < 0.05. For Trial 2 in which only two treatment 
groups existed, a Mann-Whitney U test was employed.  
Finally, a combined analysis of some of the PsLN data from the first PT21/28 Stx2c+ trial 
and the second PT21/28 Stx2c+ trial was performed by Dr Javier Palarea using a two-way 
ANOVA approach of the log transformed response data to look for interactions between the 
repeats of the PT21/28 Stx2c+ trials. Treatment and trial were the main effects and the 
interaction between the two trials was analysed.  






4.3  Results  
4.3.1  Trial 1- Bacterial shedding 
 
Individual shedding curves for each calf orally challenged with STEC O157 are shown in 
Figure 35. All calves were shedding greater than 103 CFU/g faeces for the first three days 
post oral challenge and continued to shed for at least 7 days. These results confirm that the 
subsequent immunological analyses were conducted on successfully colonised calves and the 
calves were colonised with STEC O157 when the primary OVA immunisation was 
administered at day 5. All faecal samples from un-challenged control calves were negative 







Figure 35: Faecal shedding curves of STEC O157 after experimental challenge of 
weaned calves. Six or seven calves in each trial were orally challenged once with ~109 
CFU of STEC O157 (PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+ Stx2c+) 
indicated by the black arrow. Calves were immunised with OVA plus Quil A via the 
subcutaneous route on two separate occasions indicated by the open arrows. For each 
strain, two calves received Quil A alone. The shedding data is expressed as log10 CFU/g 
faeces + 1. Each curve represents an individual animal. The grey symbols represent 
calves that were challenged only and the black symbols calves which were both OVA 





4.3.2  Trial 1- Systemic OVA-specific cellular immune 
responses 
 
Figure 36 demonstrates OVA-specific cellular immune responses in calves challenged with 
either PT21/28 Stx2c+, PT32 Stx2c+ or PT21/28 Stx2a+Stx2c+ STEC O157 strains. Overall 
for the PT21/28 Stx2c+ strain, there was a statistically significant difference in OVA-specific 
proliferation between the three treatment group (p = 0.0023); subsequent pairwise testing 
revealed statistically significant differences between challenged only (C-only) and 
immunised only (I-only) groups (p = 0.0006) but not between I-only and challenged and 
immunised (C-I) groups (p = 0.1054) or C-I and C-only (p = 0.1873). Overall for the PT32 
Stx2c+ strain, there was a statistically significant difference in OVA-specific proliferation 
between the three treatment groups (p < 0.0001); subsequent pairwise testing revealed no 
statistically significant differences between the I-only and C-I groups (p = 0.2468), there was 
a statistically significant difference between the C-I and C-only groups (p < 0.0001) and also 
between the C-only and I-only groups (p < 0.0001). Overall for the PT21/28 Stx2a+Stx2c+ 
strain there was a statistically significant difference in OVA-specific proliferation between 
the three treatment groups (p < 0.0001); subsequent pairwise testing revealed no statistically 
significant differences between the I-only and C-I groups (p = 0.0608), there was a 
statistically significant difference between the C-I and C-only groups (p < 0.0001) and also 
between the C-only and I-only groups (p < 0.0001).  
Overall for the PT21/28 Stx2c+, there was no statistically significant difference in OVA-
specific IFN-γ spot forming units between the three treatment groups (p = 0.4487). Overall 
for the PT32 Stx2c+ strain, there was a statistically significant difference in OVA-specific 
IFN-γ sport forming units between the three treatment groups (p = 0.0034); subsequent 
pairwise testing revealed no significant differences between the I-only and C-I groups (p = 
0.2559), there was a statistically significant difference between the C-I and C-only groups (p 
= 0.0264) and no statistically significant difference between the C-only and I-only groups (p 
= 0.1089). Overall for the PT21/28 Stx2a+Stx2c+ strain, there was a statistically significant 
differences in OVA-specific IFN-γ spot forming units between the three treatment groups (p 
= 0.0171); subsequent pairwise comparisons revealed no significant differences between the 
I-only and C-I groups (p = 0.1476), there was a statistically significant difference between 






OVA-specific systemic IL-10 cytokine levels were determined by ELISAs in supernatants 
collected from OVA-stimulated PBMC from calves challenged with PT21/28 Stx2c+, PT32 
Stx2c+ and PT21/28 Stx2a+Stx2c+ STEC O157 strains. The results are shown in Figure 37. 
Overall for the PT21/28 Stx2c+ strain, there was a statistically significant difference in 
OVA-specific IL-10 between the three treatment group (p = 0.0013); subsequent pairwise 
testing revealed statistically significant differences between challenged only (C-only) and 
immunised only (I-only) groups (p = 0.0004) but not between I-only and challenged and 
immunised (C-I) groups. Overall for the PT32 Stx2c+ strain, there was no statistically 
significant difference in OVA-specific IL-10 between the three treatment groups (p = 
0.1080). Overall for the PT21/28 Stx2a+Stx2c+ strain there was a statistically significant 
difference in OVA-specific IL-10 between the three treatment groups (p < 0.0001); 
subsequent pairwise testing revealed statistically significant differences between all three 
treatment groups, C-I versus C-only (p = 0.0002), C-I versus I-only (p = 0.0231) and also C-
only versus I-only (p < 0.0001). The C-I group had generally lower OVA-specific IL-10 






Figure 36: OVA-specific lymphocyte proliferation and bovine IFN-γ spot forming units 
in PBMC prepared at weekly time points throughout the PT21/28 Stx2c+ (A and B), 
PT32 Stx2c+ (C and D) and PT21/28 Stx2a+Stx2c+ (E and F) challenge experiments 
within trial 1. For each strain, calves were STEC O157 challenged and OVA 
immunised (Challenged + immunised), STEC O157 challenged but not immunised 
(Challenged only) or unchallenged but OVA immunised (Immunised only). 
Proliferation (A, C and E) determined by a lymphocyte stimulation assay is expressed 
as stimulation indices, representing fold changes in the response to OVA from levels 
with the relevant PBS control. Bovine IFN-γ releasing cells were determined by bovine 
IFN-γ ELISpot (B, D and F) and expressed as spot forming units per 106 cells in 
response to OVA, responses of non-stimulated (PBS) cultures were subtracted before 
the data was analysed. The circles represent the mean and errors bars the standard 
error of the mean (SEM). Black arrows represent STEC O157 challenge and open 







Figure 37: OVA-specific IL-10 release from PBMC prepared at weekly time points 
throughout the PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+ challenge 
experiments within trial 1. For each strain calves were STEC O157 challenged and 
OVA immunised (Challenged + immunised), STEC O157 challenged but not 
immunised (Challenged only) or unchallenged but OVA immunised (Immunised only). 
PBMC were stimulated with OVA or PBS for 4 days and levels of OVA-specific IL-10 
release determined at day 5 by ELISA, OVA-specific response were calculated by 
subtracting background IL-10 amounts (PBS stimulated) from OVA stimulated levels. 
The black arrows represent STEC O157 challenge and the open arrows OVA 
immunisations. Black symbols represent challenged and OVA immunised calves (C-I), 
black open symbols calves that were only OVA immunised (I) and grey symbols calves 
that were STEC O157 challenged but not OVA immunised (C). The symbols represent 








4.3.3  Trial 1- OVA-specific systemic antibody responses 
 
Figure 38 compares systemic OVA-specific IgG1 and IgG2 antibody responses in calves 
challenged with PT21/28 Stx2c+, PT32 St2xc+ and PT21/28 Stx2a+Stx2c+ STEC O157 
strains. Overall for the PT21/28 Stx2c+ strain, there was a statistically significant difference 
in mean OVA-specific IgG1 responses between the three treatment groups (p < 0.0001); 
subsequent pairwise analysis revealed significant differences between I-only and C-I groups 
(p = 0.0008), C-I and I-only groups (p < 0.0001) and also C-only and I-only groups (p = 
0.0228). Overall for the PT21/28 Stx2c+ strain, there was a statistically significant difference 
in mean OVA-specific IgG2 responses between the three treatment groups (p = 0.0001); but 
subsequent pairwise analysis did not reveal any statistically significant differences between 
the I-only and C-I groups (p = 0.1692), there was a statistically significant difference 
between the C-I and C-only groups (p = 0.0003) and also between the C-only and I-only 
groups (p = 0.112). 
Overall for the PT32 Stx2c+ strain, there was no statistically significant difference in mean 
OVA-specific systemic IgG1 (p = 0.2810) or IgG2 (p = 0.1180) between the three treatment 
groups. Overall for the PT21/28 Stx2a+Stx2c+ strain there was a statistically significant 
difference in mean OVA-specific systemic IgG1 (p < 0.001) between the three treatment 
groups; subsequent pairwise comparisons did not reveal any statistically significant 
differences between the I-only and C-I groups (p = 0.6290), there was a statistically 
significant difference between the C-I and C-only groups (p = 0.0014) and also between the 
C-only and I-only groups (p < 0.0001). Overall for the PT21/28 Stx2a+Stx2c+ strain there 
was no statistically significant difference in mean OVA-specific systemic IgG2 (p = 0.5010) 







Figure 38: OVA-specific antibody levels in serum prepared at weekly time points 
throughout the PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+ challenge 
experiments within trial 1. Calves were STEC O157 challenged and OVA immunised 
(Challenged + immunised), STEC O157 challenged but not immunised (Challenged 
only) or unchallenged but OVA immunised (Immunised only). The OVA specific 
antibody levels were determined by ELISA for each isotype (IgG1 or IgG2) and are 
expressed as the mean optical density (OD) at 492 nm of duplicate wells normalised to a 
positive control sample. The symbols represent the mean for each group and error bars 
the SEM. Black arrows represent the oral STEC O157 challenge and open arrows OVA 
immunisations. 
 
4.3.4  Trial 1- PsLN OVA-specific immune responses 
 
Figure 39 indicates OVA-specific proliferation in cells from the PsLN. There was an overall 
statistically significant difference between the three treatment groups for the PT21/28 Stx2c+ 
trial OVA-specific lymphocyte proliferation (p = 0.0464), with mean proliferation being 
highest in the C-I group and similar between I-only and C-only groups; there was no 
statistically significant difference between the C-I and I-only group following pairwise 
comparisons. The PT32 Stx2c+ calves also followed the same trends but there were no 
statistically significant differences (p = 0.3921) between the three treatment groups. In the 
PT21/28 Stx2a+Stx2c+ experiment the three treatment groups showed no statistically 






Figure 39: OVA-specific proliferation in bovine lymph node cells isolated post mortem 
from the PsLN. Calves were STEC O157 challenged and OVA immunised (Challenged 
+ immunised), STEC O157 challenged but not immunised (Challenged only) or 
unchallenged but OVA immunised (Immunised only). Proliferation was determined by 
a lymphocyte stimulation assay and is expressed as stimulation index, representing 
changes in the response to OVA from levels with the relevant PBS control. Symbols 
represent individual animals within the experiments within trial 1, black symbols are 
challenged and immunised calves (C-I), clear symbols OVA immunised only (I) and 
grey symbols challenged only calves (C). Error bars represent median and IQR of the 
group. The p-values were determined by Kruskal-Wallis H test for differences between 
the treatments (for each strain) and are expressed as overall p-values. 
 
Figurse 40 and 41 shows the gating strategy for flow cytometry used to determine activated 
(CD25+) CD4+ and CD8+ T-cells in the PsLN cells following ex vivo stimulation with OVA. 
Figure 42 shows OVA-specific CD4+CD25+ and CD8+CD25+ cells in the PsLN. Overall for 
the PT21/28 Stx2c+ experiments, there was a statistically significant difference between the 
three treatment groups in the number of OVA-specific PsLN CD8+CD25+ cells (p = 0.0364); 
subsequent pairwise comparisons showed no significant differences between I-only and C-I 
groups, however the trend was for a more OVA-specific CD8+CD25+ cells in the C-I group 
compared to the I-only group. Overall for the PT32 Stx2c+ strain, there was no statistically 
significant differences between the three treatment groups in the OVA-specific pre-scapular 
CD8+CD25+ cells (p  = 0.1482). Overall for the PT21/28 Stx2a+Stx2c+ strain, there was no 
statistically significant differences between the three treatment groups in the OVA-specific 





There were no statistically significant differences between the OVA-specific pre-scapular 
CD4+CD25+ cells, in either the PT21/28 Stx2c+ (p = 0.0641), PT32 Stx2c+ (p = 0.0628) or 



























Figure 40: Gating strategy used to determine single live activated (i.e. CD25+) CD4+ or 
CD8+ pre-scapular lymph node cells by flow cytometry. Figure A is all the events 
captured, the gate is lymphocytes, figure B is lymphocytes captured and the gate 
captures single lymphocytes. Figure C is the events sitting in the single cell gate and the 
gate represents live cells discriminated versus dead cells by SYTOXTM Blue staining 
(fluorescence in the VioBlue channel). Figures F, G, H and I are FMO controls. Figure 
F is SYTOX Blue FMO. Figures D, E, G, H and I capture events gated for single, live 
lymphocytes, they are cells stimulated with ConA and subsequently labelled for surface 
expression of CD25 (with APC) and either CD4 or CD8 (FITC). Figure G is FMO for 
CD4 and CD8, H is FMO for CD25 (with CD4 labelling) and I is FMO for CD25 (with 







Figure 41: Representative flow cytometry histograms and density dot plots of CD25 
expression on PsLN cells stimulated ex vivo for 5 days with Ovalbumin (OVA), 
Concanavalin A (ConA) or PBS. (A) histogram of cells from a single animal that have 
been pre-gated for lymphocytes, single and live cells, stimulated with PBS, ConA or 
OVA and subsequently labelled for surface expression of CD25 (with APC). (B) Dot 
plot of cells stimulated with ConA and subsequently labelled for surface expression of 
CD25 (with APC) and CD4 (with FITC). (C) Dot plot of cells stimulated with ConA and 
subsequently labelled for surface expression of CD25 (with APC) and CD8 (with 






Figure 42: Levels of OVA-specific activated CD4+ and CD8+ T-cells in re-stimulated 
bovine PsLN cells isolated at post mortem. Calves were STEC O157 challenged and 
OVA immunised (Challenged + immunised), STEC O157 challenged but not 
immunised (Challenged only) or unchallenged but OVA immunised (Immunised only). 
Cells were stimulated for 5 days with OVA or PBS and the activation status of CD4+ 
and CD8+ cells evaluated by surface expression of CD25, as determined by flow 
cytometry. OVA-specific activation as expressed as a fold change in double positive 
cells in OVA-stimulated cells compared to PBS stimulated controls. Symbols represent 
individual animals within the trial, black symbols are challenged and immunised calves 
(C-I), clear symbols OVA immunised only (I) and grey symbols challenged only calves 
(C). Error bars represent median and IQR of the group. The p-values were determined 
by Kruskal-Wallis H test for differences between the treatments (for each strain) and 






The OVA specific cytokine release from ex vivo stimulated PsLN cells was determined 
(Figure 43). Overall for the PT21/28 Stx2c+ strain, there was a statistically significant 
difference in OVA-specific IFN-γ release from stimulated PsLN cells between the three 
treatment groups (p = 0.0208); subsequent pairwise testing showed there was a statistically 
significant difference between the C-I and the I-only group (p = 0.0355) with more OVA 
specific IFN-γ released in the C-I compared to the I-only group. Overall for the PT32 Stx2c+ 
strain, there was no statistically significant difference in OVA-specific IFN-γ release from 
stimulated PsLN cells between the three treatment groups (p = 0.1042). Overall for the 
PT21/28 Stx2a+Stx2c+ strain, there was no statistically significant difference in OVA-
specific IFN-γ release from stimulated PsLN cells between the three treatment groups (p = 
0.1463). There were no statistically significant differences in OVA-specific IL-10 released 
from stimulated PsLN cells between the three treatment groups in either the PT21/28 Stx2c+ 







Figure 43: OVA-specific releases of bovine cytokines (IL-10 and IFN-γ) were 
determined by ELISA in supernatants from PsLN node cells stimulated for 5 days ex 
vivo with OVA. Calves were STEC O157 challenged and OVA immunised (Challenged 
+ immunised), STEC O157 challenged but not immunised (Challenged only) or 
unchallenged but OVA immunised (Immunised only). Symbols represent individual 
animals within the trial, black symbols are challenged and immunised calves (C-I), 
clear symbols OVA immunised only (I) and grey symbols challenged only calves (C). 
Error bars represent median and IQR of the group. The p-values were determined by 
Kruskal-Wallis H test for differences between the treatments (for each strain) and are 





OVA-specific antibody levels were determined from antibody secreting cell probes 
generated from the PsLN cells (Figure 44). There were no statistically significant differences 
in OVA-IgA, OVA-IgG1, or OVA-IgG2 between C-I, I-only or C-only treatment for any of 
the three STEC O157 strains, although for the PT21/28 Stx2c+ strain, OVA-IgG1 responses 
followed the same trend as seen with the serum antibody responses, being higher in the C-I 









Figure 44: OVA-specific IgA, IgG1 and IgG2 antibody levels in antibody secreting cell probes generated from PsLN cells. Calves were STEC 
O157 challenged and OVA immunised (Challenged + immunised), STEC O157 challenged but not immunised (Challenged only) or 
unchallenged but OVA immunised (Immunised only). Antibody levels determined by ELISA are expressed as the mean OD at 492 nm of 
duplicate wells normalised to a positive control sample. Symbols represent individual animals within the trial, black symbols are challenged 
and immunised calves (C-I), clear symbols OVA immunised only (I) and grey symbols challenged only calves (C). Error bars represent 






4.3.5  Trial 2 
 
The results from Trial 1 indicated a marginally statistically significant difference between 
the three treatment groups (C-I, I-only and C-only) in OVA-specific lymphocyte 
proliferation, OVA-specific IFN-γ release, OVA-specific CD8+CD25+ cells and anti-OVA 
IgG1 in the PsLN cells in the PT21/28 Stx2c+ challenge. With a trend for increase in these 
OVA-specific responses in the C-I treatment group compared to both the I-only and C-only 
group with the PT21/28 Stxc2+ challenge. This suggested that colonisation with the PT21/28 
Stx2c+ resulted in enhancement of OVA-specific immune responses in the PsLN. To 
validate these results, the trial was repeated.  
Daily bacterial shedding by calves in the second PT21/28 Stx2c+ trial is shown in Figure 45. 
These results confirmed that the subsequent immunological analyses were conducted on 
successfully colonised calves and the calves were colonised when the primary OVA 
immunisation was administered at day 5. All faecal samples from un-challenged control 








Figure 45: Faecal shedding curves of STEC O157 after experimental infection of 
weaned calves in the second PT21/28 Stx2c+ trial. Six calves were orally challenged 
with STEC O157 PT21/28 Stx2c+ indicated by the black arrow. The calves were also 
OVA immunised by subcutaneous injection on two separate occasions indicated by the 
open arrows. The shedding data is expressed as log10 CFU/g faeces+ 1. Each curve 
represents an individual animal.  
4.3.6  Trial 2- Systemic OVA-specific immune responses 
 
Figure 46 shows systemic OVA-specific IFN-γ release and lymphocyte proliferation of 
PBMC, and serum levels of OVA-specific IgG1 and IgG2 antibody responses in calves from 
PT21/28 Stx2c+ Trial 2. There was no statistically significant difference between treatments 
in the OVA-specific bovine IFN-γ (p = 0.0682, Figure 46 A). There was also no significant 
difference in the mean log (stimulation index) between the treatment groups (p = 0.0982, 
Figure 46 B). However, these results showed a similar trend to PT21/28 Stx2c+ calves 
challenged with Trial 1 with the I-only group having a higher (but not significantly) OVA-
specific response than the C-I group.  
Serum OVA-specific circulating IgG1 antibody responses PT21/28 Stx2c+ are shown in 
Figure 46 C. A statistically significant difference between the C-I and the I-only group (p < 





statistically significant differences in serum OVA-specific IgG2 antibody levels were 
detected between the C-I or I only groups (p = 0.544, Figure 46 D). 
OVA specific IL-10 cytokine levels in supernatants collected from OVA stimulated PBMC 
from calves challenged with PT21/28 Stx2c+ in the second trial did not statistically 












Figure 46: OVA-specific lymphocyte proliferation, bovine IFN-γ spot forming units in 
PBMC and IgG1 and IgG2 levels in serum prepared at weekly time points throughout 
the second PT21/28 Stx2c+ trial. Six calves were orally challenged with PT21/28 
Stx2c+strain and OVA immunised (C-I) and six calves were OVA immunised only (I). 
Bovine IFN-γ positive cells were determined by ELISpot are expressed as spot forming 
units per 106 cells in response to OVA with the relevant background PBS controls 
subtracted (A); the circles represent the mean and error bars the SEM. OVA-specific 
proliferation (B) determined by a lymphocyte stimulation assay is expressed as indices, 
representing changes in response to OVA compared to non-stimulated cells. The OVA-
specific IgG1 (C) and IgG2 (D) were determined by ELISA and are expressed as the 
mean OD of duplicate wells normalised to a positive control sample. The circles 
represent the mean of the groups and the error bars the standard error of the mean (C 








Figure 47: OVA-specific IL-10 release from PBMC prepared at weekly time points 
throughout the PT21/28 Stx2c+ second challenge trial. Calves were STEC O157 
challenged and OVA immunised (Challenged + immunised) or unchallenged but OVA 
immunised (Immunised only). PBMC were stimulated with OVA or PBS for 4 days and 
levels of OVA-specific IL-10 release determined at day 5 by ELISA. OVA-specific 
responses were calculated by subtracting background IL-10 amounts (PBS incubated) 
from OVA stimulated levels. The black arrows represent STEC O157 challenge and the 
open arrows OVA immunisations. Black symbols represent challenged and OVA 
immunised calves (C-I) and black open symbols calves that were only OVA immunised 
(I). The symbols represent the mean for each group and the error bars the standard 
error of the mean (SEM). 
 
4.3.7  Trial 2- OVA-specific immune responses within PsLN 
 
PsLN cells were prepared from calves in the second PT21/28 Stx2c+ trial at post mortem to 
allow analysis of the local immune response to OVA immunisations (Figure 48). OVA-
specific lymphocyte proliferation of PsLN cells significantly differed between the two 
treatment groups with the C-I group showing higher OVA-specific lymphocyte proliferation 
than the I-only group (p = 0.0039, Figure 48 A). OVA-specific IgG1 antibody levels within 
ASC probes generated from the PsLNs were also statistically significantly different between 
the two treatment groups with the I-only group having higher OVA-specific IgG1 antibody 





Levels of OVA-specific CD4+CD25+ (activated CD4+ T-cells) PsLN cells were not 
significantly different between the two treatment groups (C-I and I-only) (p = 0.07817, 
Figure 48 C). In contrast, OVA-specific CD8+ CD25+ PsLN cells were significantly different 
between the groups (p = 0.0374), being higher in the C-I group higher compared to the I-
only group (Figure 48 D). 
 
Figure 48: OVA-specific proliferation, IgG1 levels, CD8
+ CD25+ and CD4+CD25+ T cells 
of bovine PsLN cells isolated post-mortem from calves in the second PT21/28 Stx2c+ 
trial and stimulated ex vivo for 5 days with OVA. Six calves were orally challenged with 
PT21/28 Stx2c+ and OVA immunised (C-I) and 6 calves were OVA immunised only (I). 
Proliferation (A) determined by a lymphocyte stimulation assay is expressed as indices, 
representing fold changes in the response to OVA from levels with the relevant non-
stimulated (PBS) control cultures. OVA-specific IgG1 antibody levels (B) determined by 
ELISA are expressed as normalised optical density (OD) at 492 nm. OVA-specific 
CD4+CD25+ cells (C) and OVA specific CD8+CD25+ cells (D) determined by flow 
cytometry are expressed as fold changes in response to OVA from levels with relevant 
non-stimulated controls. Error bars represent median and IQR. The p-values were 
determined from by Mann-Whitney U (non-parametric) test for differences between 






The OVA specific cytokine release from ex vivo stimulated PsLN cells was determined 
(Figure 49). In Trial 2 with the PT21/28 Stx2c+ strain, there was a statistically significant 
difference in OVA-specific IL-10 release from stimulated PsLN cells between the two 
treatment groups (p = 0.0022) with the challenged calves having significantly lower levels of 
OVA-specific IL-10. There was no statistically significant difference in OVA-specific IFN-γ 
release between the two treatment groups (p = 0.1797). 
 
Figure 49: OVA-specific bovine cytokine releases (IL-10 and IFN-γ) were determined 
by ELISA in supernatant from PsLN node cells stimulated for 5 days ex vivo with 
OVA. Calves were STEC O157 challenged and OVA immunised (Challenged + 
immunised) or unchallenged but OVA immunised (Immunised only). Symbols 
represent individual animals within the trial, black symbols are challenged and 
immunised calves (C-I) and clear symbols OVA immunised only (I). Error bars 
represent median and IQR of the group. The p-values were determined by Mann-
Whitney U test for differences between the two treatment groups. 
 
4.3.8  Combined analysis of Trial 1 and Trial 2 
 
In order to increase the statistical power of the analysis, some of the PsLN data relating to 
the PT21/28 Sx2c+ challenges in Trials 1 and 2 were combined and analysed together, with 
treatment and trial as main effects.  
The combined OVA-specific proliferation data from the two PT21/28 Stx2c+ trials were 
analysed using a two-way ANOVA of the log transformed data and an interaction plot is 
shown in Figure 50. This analysis identified a statistically significant difference between 





proliferation than the I-only in both trials. There was also a statistically significant difference 
in mean values between trials (p = 0.037), reflecting generally higher proliferative responses 
in Trial 2. 
Combined OVA-specific IgG1 data from ASC probes generated from both PT21/28 Stx2c+ 
trials were analysed together using a two-way ANOVA of the log transformed data and an 
interaction plot is shown in Figure 51. A statistically significant difference in mean OVA-
specific IgG1 in PsLN ASC probes was identified between the treatment groups (p = 0.0005); 
however a significant treatment × trial interaction was also identified (p < 0.0001). This 
reflected the different effects of colonisation with PT21/28 Stx2c+ strain on PsLN OVA-
specific IgG1 responses between the two trials, with OVA-specific IgG1 response in the C-I 
group being significantly higher than those in the I-only group in Trial 1, but lower in Trial 
2.  
Finally, combined PsLN OVA-specific CD4+CD25+ and OVA-specific CD8+CD25+ cell data 
from both of the PT21/28 trials was analysed and interaction plots are shown in Figure 52. 
For OVA-specific CD4+CD25+ cells, there was a statistically significant difference between 
the treatment groups (p = 0.04911) with OVA specific CD4+ CD25+ cells being marginally 
higher in the C-I group compared to the I-only group.  
For OVA-specific CD8+CD25+ cells, a significant effect of treatment (p = 0.0001) and trial 
(p < 0.0001) was identified but no treatment × trial interaction. This reflected an increase in 







Figure 50: Interaction plot of OVA-specific PsLN lymphocyte proliferation ex vivo of 
calves from both PT21/28 Stx2c+ challenge trials. Lymph node cells were isolated post-
mortem from the left hand side PsLN from calves and re-stimulated ex vivo for 5 days 
with OVA. OVA-specific lymphocyte proliferation was determined by a lymphocyte 
stimulation assay and is expressed as predicted mean log stimulation indices for each 






Figure 51: Interaction plot of OVA-specific IgG1 antibody responses of PsLN 
lymphocytes ex vivo of calves from both PT21/28 Stx2c+ challenge trials. IgG1 antibody 
levels were determined by ELISA and are expressed as the log of the normalised mean 
(of technical replicates) OD at 492 nm. The symbols represent the predicated mean of 










Figure 52: Interaction plots of OVA-specific CD4+CD25+ (A) and CD8+ CD25+ (B) cells 
from the PsLN of calves from both PT21/28 Stx2c+ challenge trials. OVA-specific 
CD4+ CD25+ cells (A) and OVA-specific CD8+CD25+ cells (B) determined by flow 
cytometry are expressed as log fold changes in OVA-stimulated cells compared to 
unstimulated controls. The symbols represent the predicted means of each group. Both 






4.4  Discussion  
 
The objective of this study was to characterise the effect of STEC O157 colonisation on the 
ability of calves to mount an immune response to a concurrently administered T-cell 
dependent antigen, OVA. Both systemic and local OVA-specific cellular and humoral 
immune responses were determined in groups of calves orally challenged with STEC O157 
and subsequently immunised with OVA and unchallenged calves immunised with OVA 
alone. Two different wild type strains (PT21/28 Stx2c+ and PT32 Stx2c+) were used for the 
STEC O157 challenges and also a genetically modified isogenic version of the PT21/28 
strain (Stx2a+Stx2c+) in which an insertion sequence (Isec8) was removed from the stx2a 
gene which allowed it to produce functional Stx2a. This enabled us to compare the effect on 
immune responses of two strains which differed only in their ability to produce Stx2a. The 
three challenge strains used in this study successfully colonised all of the orally challenged 
calves. 
OVA was used for the immunisations as it is a protein known to lead to significant specific 
cellular and humoral immune responses in calves208,209. This allowed us to monitor both local 
and systemic immune responses and to compare them between groups of STEC O157 
challenged and unchallenged control calves. In the first trial two calves in each STEC O157 
challenge group received no OVA, which allowed us to determine that the OVA specific 
responses detected in immunised calves were OVA-specific. Furthermore, as OVA shares no 
homology with known O157 antigens, any OVA-specific immune response detected could 
be attributed to the immunisations. Also, as natural exposure of cattle to OVA is unlikely, no 
maternal transfer of OVA-specific antibodies was likely to occur, which could have 
complicated the results217. 
It has been hypothesised that it is T-cell priming that is affected by Stx and not suppression 
of an already established T-cell response. A study demonstrated that PBMCs from stx-
negative E. coli O157 challenged calves developed proliferative responses to heat killed 
STEC O157 which also increased after re-challenge with a stx2-positive strain126. The same 
study also showed that PBMC from stx-positive E. coli O157 challenged calves did not 
develop consistent proliferative responses to heat killed STEC O157126, suggesting that Stx 
can block induction of cellular immune responses. Since calves initially challenged with a 
stx-negative strain generated proliferative responses to heat killed STEC O157 following stx-





priming of cellular immune responses and do not block the recall of existing antigen specific 
cellular responses126. Thus calves in this study had their primary immunisation with OVA 
five days after been orally challenged with STEC O157, so we would be able to demonstrate 
if there was an effect on priming of the OVA immune response.  
Systemic immune responses to OVA were determined by performing lymphocyte 
stimulation assays and bovine IFN-γ ELISpots on PBMC from the calves. IFN-γ producing 
cells were determined because in a previous study97 it was demonstrated that IFN-γ release in 
response to Concanavalin A (a non-specific T cell mitogen) and LPS were reduced in the 
PsLN of calves which were orally challenged with a PT32 Stx2c+ strain of STEC O157 
compared to PT21/28 Stx2c+ challenged calves and controls (unchallenged calves). Also the 
adjuvant Quil A used in this study has been previously shown to lead to an IFN-γ 
response218,219. There was a general trend in this study that the C-I calves, compared to the I-
only calves, had lower OVA-specific systemic cellular immune responses particularly with 
the PT21/28 Stx2c+ challenged calves which was different to the previous study by 
Corbishley et al. (2014) when the PT32 Stx2c+ strain challenge lead to lower IFN-γ release 
in response to ConA compared to PT21/28 Stx2c+ challenged calves. In this study we 
determined OVA-specific responses compared to non-specific T-cell mitogen stimulation in 
the previous study, which may account for the different results. Also there were no 
statistically significant differences between the C-I and I- only calves in any of the systemic 
OVA-specific cellular responses determined in this study. Due to logistical constraints, the 
timing of the OVA immunisation was short, with only two immunisations given two weeks 
apart, and the responses were only followed for one week post the second OVA 
immunisation. However other studies have shown that peak circulating T and B-cell 
responses occur around 1 week post-immunisation in cattle, and therefore one would have 
expected to see differences in the systemic cellular responses during this time-frame220.  
IL-10 is an immunoregulatory cytokine promoting anti-inflammatory responses by inhibition 
of certain cellular responses. In infections, IL-10 suppresses macrophages and dendritic cell 
function, and thus limits TH1 and TH2 effector cell responses221. It has been demonstrated in 
bovines that IL-10 signaling leads to lack of T-cell responsiveness in the acute phase of foot 
and mouth disease virus infections222. Thus we wanted to determine if systemic OVA-
specific IL-10 responses could be affected by concurrent STEC O157 colonisation in cattle. 
In Trial 1 there was significantly lower OVA-specific IL-10 release from ex vivo stimulated 
PBMC from PT21/28 Stx2a+Stx2c+ C-I calves compared to I-only calves. There was no 





followed the same trend. Similarly, there was no statistically significant difference in OVA-
specific IL-10 between C-I calves and I-only calves detectable in Trial 2. However in Trial 2 
the IL-10 values were higher in the I-only calves compare to the C-I calves, which does 
suggest that challenge with PT21/28 Stx2c+ reduces the IL-10 response to OVA which is 
potentially indicating an enhancement of the immune response.  
Compared to I-only controls, OVA-specific IgG1 serum antibody levels were significantly 
increased in the PT21/28 Stx2c+ C-I calves in the first trial but lower in the second PT21/28 
Stx2c+ trial, indicating significant variation in the humoral immune responses. The 
experimental protocols, bacterial strain and antigen were identical between the two trials but 
calves were sourced from different farms and therefore genetic and/or other environmental 
effects may have played a role.  
Systemic OVA-specific cellular immune responses showed some general trends implying 
that STEC O157 colonisation impairs such responses, although differences were not 
statistically significant. OVA-specific cellular responses may have been diluted by 
potentially low frequencies of circulating antigen-specific T-cells. Following sub-cutaneous 
immunisation antigen is presented in the draining lymph node and other secondary lymphoid 
tissue leading to an expansion of antigen-specific T-cells and re-circulation through the 
blood to effector sites178,223. Within PBMC these antigen-specific re-circulating lymphocytes 
can exist at very low frequencies224, which is likely to contribute to the high levels of 
variation in measurements of the OVA-specific T-cell responses within the PBMC in this 
study. This in turn may have accounted for the lack of observable differences in cellular 
responses between challenged and unchallenged calves.  
We hypothesised that it may be possible to determine differences between the treatment 
groups at the local lymph node due to increase in OVA-specific T-cells within the lymph 
node draining the site of immunisation. Analysis of immune responses in the left pre-
scapular lymph node (PsLN) revealed a significantly enhanced OVA-specific cellular 
immune response in the PsLN in calves challenged with the PT21/28 Stx2c+ strain and 
subsequently immunised with OVA compared to I-only controls. Using CD25 as a marker of 
T-cell activation225-228, it was shown that the enhanced cellular response was more 
pronounced for CD8+ T-cells compared to CD4+ T-cells. No similar enhancement in cellular 
immune responses were seen when calves were challenged with the other two STEC O157 
strains. 
In contrast to the enhancement of local cellular immune responses, local antibody responses 





enhanced in C-I calves compared to I-only controls in Trial 1 but the opposite was observed 
in Trial 2. The effects on B-cell responses in this study seem to be much less clear than any 
effect on T-cell responses, an observation which is consistent with another in vivo cattle 
study which indicates that T-cells are more affected by Stx than B-cells126. As OVA is a T-
cell dependent antigen and IgG1 is a class switched antibody169, OVA-specific IgG1 
responses are dependent on CD4+ T-cell help. Therefore differences in the effects of 
challenge on the local OVA-specific IgG1 response between the two trials may relate to 
differences in the response of B-cells and/or CD4+ cells. CD4 responses appeared to be 
enhanced in PT21/28 Stx2c+ challenged calves in both Trial 1 and Trial 2, suggesting that 
the differences in IgG1 responses were not due to differences in T-cell help. However, the 
OVA-specific cytokine release by local immune cells was more variable. There was a 
statistically significant difference in OVA-specific IFN-γ release in Trial 1 PT21/28 Stx2c+ 
challenge, but this was not repeated in Trial 2. There was no statistically significant 
difference in OVA-specific IL-10 release in Trial 1 with the PT21/28 Stx2c+ challenge but 
we did determine a statistically significant difference between the C-I and I-only calves in 
Trial 2 with the PT21/28 Stx2c+ challenge. The I-only calves had higher OVA specific IL-10 
levels than the C-I group. This agreed with the systemic OVA-specific IL-10 responses, both 
suggesting that STEC O157 challenge downregulates IL-10 responses, suggesting an 
enhancement effect on immunity. 
The differences between trial 1 and trial 2 with regards to OVA-specific IgG1 responses both 
systemically and locally were not seen with the EHEC specific antibody responses. The H7, 
Tir, Intimin and EspA specific antibody responses both systemically and locally were 
determined for the calves in both trial 1 (Chapter 3, Figures 27-31) and trial 2 (data not 
shown), the results were very similar for both trials with no contrasting results between the 
two trials as seen with the OVA specific IgG1 responses. This indicates that these opposing 
results are not generalised changes in antibody responses between calves in the two trials.In 
this study the PT21/28 Stx2c+ challenged animals showed a significant increase in OVA-
specific cellular responses in the local PsLN which was not demonstrated with the isogenic 
PT21/28 Stx2a+Stx2c+ strain. The wild-type PT21/28 Stx2c+ strain has an insertion 
sequence Isec8 within the Stx2a A subunit (which has been genetically removed from the 
PT21/28 Stx2a+Stx2c+ strain), which prevents the generation of functional Stx2a, as 
determined by a lack of in vitro verocytotoxicity (Dr Stephen Fitzgerald, personal 
communication). PCR analysis using primers specific to the B-subunit of stx2a and ELISA 
specific for the Stx2 B-subunit demonstrate, at least in vitro, that the B-subunit of Stx2a gene 





communication). The B-subunit of Stx has been shown to act as an adjuvant via direct 
interaction with antigen-presenting cells229,230.  
The genes for the A and B subunit of Stx are carried in the late region of lysogenic 
bacteriophages49. Once the bacterial SOS stress response triggers viral lytic replication of the 
bacteriophage, Stx transcription starts. A recent paper has demonstrated that the A and B 
subunit are not released as a holotoxin and that pre-assembly is not required for toxicity231. It 
is also believed that Stx, especially Stx2a, unlike other AB5 toxins, including cholera, have a 
decreased tendency to maintain an intact AB5 conformation. This seems to be due to a small 
hydrophobic patch in the central pore of the B pentamer which in other AB5 toxins is larger 
and plays a critical role in the assembly of the A subunit with the B pentamer232. In the 
absence of Stx A subunit the Stx B subunit can still adopt a pentameric structure that is 
functionally equivalent to the holotoxin in receptor binding233. The B subunit binds to the 
CD77 receptor initiating endocytosis and if the A subunit is present this leads to inactivation 
of protein synthesis and thus cell death. A study in mice has shown that the B-subunit of 
Stx1 can act as an adjuvant to subcutaneous OVA immunisations by eliciting antigen 
specific CD4 TH1 and TH2 type responses and the subsequent induction of antigen-specific 
IgG1 and IgG2a antibody responses229. Another study in mice using a StxB-OVA recombinant 
protein to stimulate splenocytes and then co-incubate with OVA-specific CD4+ T cells 
demonstrated both IL-2 and IFN-γ secretions were enhanced, indicating that a TH1 type 
response was induced by the B subunit230. It is possible that the enhanced OVA-specific 
cellular immune response seen with the wild type PT21/28 Stx2c+ strain in this current study 
is due to production and dissemination of the Stx2a B-subunit without an active (and toxic) 
A-subunit. This would explain the lack of any adjuvant effect with the repaired PT21/28 
strain as any Stx2a B-subunits would have an active A subunit, which would mitigate any 
immunostimulatory effects of the B-subunit via direct cytotoxic effects.  
This study indicates that colonisation with STEC O157 can alter local adaptive immune 
responses to a non-bacterial antigen, but this immunomodulation is strain dependent. 
Corbishley et al. (2015) previously demonstrated temporal differences in both STEC 
antigens (T3SPs) and non-antigen specific cellular responses (ConA) between the two STEC 
O157 wild type strains (PT21/28 Stx2c+ and PT32 Stx2c+) used in this study, again 
demonstrating the variable effect of immune regulation with different stx positive STEC 
O157 strains. This study demonstrates the variation in cellular and humoral immune 
responses to immunisations in individual cattle. Immunisations against a variety of bacteria 





frequently the herd response that enables the vaccine to work efficiently188,234. In this study a 
large bolus doses of STEC O157 were used to challenge the calves while natural infections 
in the field will involve intake of low doses over a longer period of time. Even with this large 
dose any differences seen in the immune responses to OVA in cattle challenged with STEC 
O157 were marginal and only demonstrated consistently at the local site of immunisation 
and not systemically. We hypothesised that STEC O157 would lead to suppression of OVA 
immune responses and in fact the only consistently significant results were an enhancement 
in the immune response. Others have previously hypothesised that any suppression of 
immune response by Stx is not generalised126, however contrasting results have previously 
indicated that the suppression may be more generalised97. Colonisation of cattle by different 
strains of STEC O157 may be contributing to some of the natural variation in individual 
animals we appreciate with immune responses to routine vaccinations and infections, but 
















Chapter 5  
Transcriptomic analysis of 
immune genes at the terminal 
rectum following experimental 
STEC O157 challenge 
5.1  Introduction  
 
Cattle are the main reservoir of STEC O157:H7 and it is known that the recto-anal junction 
(RAJ) is the primary site of colonisation within the bovine gastro-intestinal tract27. 
Colonisation of the rectal epithelium is thought to be initiated by the bacterial flagella (H7 
flagella) which form physical contact points with the rectal epithelial cells235. Once 
anchoring of the bacteria to the epithelium has occurred, flagellar expression is down-
regulated and other bacterial adhesion mechanisms such as the T3SS takes over. The T3SS is 
essential for colonisation of cattle as deletion of the LEE4 operon, which encodes for several 
T3SS proteins including the Esps (EPEC secreted proteins) A, B, D and F, SepL and EscF, 
completely abrogates colonisation32. Cattle which are either experimentally or naturally 
colonised with STEC O157 are able to control the infection over a number of days or weeks 
down to shedding levels undetectable by PCR and culture at several sampling points; 
however, the exact mechanism by which bacteria are cleared from the epithelium is unclear. 
As discussed in Chapter 2, antibodies against a number of STEC antigens are induced 
following exposure116,118,175; however, the presence of these antibodies is poorly correlated 
with protection against repeated STEC O157 exposure236,237. A recent study has shown that 
oral STEC O157 challenge results in an up-regulation of transcription of TH1 associated 
cytokines within the rectal mucosa and an increase in the proportion of CD4+ T-cells within 
the rectal lymph nodes, indicating that cattle mount a local cellular immune response during 
colonisation with STEC O15797. CD4+ T-cells from this same study have been shown to 
recognise specific STEC O157 antigens179. This study also demonstrated that the temporal 





clear that STEC O157 induces local adaptive immune responses at the primary site of 
infection although it is unclear how much it contributes to bacterial clearance or protection 
from re-infection. 
Cattle shedding more than 104 CFU STEC O157 per gram of faeces are defined as super 
shedders5 and it is believed that these animals are the source of most of the bacteria that 
contaminate the environment and enter the food chain15. It is largely unknown why some 
animals become super shedders and some only shed at low levels and apparently are able to 
quickly clear the bacteria; factors involved are hypothesised to be bacterial strain, host 
genotype, host animals management/ environmental factors and gastrointestinal microbiome 
of the host animal238. Some strains of STEC O157 (for example containing specific phage-
types) are more likely to be associated with super shedding than others5,28. Host animal’s diet 
has been linked with super shedding; however, changes in diet do not consistently correlate 
with faecal shedding in cattle89,90,92. Other environmental factors such as rainfall, relative 
humidity and pasture growth have been shown in one longitudinal study to be positively 
associated with increased shedding in heifers at pasture239. Farms with cows, young animals, 
and concentrated calving periods all appear to be at more risk of observing a high-level 
shedder5. The host genotype is also likely to be a contributing factor to shedding levels and 
the Scottish IPRAVE study determined that female breeding cattle were more likely to be 
associated with high levels of shedding5, although it is difficult to determine if this is just a 
gender effect as these animals will not only be different genders but also kept in different 
conditions to male cattle kept for meat production. There have also been links between 
STEC O157 colonisation in cattle and the nature of the microbial community that inhabits 
the digestive tract of super shedding animals240. However a recent study has demonstrated 
that the overall bacterial community structure was not associated with STEC O157 shedding 
status, although the authors did demonstrate that several of the major bacterial genera were 
differentially abundant in super shedding verses non-shedding cattle, although interestingly 
not at the terminal rectum241.  
A previous study by Wang et al. (2016) has identified 47 genes with lower levels in the 
terminal rectum of naturally infected super shedding cattle by RNA sequencing of rectal 
mucosal biopsies taken at post mortem129. Of these, 31 genes were associated with innate and 
adaptive immune functions, 10 of which were selected for qPCR validation. Expression of 
seven chosen genes (CD22, IL2RA, LTB, CCR7, CD19, POU2AF1, CXCL13) were 
significantly lower in super-shedding compared to non-shedding cattle, the transcription of 





the super-shedding cattle129. The major limitation of the study was that only one sampling 
time point was analysed, and therefore it is unclear whether the lower level of immune genes 
was due to immunosuppressive effects of the bacteria during colonisation, or represented an 
inherent deficiency in rectal immune function in the super-shedding individuals which in 
turn increased their susceptibility to colonisation and super shedding.  
The 10 immune gene transcripts with lower levels in super shedding cattle that Wang et al. 
(2016) validated by qPCR are listed in Table 12 and the following briefly describes their 
function relating to the immune system.  
Membrane spanning 4-domains, subfamily A, member 1 (MS4A1) encodes for CD20, which 
is expressed on the surface of B-cells and plays a role in the development and differentiation 
of B-cells into plasma cells (it is not expressed on plasma cells)242. MS4A1 enables optimal 
B-cell immune response, specifically against T-independent antigens243.  
CCL21 a chemokine, is expressed in various lymphoid tissues and activates B and T 
lymphocytes. CCL21 is a chemoattractant for B-cells and regulates B-cell movement in 
secondary lymphoid tissues244, and also leads to migration of dendritic cells245 and T-cells244. 
SH2D1A (SH2 domain protein 1A) in humans is expressed on activated T-cells and NK cells 
but not on macrophages or activated B-cells246.  
CD22 acts as an accessory component of the B-cell receptor (BCR), is expressed on the 
surface of mature B-cells and acts to help to control over-activation of the immune system247 
248.  
Interleukin 2 receptor alpha (IL2RA), also known as CD25, is up-regulated on activated T-
cells249. Interleukin 2 (IL-2) is produced by activated TH1 cells; it stimulates cell 
proliferation, antibody and IFN-γ production and enhances cytotoxicity250,251. IL-2 also 
supports the survival of regulatory T-cells and is thus important in the regulation of immune 
responses252. 
Lymphotoxin beta (LTB) is also known as Tumour necrosis factor C and is expressed by 
mature B, T and NK cells253,254. LTB is an inducer of the inflammatory response system and 
involved in the normal development of lymphoid tissue. Decreases in LTB leads to a 
reduction in the number of lymphoid follicles in the gastrointestinal tract in mice255. 
Chemokine receptor 7 (CCR7) is involved in homing of T-cells to lymph nodes and other 





express CCR7 on their surface257. CCR7 recognises CCL19 and CCL21 which are produced 
in lymph nodes, guide the migration of the activated dendritic cells into the lymph nodes and 
stimulate dendritic cell expression of MHC class I or Class II245. 
CD19 is a B-cell specific molecule and, like CD22, positively regulates B-cells activity; 
through complexing with the BCR258 259, CD19 also regulates TLR B-cell activation259.  
POU class 2 associating factor 1 (POU2AF1), also known as OCT-1, is involved in B-cell 
proliferation and germinal centre formation260.  
Chemokine ligand 13 (CXCL13) is a small cytokine and a chemoattractant of B-cells. 
Expression of this gene is required for migration of B-cells to gut associated tissues and 
formation of lymphoid follicles261,262. CXCL13 elicits its effects by interacting with the 
chemokine receptor CXCR5263. A study by St John et al. (2009) in mice demonstrated that 
following experimental infection, via injections of Salmonella typhimurium into the footpads 
and consequently trafficking of S.typhimurium through the draining lymph node (popliteal 
lymph node), there was down-regulation of CXCL13 and CCL21 in the popliteal lymph 
node264. The S. typhimurium disrupts the lymph node architecture and cellular trafficking, 
which enhances its virulence and this could serve as a mechanism of immune suppression 
used by other pathogens that primarily target lymphoid tissue264.  
All these genes of interest are directly related to immune function and down-regulation could 
allow bacteria to survive and colonise more successfully at the terminal rectum. 
Another recent study using an experimental STEC O157 challenge concluded that genes 
associated with immune responses in the ileal peyer’s patches were more influenced by 
STEC O157 infection in comparison to the recto-anal junction130. In this study calves were 
challenged once or twice with a stx-negative strain of E. coli O157 and samples of ileal and 
rectal mucosa collected for RNA sequencing, with results compared to non-challenged 
controls. This study identified significantly more differentially expressed genes in the ileum 
compared to the recto-anal junction following primary infection (1159 and 15 differentially 
expressed genes for ileum and recto-anal junction, respectively) but a similar number of 
differentially expressed genes at both sites following secondary infection (17 and 10 genes 
for ileum and rectum, respectively). Of the differentially expressed genes, 69 
immunostimulatory genes were down-regulated and 7 immunosuppressive genes were up-
regulated in the STEC O157 colonised calves. One major limitation of this study was that the 





unchallenged controls were both older and weaned. Therefore the differences between 
primary challenged and control calves may largely be due to age and/or diet effects265-267. 
Nevertheless, consistent with the Wang study, these data suggest that STEC O157 
colonisation is associated with down-regulation of mucosal immune responses. 
Table 12: Immune genes with lower levels in super shedding cattle taken from Wang et 
al. (2016) and modified. 
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(Chemokine ligand 13) 
Chemoattractant for B cells, 
essential for migration in 
GIT261 
-4.3 Significant 
*log 2 (fold change) is log ratio of gene expression level in super-shedders to non-shedders. 
A study using a bovine-specific cDNA microarray to analyse rectal biopsy specimens taken 7 





response to colonisation with STEC O157 across a range of different pathways271 and also 
up-regulation of 22 genes. None of the gene transcripts which were determined to be up or 
down-regulated 1 or 7 days after rectal challenge with STEC O157 were the same genes as 
the gene transcripts found to be differentially expressed in the Wang et al. (2016) study. Four 
of the genes down-regulated at day 7 were believed to be directly associated with immune 
function. Unfortunately because a subset of 1,676 genes were present on the microarray and 
the list of genes is no longer available we cannot determine if the genes in the Wang et al. 
(2016) study were analysed or not.  
This current study aims to aid in the further investigation of suppression of gene transcripts 
related to immune function at the terminal rectum in stx positive STEC O157 colonised 
calves. Importantly repeated rectal biopsies (pre, peak and post challenge) were taken from 
calves who were experimentally orally challenged with STEC O157, allowing us to 
determine if there is a temporal down-regulation of the immune genes identified by Wang et 
al. (2016) during STEC O157 colonisation which would be suggestive of active immune 
suppression by the bacteria. Two other genes, CD80 and CD86, which are key genes for 
adaptive immune induction were also analysed. CD80 and CD86 work in tandem to prime T-
cells272. CD80 is present on the surface of dendritic, activated B-cells and monocytes273 and 
provides a co-stimulatory signal necessary for T-cell activation and survival274. CD86 is 
expressed on antigen presenting cells and provides the co-stimulatory signals with CD80 
necessary for T-cell activation and survival274,275. As many of the genes determined to be 
downregulated by Wang et al. (2016) are directly involved in T-cell activation, we 
anticipated that these two genes involved in the induction of the adaptive immune response 
may also be affected by STEC O157 colonisation. 
Main Aim 
To quantify transcripts for specific genes involved in immunity at the terminal 






5.2  Materials and Methods 
5.2.1  Experimental animal challenge trials 
 
See chapter 2 material and methods for the challenge animal trials involving calves orally 
challenged with three different STEC O157 strains (PT21/28 Stx2c+, PT32 Stx2c+ and 
PT21/28 Stx2a+Stx2c+).  
5.2.2  Rectal Biopsies 
 
Rectal biopsies were taken from challenged and control calves pre-challenge (day -3), peak 
(day 7) and post challenge (day 26). A local anaesthetic was applied to the anal sphincter (5 
% EMLA, Astra Zeneca, UK), and a rectal speculum was applied to allow visualisation and 
access to the rectal mucosa. Pinch biopsies were taken approximately 5 cm proximal to the 
recto-anal junction; biopsies were taken from two opposing sites at each time point. 
Different sites of rectal mucosa were biopsied at each time point. Biopsies were put into 
RNA later (Ambion, Paisley, UK) at 4 oC overnight and then stored at -80 oC. For long term 
storage the biopsies were removed from the RNA later and stored at -80 oC.  
5.2.3  cDNA preparation 
 
RNA was extracted from the rectal biopsies using QIAshredder kit (Qiagen, Germany) and 
then the RNeasy Plus mini kit (Qiagen, Germany). Biopsies (weighing 20-30 mg) were 
initially disrupted in Precellys CK28 tubes (Stretton Scientific, UK) using 3 × 23 second 
cycles at 5,800 revolutions per minute (rpm) in a tissue homogeniser (Percellys24, Bertin 
Instruments, France). Tubes were placed on ice for 2 minutes between cycles. Residual DNA 
was digested on the RNeasy Plus mini kit column with DNase I (Qiagen, Germany).  
RNA yield was estimated using a Nanodrop ND1000 spectrophotometer (Thermo Scientific, 
Waltham, USA). The ratio of absorbance at 260 nm and 280 nm was used to help assess the 
purity of RNA and also the 260 nm and 230 nm absorbance; RNA was only used if both 





and 2100 Bioanalyzer (Agilent Technologies, Wokingham, UK). All RNA samples used to 
make cDNA had a RNA integrity number (RIN) above 7.0. A number of samples with low 
absorbance ratios as per the nanodrop measurement were run through a second RNeasy Plus 
mini column (Qiagen) and cleaned up as per the manufacturer’s instructions.  
cDNA was synthesised as per manufacturer’s instructions using Superscript II (Invitrogen, 
UK) reverse transcriptase, RNAseOUT (Invitrogen), dNTP mix (Invitrogen) and Oligo (dT)-
23 primers (Sigma-Aldrich, UK) from 2 µg RNA, where 1 µg was pooled from each of the 
two biopsies taken at each time point. Reaction volume was 40 µl. Cycling conditions were 
42 oC for 2 minutes followed by addition of reverse transcriptase, 42 oC for 50 minutes and 
70 ˚C for 15 minutes. cDNA was diluted 1 in 10 using nuclease-free water and stored at -20 






Table 13: Primers used for reverse transcriptase quantitative PCR analysis of gene 
expression and sequencing of plasmid inserts. 
Gene Direction Sequence Reference 
CCL21 F GCTATCCTGTTCTCGCCTCG Wang et al. (2016) 
CCL21 R ACTGGGCTATGGCCCTTTTG Wang et al. (2016) 
CCR7 F ACCCTCGCTAGCTACCTCAA Wang et al. (2016) 
CCR7 R CGGTCTCTTGTCTTGGGGAC Wang et al. (2016) 
CD22 F ACCTCAGTTTCCAGCCCAAG Wang et al. (2016) 
CD22 R CCTCATGGTCACAGACTCGC Wang et al. (2016) 
CXCL13 F AACCCTCAAGCCAAATGGACA Wang et al. (2016) 
CXCL13 R AACCCGGAGCAGGAATGTTG Wang et al. (2016) 
LTB F TGGGAAGAGGAGGTCAGTCC Wang et al. (2016) 
LTB R TAGCTTGCCATAAGTCGGGC Wang et al. (2016) 
MS4A1 F GCGGAGAAGAACTCCACACA Wang et al. (2016) 
MS4A1 R GGGTTAGCTCGCTCACAGTT Wang et al. (2016) 
IL2RA F GCACGGTCAGGCTTCAGAT Wang et al. (2016) 
IL2RA R TTCTTGACTTCTTCTGGCCTTG Wang et al. (2016) 
CD19 F CTCCCATACCTCCCTGGTCA Wang et al. (2016) 
CD19 R GCCCATGACCCACATCTCTC Wang et al. (2016) 
POU2AF1 F GAGACCATGGTGACTGGTGG Wang et al. (2016) 
POU2AF1 R AATACGGCCATTGTGGGGAG Wang et al. (2016) 
SH2D1A F CAGCACCGGGGGTACATAAA Wang et al. (2016) 






Table 13 continued: Primers used for reverse transcriptase quantitative PCR analysis 
of gene expression and sequencing of plasmid inserts 
Gene Direction Sequence Reference 
CD80 F CTGTGATTACAACACGACCACTGA Peimin Lio Personal 
communication (Edinburgh 
University, UK) 
CD80 R ATGGTGCGGTTCTCGTATTCA Peimin Lio Personal 
communication 
CD86 F GCCAAGAGAAGCCCAATAACG Peimin Lio Personal 
communication 
CD86 R CAGTCCTTGGGACCTTCTATCATG Peimin Lio Personal 
communication 
T7 F TAATACGACTCACTATAGG Eurofins (Paris, France) 
Sp6 R ATTTAGGTGACACTATAG  Eurofins (Paris, France) 
 
5.2.4  Quantitative PCR 
 
Unless stated otherwise quantitative PCR reactions were conducted in duplicate in 96 well 
qPCR plates using SYBRgreen ER qPCR super mix (Invitrogen) with ROX and an ABI 
prism 7500 qPCR instrument (Applied Biosystems, Paisley, UK) as per manufacturer’s 
instructions. The reaction volume was 20 µl. Cycling conditions were 50 oC for 2 minutes, 95 
oC for 10 minutes and then 40 cycles of 95 oC for 15 seconds, 60 oC for 30 seconds and 72 oC 
for 30 seconds, with the exception of the IL2RA PCR in which cycling conditions used were 
50 oC for 2 minutes, 95 oC for 10 minutes and then 40 cycles of 95 oC for 30 seconds, 60 oC 
for 60 seconds. Melting curve analysis was performed at the end of each PCR run to confirm 
the specificity of the reactions. Primers and standard curve plasmids for GAPDH and 
ATP5B were supplied by Primer Design and used as per manufacturer’s instructions. All 






5.2.5  Reference gene selection 
 
Reference genes were selected using the bovine GeNorm kit 9 primer design containing 
primers ATP5B, EIF2B2, ACTB, SDHA, RPL12 and GAPDH as per manufacturer’s 
instructions, qPCR reactions were prepared using 5 µl cDNA from 3 time points for eight 
animals (4 controls and 4 challenged calves). qBasePLUSv2.4 (Biogazella, Zwijnaarde, 
Belgium) software was used to select GAPDH and ATP5B as the most stably expressed 
genes. CT values were converted into relative quantities for analysis with GeNorm, 
considering the PCR efficiencies of the genes. The program selects from a panel of candidate 
reference genes the two most stable genes or a combination of multiple stable genes for 
normalization. The stability value is based on the combined estimate of intra- and intergroup 
expression variations of the genes studied.  
5.2.6  Plasmid generation 
 
PCR primers for the genes of interest were previously designed by Wang et al. (2016) or 
within the group (CD80 and CD86) see Table 13. Gene fragments were generated using Go 
Taq G2 DNA polymerase (Promega, UK), dNTPs (Invitrogen) and bovine cDNA from a 
rectal biopsy as per manufacturer’s instructions. Cycling conditions were 95  oC for 2 
minutes, 35 cycles of 95 oC for 30 seconds, 60 oC for 30 seconds, 72 oC for 1 minute and then 
72 oC for 5 minutes. Samples were run on a 1 % agarose gel with gel red detection to confirm 
a product of the correct size. QIAquick PCR purification kit was used (Qiagen, Germany) to 
purify the PCR product. The amount of product was then estimated using Nanodrop ND1000 
spectrophotometer (Thermo Scientific) and then ligated into pGEM-T Easy vector plasmids 
(Promega) as per manufacturer’s instructions. 
XLI blue, Ultracompetent cells (Agilent technology, UK) were transformed with the 
plasmids as per manufacturer’s instructions. X-gal and IPTG were used to screen colonies. 
Two colonies were picked for each gene of interest, and PCR performed as above (using the 
primers for the gene of interest) to check for a correct size insert. One PCR positive colony 
for each gene of interest was inoculated into 10 ml LB broth and incubated at 37 oC 
overnight. QIAprep Spin Miniprep kit (Qiagen) was used as per manufacturer’s instructions 





the T7 and Sp6 primers (Table 13). Sequences were checked against the Bos taurus Refseq 
RNA database using BLAST (NCBI) and primers for the gene of interest using EMBL-EBI 
cluster analysis tool. DNA concentrations were estimated using Nanodrop ND1000 
spectrophotometer and diluted using PCR water to 109 copies per µl and stored at -20 oC 
until required. 
Plasmids were diluted across the dynamic ranges indicated in Table 14 and used to generate 





Table 14: qPCR standard curve dynamic range 




Gene copies/well  
Bottom Standard 
CCL21 0.993-0.998 108 103 
LTB 0.99-0.999 108 103 
CXCL13 0.997-0.999 108 102 
CCR7 0.992-0.999 108 103 
CD19 0.994-0.999 108 102 
CD22 0.992-0.997 108 102 
POU2AF1 0.99-0.998 108 102 
MS4A1 0.996-0.999 108 102 
SH2D1AF 0.99-0.996 108 102 
IL2RA 0.998-1 108 103 
CD80 0.991-0.998 108 103 
CD86 0.988-0.993 108 102 
 
5.2.7  Copy number calculation 
 
Standard curves were calculated from the cycle threshold (CT) values using Prism 7500 SD 





arithmetic mean for the technical repeats was calculated and then each gene was normalised 
to the geometric mean of the reference genes ATP5B and GAPDH as previously 
described276. Briefly a normalisation factor was calculated based on the expression level of 
the two chosen housekeeping genes. For accurate averaging of the control genes, the 
geometric mean was used instead of the arithmetic mean as it controls better for possible 
outlying values and abundance differences between the different genes276.  
5.2.8  Statistical analysis 
 
Statistical analysis was performed using R version 10 by Javier Palarea (Biomathematics and 
Statistics; Scotland; BioSS). RT-qPCR data was used to compare changes in gene expression 
in challenged vs. control treatment groups across 12 genes. Results for each STEC O157 
challenge strain group were analysed separately together with their respective unchallenged 
controls. Fold changes in gene copy numbers from pre-challenge levels over the two time 
points (7 and 26 days post challenge) were log10 transformed and linear mixed models 
(LMMs) were fitted, with log10 transformed pre-challenge gene copies, treatment group, days 
post challenge and the interaction between group and days post challenge were fixed effects 
and animal was fitted as a random effect. Statistical significance was concluded at a p-value 






5.3  Results 
5.3.1  Faecal shedding data  
 
Figure 24 in chapter 3 shows the faecal shedding data for the orally challenged calves, all 
control calves were STEC O157 negative throughout the trial (data not shown).  
5.3.2  Reference gene selection 
 
The stability of six reference genes was assessed using the GeNorm algorithm276 
incorporated in the qBasePLUS software package by comparison of the CT values for these 
genes across a representative sample of reverse transcription reactions. The GeNorm M 
value indicates the stability of expression of the genes276. Figure 53 indicates the GeNorm M 
value for the 4 most stable genes, and indicates that ATP5B and GAPDH are the most stable 
genes.  
 
Figure 53: Indicates the average expression stability of the four most stable reference 
genes used to determine the suitable reference genes for the qPCR. 
 
The optimal number of reference genes was selected using the GeNorm V values indicated 






Figure 54: The GeNorm V values calculated to determine the optimal number of 
reference genes for the study. 
The optimal number of reference targets was 2 (GeNorm V < 0.15) when comparing a 
normalisation factor based on the 2 or 3 most stable targets. As such, the optimal 








Figure 55: An example of electrophoresis of RNA samples using the BioAnalyzer. All 
samples run on this chip were acceptable. 
 
Figure 56: RNA integrity numbers and graphs of 12 RNA example samples extracted 






5.3.3  RNA extraction 
 
Figure 55 and 56 are representative examples of bioanalyzer runs on a 12 sample chip. All 
RNA samples used to generate cDNA had a RIN value 7.0 or above.   
5.3.4  Gene expression at the terminal rectum 
 
The numbers of transcripts for specific immune genes were compared between STEC O157 
challenged and unchallenged calves. Three different strains of STEC O157 were used for 
challenge (PT21/28 Stx2c+, PT32 Stx2c+ and PT21/28 Stx2a+Stx2c+), and comparisons 
were only made within trial (i.e. not between different STEC O157 strains). As there was 
significant variation in transcript levels between calves at the pre-challenge time point, 
changes in gene expression were determined within each individual by comparing fold-
changes in transcript levels relative to pre-challenge levels.  
5.3.5  Gene expression following PT21/28 Stx2c+ challenge 
 
There was a general trend across ten of the immune genes (CCL21, CCR7, CD19, CD22, 
CXCL13, IL2RA, LTB, MS4A1, POU2AF1 and SH2D1A) for the unchallenged calves to 
have a fold increase in gene transcripts at 26 days compared to the challenged group (Figure 
57). However there was often significant variation within the groups, with overlapping 95 % 
Confidence Intervals (CI) predicated from the linear mixed model (the predicted means and 
CI from the linear mixed model are represented in Figure 60 in the Appendix and Table 18 in 
the Appendix). There was no statistically significant difference found between the treatment 
groups (challenged vs. unchallenged calves) for any of the ten genes listed above (see Table 
15 in Appendix for p-values). Although some of the graphs show diverging slopes for these 
genes especially from day 7 to day 26 between the challenged and control group, again no 
statistically significance of the treatment group nor treatment × time interaction effect was 
found for any of the 10 genes (see Table 15 in Appendix for p-values). 
The fold change from pre-challenge in transcripts for CD80 and CD86 showed a different 





treatment groups had returned to pre-challenge levels. There was no statistically significant 
difference between the treatment groups nor any treatment × time interaction; however there 
was a statistically significant difference in CD80 levels over time (independent of challenge; 
p = 0.0003). CD86 fold change in transcript levels were close to 1 at day 7 and day 26 for 
both challenged and unchallenged controls. Again there was no statistically significant 







Figure 57: Fold change relative to pre-challenge, gene expression at the terminal 
rectum of calves orally challenged with STEC O157 PT21/28 Stx2c+. The graphs 
represent mean fold changes (± standard error of the mean, SEM) in gene copy 
numbers relative to the pre-challenge (day -3) gene copy numbers at day -3, 7 and 26 
for each gene considered. The gene copy number is calculated using a plasmid standard 
for each gene and normalisation to two housekeeping genes. The black circles represent 
the mean of the challenged calf group and the open black squares the unchallenged 






5.3.6  Gene expression following PT32 Stx2c+ challenge 
 
All the genes of interest had a fold change increase in transcript at day 7 (see Figure 58) 
which generally decreased towards pre-challenge levels by day 26 in both challenged and 
unchallenged controls. CD19, CD86 and POU2AF1 fold changes in transcript levels were 
very similar between challenged and unchallenged controls at both day 7 and 26 time points 
which is reflected by very similar predicted means and overlapping confidence intervals for 
both treatment groups (Figure 61 in Appendix and Table 18 in Appendix). CCL21, CD80, 
CXCL13, LTB and SH2D1A showed similar patterns, with a fold change increase at day 7 
and then a decrease towards pre-challenge levels by day 26. Generally the challenged group 
had a greater fold change increase compared to the unchallenged controls. CCR7, CD22, 
IL2RA and MS4A1 showed a similar pattern with a fold change increase in the controls at 
day 7 and then a decrease towards pre-challenge levels by day 26. For these transcripts the 
challenged group followed a similar pattern but at a lower level than the unchallenged 
control group. There was no statistically significant difference between treatment groups, or 
any significant treatment × time interaction interactions for any of the genes of interest (see 
Table 16 in appendix for p-values). There was a statistically significant difference in the fold 
change transcript levels for CD80, CD86, MS4A1, IL2RA and LTB over time which was 
independent of treatment (p = 0.004, p = 0.001, p = 0.032, p = 0.018 and p = 0.011 for 






Figure 58: Fold change relative to pre-challenge, gene expression at the terminal 
rectum of calves orally challenged with STEC O157 PT32 Stx2c+. The graphs 
represent mean fold changes (± SEM) in gene copy numbers relative to the pre-
challenge (day -3) gene copy numbers at day -3, 7 and 26 for each gene considered. The 
gene copy number is calculated using a plasmid standard for each gene and 
normalisation to two housekeeping genes. The black circles represent the mean of the 





5.3.7  Gene expression following PT21/28 Stx2a+Stx2c+ 
challenge 
 
CCL21, CCR7, CD19, CD22, CD80, CD86, CXCL13, LTB, MS4A1 and POU2AF1 showed 
a similar pattern in fold change compared to pre-challenge transcript levels for the challenge 
group increasing at day 7 and then reducing towards pre-challenge levels by day 26 (Figure 
59). Fold-changes in the unchallenged control group also showed a general increase at day 7, 
but these changes were less pronounced compared than those seen in the challenged group. 
The SH2D1A gene transcripts showed a slightly different pattern with the challenged 
animals having a further fold change increase at day 26. However there was no statistically 
significant difference between treatment groups or any treatment × time interactions for any 
of the above genes (see Table 17 in Appendix for p- values). The predicted means for 
challenged and unchallenged controls were very similar and there was overlapping CI from 
the linear mixed model (Figure 62 in Appendix and Table 18 in Appendix). CD80, CD86 
and LTB did show a statistically significant difference in fold change over time which was 
independent of treatment group (p < 0.0001, p = 0.0075 and p = 0.0261 respectively).  
IL2RA showed a different pattern of gene expression between challenged and unchallenged 
calves: in the control group there was a fold-change increase in IL2RA transcripts over time, 
whereas in the challenged group, IL2RA transcripts decreased at day 7 before increasing by 
day 26 to levels still below those of the unchallenged controls. This was reflected in a 
statistically significance treatment × time interaction (p = 0.0194), although there was no 





Figure 59: Fold change relative to pre-challenge, gene expression at the terminal 
rectum of calves orally challenged with STEC O157 PT21/28 Stx2a+Stx2c+. The graphs 
represent mean fold changes (± SEM) in gene copy numbers relative to the pre-
challenge (day -3) gene copy numbers at day -3, 7 and 26 for each gene considered. The 
gene copy number is calculated using a plasmid standard for each gene and 
normalisation to two housekeeping genes. The black circles represent the mean of the 





5.4  Discussion 
 
It has been previously demonstrated that the terminal rectum is the primary site of 
colonisation for STEC O157 in the bovine host27. However STEC O157 can be isolated from 
multiple sites within the bovine gastro-intestinal tract277. The terminal rectum is accessible 
for taking repeated biopsies with minimal stress to the animal. Such sampling allows the 
interaction between the bacteria and the mucosal surfaces to be studied at different stages of 
colonisation. Sampling the same calf repeatedly also allows us to account for inter-animal 
variation. In this study the bacterial counts indicated that peak shedding for oral challenged 
calves occurred between 5 and 7 days hence confirming the rationale for sampling at 7 days 
post challenge and then at post mortem (26 days post challenge) in the orally challenged and 
unchallenged control calves. A previous study demonstrated the stability of TNF-α gene 
expression in a similar study involving multiple rectal biopsy taken from control 
(unchallenged) calves over time, indicating that the process of taking the biopsies does not 
appear to induce a general inflammatory response within the rectal mucosa97. In this study, in 
order to mitigate the effects of the biopsy procedure on the rectal transcriptome, biopsies 
were taken at different sites in the rectum at each time point. Furthermore, two biopsies were 
taken at opposing sites at each time point to try and capture a true representation of the rectal 
transcriptome, with equal quantities of RNA from each site pooled for down-stream 
transcriptional analysis. 
For the reverse transcriptase quantitative PCR (RT-qPCR) to avoid problems with variation 
in PCR efficiency which can affect relative quantitative approaches absolute quantification 
of gene copy number was used, with serial dilutions of a plasmid used to generate a standard 
curve for each gene on each qPCR plate. The copy number was then normalised to the 
geometric mean of the most suitable two reference genes, which for the samples used in this 
study were determined to be ATP5B and GAPDH. The number of cDNA gene copies at the 
start of each qPCR reaction will depend on the number of mRNA transcripts per unit mass of 
tissue processed but also on the variable efficiency of each RT reaction, errors in 
spectrophotometric estimation of RNA concentration and pipetting inaccuracies. Thus to 
control for this unavoidable technical variation, a suitable reference is required, against 
which expression of the gene of interest could be compared. Other studies use relative 
quantification which compares the expression of the gene of interest versus a single 




experimental conditions278,279. The CT value is the PCR cycle number when the fluorescent 
signal from the qPCR reaction intersects with a threshold set on the linear part of the 
amplification curve at the start of the exponential phase. The CT value is affected by the 
reaction conditions including the master mix, cycler and efficiency of the primers used. 
Previous studies have shown that a single reference gene is inappropriate and that at least 
two carefully selected reference genes should be used for accurate RT-qPCR experiments276. 
Therefore in this study two genes were selected for use as reference genes.  
The gene transcripts to be quantified were chosen following a recent study in the literature 
discussed in the introduction of this chapter129 and also another two genes, CD80 and CD86, 
which are involved in the induction of the adaptive immune response. The previous study by 
Wang et al. (2016) had demonstrated down-regulation of these ten genes at the terminal 
rectum in cattle super shedding STEC O157 compared to cattle sampled negative for STEC 
O157. In this current study the only statistically significant difference we determined 
between STEC O157 challenged calves and unchallenged control calves was a reduced mean 
fold change in transcripts of IL2RA in PT21/28 Stx2a+Stx2+ challenged calves compared to 
control calves at the time of peak shedding. No other statistically significant differences 
occurred between challenged and unchallenged control calves with the other genes of 
interests or STEC O157 challenge strains. The challenge group is generally associated with 
higher fold changes in gene expression, particularly for the PT2128 Stx2a+Stx2c+ challenge 
strain, but the control unchallenged group was higher in several cases as well. The overall 
difference in mean fold change from 7 to 26 days post challenge is statistically significant in 
several cases, but this is not always in the same direction. There was an overall statistically 
significant fold change difference from 7 to 26 days post challenge for genes CD80 and 
CD86 for the three strains, significant differences between days post challenge are obtained 
for some additional genes for PT32 Stx2c+ challenge strain (IL2RA, LTB, MS4A1) and 
PT2128 Stx2a+Stx2c+ challenge strain (IL2RA, LTB). For IL2RA in the PT32 Stx2c+ 
challenge trial the fold change is lower at day 26 compared to day 7, whereas in the PT21/28 
Stx2a+Stx2c+ challenge trial the fold change is higher at day 26 compared to day 7. 
This current study was using much younger animals of a different breed (Holstein-Friesian) 
than in the Wang et al. (2016) study, which used adult British cross Continental feedlot 
yearling steers fed on a barley-grain based finishing diet129. As discussed in the introduction, 
age can effect immune gene transcription in the gastrointestinal tract265,266; indeed in this 
study we found that transcript levels often increased over time for a number of genes in the 




intestinal immune system and which could have partly confounded our results. Unfortunately 
due to the nature and size of the containment level 3 facilities at Moredun Research Institute, 
we were unable to perform these experiments on adult animals in which the mucosal 
immune system may be more transcriptionally stable. 
Another important consideration is that the calves in the present study were experimentally 
orally challenged with a large bolus dose of STEC O157; in the Wang et al. (2016) study 
cattle were naturally colonised with STEC O157. This oral challenge model is unlike the 
natural situation in which calves are more likely to be ingesting smaller numbers of bacteria 
over a more prolonged period. Therefore the resulting immune response may be different, 
with a large bolus more likely to result in a more coordinated and potentially more robust 
local immune response compared to that seen in the field.  
The cattle in the study by Wang et al. (2016) had varying levels of shedding pre-slaughter 
and at slaughter when the biopsy samples were taken; 2 of the five cattle were actually 
shedding less than 104 CFU/g in their faeces on the day of slaughter129,280. Super shedding 
cattle can be grouped into three different types: persistent shedders which shed for several 
months, moderate shedders which shed for about 30 days and non-persistent shedders which 
shed for less than 14 days281. Due to the nature of the Wang et al. (2016) study it is not 
known which group the super shedding cattle were in. Because there were only 5 super 
shedding cattle, this group could have been highly skewed by a number of non-persistent 
super shedders. There is certainly lots of heterogeneity in natural STEC O157 shedding, with 
some studies noting significant variation in shedding levels even within a day282,283. 
Challenge strains are also likely to be different in this present study compared to the 
naturally occurring strains in Canada in the study by Wang et al. (2016). In this experimental 
study defined strains of STEC O157 were used for the challenge, but in the Wang et al. 
(2016) study it is highly likely that multiple strains of STEC O157 along with non-O157 
STEC strains were circulating within the feedlot. We do not know if all the super shedders 
were shedding the same strain and/or if they were shedding multiple strains of STEC O157. 
A number of studies have shown that individual cattle can shed multiple strains of STEC 
O157284-286. Challenge with different strains of STEC O157 has led to differences in immune 
responses in our study, e.g. differences between challenges with strains PT21/28 
Stx2a+Stx2c+ and PT21/28 Stx2c+ which only differ in the expression of a functional A 
subunit of Stx2a+. Another study has demonstrated significant difference in host responses 




Stx proposed to affect the host immune response, the bacteria produce other effector 
molecules which are likely to affect the host immune response. The production of these 
effector molecules will differ between STEC O157 strains, thus any suppressive effect seen 
with one STEC O157 strain may not be seen with another STEC O157 strain even if they 
produce the same Stx types. 
Wang et al. (2017) have now also demonstrated that samples taken at post mortem from the 
distal jejunum and descending colon of super shedding cattle showed potentially higher 
levels of transcripts involved in T-cell migration and proliferation. This agrees with 
Corbishley et al. (2014) who found an increased expression in Ki-67 a marker for 
proliferation on T-cells in the rectal lymph nodes of STEC O157 challenged calves97. The 
combination of these two studies by Wang et al. suggest a higher level of T-cell migration in 
locations anterior to the recto-anal junction, while lower T-cell migration and quantity at the 
recto-anal junction, which suggests a potential dysregulation of the migration of T-cell in 
super shedding cattle at the rectal site129,280. The 2017 study by Wang et al. has also 
demonstrated transcriptome analyses suggesting inhibition of B-cell signalling pathways in 
the distal jejunum and the trend of reduction in lymphocyte activation and migration in the 
cecum of super shedding cattle280.  
A RNA-seq study using a stx negative E. coli O157 challenge strain, demonstrated that 
changes in gene expression (between challenged and unchallenged control calves) was 
remarkably higher in the ileal Peyer’s patches (1159 genes) than the RAJ (15 genes) during 
primary infection130. However the effect was much less obvious after re-infection with the 
stx negative E. coli O157 challenge strain (17 and 10 genes respectively)130. At the RAJ only 
one gene (FABP2 with encodes for fatty acid binding protein 2, which is not directly 
involved in immune function) was affected by primary and secondary infection. In the ileal 
Peyer’s patches 7 genes were affected by both primary and secondary infection130, although 
as discussed in the introduction, this study was confounded as primary and secondary 
infected calves were of different ages and weaning status. Our calves were screened pre-
challenge 5 times at weekly intervals for STEC O157 shedding, but we still cannot 
categorically rule out that the calves were not previously exposed to STEC O157 prior to 
oral challenge. If this was their second exposure to STEC O157 this may have affected the 
results from the current study. 
IL2RA is the only gene with statistically significant differences between the PT21/28 




IL-2 receptor alpha chain (also called CD25), which, together with the beta and common 
gamma chain, constitute the IL-2 receptor287. Different associations of the individual 
subunits can produce 3 different IL-2 receptors which differ in their affinity to IL-2, IL2RA 
is essential for the high affinity IL-2 receptor287. However the IL-2 receptor of intermediate 
affinity does not require IL2RA288. IL2RA is up-regulated on activated T-cells and we have 
used IL2RA (CD25) as a marker of T-cell activation in chapter 4. IL-2 is produced by 
activated CD4+ TH1 cells, and Corbishley et al.(2014) demonstrated a TH1 skew in response 
to STEC O157 challenge and a reciprocal down-regulation of TREG response97.  
The data from this study, and the previous transcriptomic studies in the literature129,130,280, 
demonstrate the complexity of trying to understand the effect of STEC O157 colonisation in 
cattle. This study demonstrated no change in 11 specific genes related to immune function at 
the terminal rectum between orally STEC O157 challenged calves and controls. It is difficult 
to conclude if the different findings by others is because of the difference in study design, i.e. 
different age of calves, different challenge type or because the cattle in the Wang et al. 
(2016) study became super shedders due to an inherent defect in their immune system at the 
terminal rectum which allowed the bacteria to colonise and shed at high levels129. Further 
studies involving repeating rectal biopsies from adult cattle during the time-course of natural 
supper-shedding events would help to clarify this further. It should also be noted that the 
studies by Wang et al. (2016 and 2017) and Kieckens et al. (2016) did not demonstrate 
consistent down-regulation of the same specific genes related to immune function, indicating 
that significant variation in the immune genes affected by STEC O157 colonisation occurs in 
different study systems. By restricting this study to only 12 immune response genes, it is 
likely that many genes that were differentially expressed between challenged and control 
calves were missed. RNA sequencing analysis of the rectal biopsy samples collected in this 
study would allow the full extent of any potential immunomodulatory effects of the STEC 









Chapter 6  
General Discussion 
 
The objective of this thesis was to further characterise humoral and cellular responses in 
bovine animals colonised with STEC O157, with a focus on how STEC O157 modulate 
adaptive immune responses in the bovine host. This study started by characterising the 
antibody responses in cattle in a natural colonisation study and then went on to study how a 
toxoid vaccination could affect STEC specific antibody responses in a natural colonisation 
situation. An experimental challenge calf study allowed analysis of both STEC O157 
specific antibody responses and cellular responses to STEC O157 in a more controlled 
experimental setting. The experimental studies enabled comparison of immune responses 
when calves were orally challenged with a genetically modified STEC O157 strain (PT21/28 
Stx2a+Stx2c+) only differing in the stx2a A subunit compared to the wild type PT21/28 
Stx2c+ strain and also another clinically relevant PT32 Stx2c+ strain. These experimental 
challenge studies also enabled us to compare the immune responses to a non-STEC O157 
antigen OVA (immunisations) in calves challenged with STEC O157 and calves which were 
not STEC O157 challenged. Allowing us to try and decipher if colonisation with STEC 
O157 is affecting an animals ability to mount immune responses to concurrent 
immunisations. 
In the natural colonisation chapter there is some evidence to support suppression of the 
bovine immune system by STEC O157. In animals which were shedding but not super 
shedding STEC O157 there were lower Tir-specific IgA compared to STEC O157 negative 
animals. There was also significantly higher Tir-Specific IgA in super shedding animals 
compared to the STEC O157 negative animals. This supports the hypothesis that STEC 
O157 could be suppressing antibody responses but not in super shedding animals. One of the 
main limitations of the natural colonisation studies was the lack of information about the 
STEC O157 strains which the cattle were shedding. In the USA trial the cattle were only 
faecal sampled at one time point so although they were grouped into negative (non-




and data in the literature indicates the heterogeneity of STEC O157 shedding even within 
one animal70,282,289. Thus some of the negative animals may not have been shedding at that 
specific time point, but could have been shedding hours before or after. Also although more 
animals were used both in the USA natural colonisation trial and the toxoid vaccination trial 
compared to the experimental challenge trials there were still relatively low number of 
animals. This section of the study could be extended to include more cattle on different units, 
and sampling could including STEC O157 strain typing. This would give us more 
information on how robust the suppression of antibody responses determined was, and if it 
was related to the stx repertoire of the STEC O157 strain the cattle were shedding.  
The toxoid immunisation trial performed in Germany provides evidence that the toxoid 
vaccination may have potential as a future STEC O157 vaccine. The concept of toxoid 
vaccinations are of interest as possible vaccines for other toxin producing pathogens. The 
toxoid vaccination in this study reduced shedding levels in cattle and there was some 
evidence that the toxoid vaccine was able to inhibit the suppressive effect on the host’s 
humoral immune response by the STEC O157 bacteria. H7, H2 and H21 specific IgG1 
antibody levels were all higher (at week 9-12) in the toxoid vaccinated calves compared to 
placebo control calves, even though less STEC O157 was detected in the vaccinated calves 
compared to the control calves. This indicates that vaccination with the toxoid allows cattle 
to mount an increase H7, H2 and H21 specific antibody response to STEC O157. Although 
there could be other mechanisms involved as discussed in the discussion of chapter 2, this 
data does fit in with the hypothesis that Stx produced by STEC O157 are suppressing the 
bovine immune response. 
The toxoid vaccination study did not involve an oral experimental challenge, however it was 
performed under controlled conditions, in a select group of calves at set ages etc. In the 
toxoid vaccine study there were a number of circulating STEC O157 strains with different 
H-types, but we still do not know at this stage how this vaccine would work in a field 
situation, with different strains of STEC O157 or against other non-O157 STEC. Future trials 
with larger numbers of animals of different ages, breeds and kept in different management 
conditions would be necessary to fully conclude the effect of toxoid vaccination on STEC 
O157 colonisation. A field vaccine trial in more natural challenge conditions would be of 
interest and whole genome sequencing of any strains shed in the trial would give us more 
information on how the vaccines works against STEC strains producing different Stxs. An 




subunit vaccines already in development40,290 to determine if the toxoid vaccination would 
enhance the efficacy of the subunit vaccines against STEC O157. 
The experimental oral challenge studies, aimed to demonstrate the immune responses in a 
more controlled manner, using STEC O157 strains with different stx repertoires. The cellular 
and humoral response to STEC O157 oral challenge results (chapter 3) are broadly consistent 
with previous data in the literature. The cellular responses to T3SP by rectal lymph node 
cells concurs with Corbishley et al. (2014) findings, with colonised calves showing cellular 
responses to the T3SP but also unchallenged calves showed responses. Multiple studies have 
looked at STEC O157 antigen specific antibody responses following experimental STEC 
O157 challenge115-117,126,236 and our data fits in with the often variable and weak antibody 
responses detected following oral STEC O157 challenge. Interestingly the local STEC O157 
antigen specific antibody responses at the terminal rectum, generally were higher in the 
calves challenged with the PT21/28 Stx2a+Stx2c+ calves compared to the calves challenged 
with the other two strains (Stx2c+ positive). This did not fit with our general hypothesis that 
Stx would suppress the immune response. Challenge with a stx negative strain would have 
helped to clarify these results further. 
The results from chapter 5, when targeted PCRs were used to compare transcripts for 
specific immune genes at the rectal anal junction were unexpected and did not consistently 
agree with the results from the initial study by Wang et al. (2016). It was expected with the 
experimental challenge studies to see suppression of the transcripts for the specific immune 
genes following STEC O157 challenge as was determined by Wang et al. (2016) in the 
natural challenge situation. However we did not see consistent suppression following STEC 
O157 challenge. These inconsistent results suggest that due to the complex interactions 
between bacteria challenge, host responses and possibly gastrointestinal bacteria the results 
will vary depending on the bacterial strain, challenge type, animal age and possibly other 
external factors as discussed previously. Performing RNA sequencing on the RNA extracted 
from the rectal biopsies taken in these trials would give us further information to support or 
contradict the data in the literature suggesting immune suppression at the terminal rectum in 
STEC O157 colonised calves. However the calves in this study were experimentally 
challenged and the antibody and cellular responses both systemically and locally did not 
consistently suggest host immune response suppression by the STEC O157 challenge strains 
used in this study. Wang et al. (2017) have more recently shown that in the same cattle as the 




throughout the gastrointestinal tract in super shedding cattle compare to the non-shedding 
control cattle.  
Chapter 4 demonstrates that STEC O157 colonisation did not significantly affect the ability 
of the host animal to respond to a concurrent immunisation under these experimental 
conditions. This is the first study to our knowledge to examine the effect of experimental 
STEC O157 challenge on concurrent immunisations. Unexpectedly the OVA-specific 
cellular and antibody responses were not consistently down regulated in STEC O157 
challenged calves compared to their unchallenged control group, in fact there were some 
enhanced local OVA immune response in calves challenged with the PT21/28 Stx2c+ strain. 
There was a statistically significant increase in OVA specific CD4+CD25+ cells in PT21/28 
Stx2c+ challenged and OVA immunised calves compare to immunised only controls. There 
was also a statistically significant decrease in OVA specific IL-10 in PT21/28 Stx2c+ 
challenged and OVA immunised calves compared to immunised only controls. One 
explanation of these findings is that the Stx2a B subunit is acting to enhance the response in 
these challenged calves, however further work would need to be done to clarify this 
hypothesis.  
The OVA immunisations were given to calves which were experimentally orally challenged 
with STEC O157 and we were also not able to demonstrate significant consistent immune 
suppression to the bacteria under these conditions (chapters 3 and 5). A field study with 
natural challenge and OVA-immunisations may give a different result but this would be 
more difficult to control, as previous data in the literature suggested that it was the priming 
of the immune response that is suppressed by Stx and in field conditions timing the primary 
immunisations with STEC O157 colonisation would be difficult to accurately achieve. The 
study by Wang et al. (2017), have also demonstrated that the STEC O157 in the natural 
challenge does not suppress immune responses throughout the gastrointestinal tract. They 
suggest that the suppression only occurs at the rectal anal junction and thus allowing 
colonisation to occur at this site, where the bacteria is able to exert its suppressive 
effects129,280. The data from the Wang et al. (2017) study does not support the hypothesis that 
STEC O157 colonisation would have a systemic immune suppressive effect.  
Some parts of this study are to continue after this PhD is finished including RNA sequencing 
analysis of the rectal biopsies from chapter 5. As discussed this will enable to look at the 
abundance of transcripts of other genes that could be affected by STEC O157 challenge. It 




technique. This study has indicated some differences in antigen specific antibody levels 
between STEC O157 positive and negative animals; also in chapter 3 between toxoid 
vaccinated and placebo vaccinated calves. To examine this further, it would be interesting to 
determine the affinity of these antibodies for the antigens in question, there are laboratory 
techniques available. This may give a better indication of the potential biological impact of 
the differences noted. Antibody affinity is recognized as being an important parameter in the 
immune response in terms of clearance of pathogens and response to vaccination291.  
Adjuvants and synthetic immunomodulators are capable of altering antibody affinity, as well 
as the actual levels of antibody production292. It would be interesting to see if the toxoid 
vaccination in particular was capable of leading to a change in antibody affinity as well as 
the level of H7 specific IgG1 produced.  
As already discussed larger field studies determining antibody responses to EHEC antigens 
and also antibody responses to other concurrent vaccinations would allow us to determine if 
what has been demonstrated in this thesis is also mirrored in the field situation. However 
these field experiments are more difficult to control and potentially any subtle differences 
may be even more difficult to determine due to natural variation in the field unless very large 
numbers of animals were used. Depending on the results of RNA sequencing which is to be 
carried out on the rectal biopsies from the experimental challenge, repeated rectal biopsy of 
naturally STEC O157 challenged cattle over an infection would also be useful. 
One of the main limitations of the experimental challenge sections of this study was the lack 
of challenge with an E. coli O157 stx negative strain as a direct comparison, to really 
compare what effect Stx specifically was having on the immune response. Due to the lack of 
significant results in the trials already performed between challenged and unchallenged 
calves, ethically and financially a stx negative challenge trial was not performed. However 
we were able to challenge with strains differing only in their stx2a A subunit and follow the 
immune responses, although having an active B subunit may have complicated the results 
demonstrated. There is some evidence within the group that the Stx activity may be effected 
by the production of other Stx within the strain so this may also have complicated the results 
with the PT21/28 Stx2a+Stx2c+ strain challenges (Dr Stephen Fitzgerald, personal 
communication). 
All of the strains used in the oral challenge trials possessed stx2, as stated previously these 
strains were chosen as they are clinically relevant strains in Scotland30. Some of the previous 




used Stx1136,140 rather than Stx2. Stx1 and Stx2 are immunologically distinct and share only 
56 % amino acid sequence identity41. In humans, strains possessing Stx2 are more likely to 
lead to severe disease42 and in mice Stx2 has been shown to be more toxigenic43. However 
we do not really know the different effect Stx1 compared to Stx2 might have on bovine 
immune cells. This in part could account for some of the differences in the results shown in 
these trials compared to what was expected from the previous research in the literature. 
Future experiments comparing the effect of Stx1 and Stx2 on bovine immune cells in vivo 
would be interesting. 
The natural colonisation chapter indicated that there was some STEC specific antibody 
suppression in STEC O157 positive cattle compared to non-shedding controls but in the 
experimental challenge studies we did not demonstrate consistent immune suppression with 
STEC O157 oral challenge. Due to the low number of animals in the experimentally 
challenged calves the calves were not split into super shedding and positive shedding calves. 
In fact all of the calves challenged in the experimental study were shedding > 104 CFU/g 
faeces at some point over the study period. So they could all have been grouped as super 
shedders, but actually many of them only super shed for a few days early on in the trial. The 
suppression on Tir specific IgA was not demonstrated in super shedding cattle in the natural 
colonisation chapter only cattle shedding > 0 but < 104 CFU/g faeces STEC O157.  
The OVA study was also performed on the experimental orally challenged calves and again 
no immune suppression was demonstrated to OVA in these experimental conditions with 
STEC O157 challenge. The experimental challenges are different to the field (natural 
colonisation) situation, the calves are challenged with one large bolus of STEC O157, rather 
than in the field when we assume they will gradually ingest smaller numbers of STEC O157 
over a more prolonged period of time. Also due to the nature of the unit, cost and safety we 
were only able to use young calves in the experimental challenge studies. This again may 
affect the results, these calves would not have fully developed immune systems, and in in 
fact they would be developing their immune system for the duration of the trial. We were 
limited with animal numbers in the experimental challenge studies. There was often large 
intra group variability and the response from one calve was able to significantly skew the 
results. Although OVA has been used in previous trials as a model vaccine antigen207-209 this 
study found that the immune responses to OVA in unchallenged OVA immunised control 
calves varied significantly within the group. This may have been due to concurrent 
infections, age and genotype of the calves or other external factors. A different vaccination 




have helped to get a more consistent OVA immune response or using a different adjuvant 
may have led to a more robust immune response to follow. 
A complicating factor with studying STEC O157 in cattle, is the limit of detection of the 
assays used to determine cattle as STEC O157 negative. Using immune-magnetic separation, 
where O157 specific antibodies bound to magnetic beads are used following enrichment of 
faecal samples, the overall sensitivity for detecting STEC O157 in cattle faeces has been 
estimated to be as low as 56 %; and if shedding is 102 CFU/g faeces the sensitivity may be as 
low as 20 %293. It can be unclear if animals shedding at low levels that are difficult to detect 
(i.e. less than 102 CFU/g faeces) are in fact colonised or merely represent flow through of 
ingested bacteria. It has been suggested that cattle that persistently shed EHEC O157 may do 
so at low levels294. Thus some of the animals in this study which were categorised as 
negative may not actually be negative for STEC O157, they may be persistent low level 
shedders or shedding low levels at the beginning or end of STEC O157 colonisation or at 
least been exposed to STEC O157 and shedding very low levels due to flow through in the 
faeces. The calves in the oral challenge experimental studies which were classed as negative 
were sampled multiple times and also PCR was performed on faecal samples pre-trial 
looking for stx and STEC O157 specific genes to try and increase the sensitivity of finding 
STEC O157 if it was present. 
Although this study was looking at STEC O157 experimental challenges, it demonstrates the 
variation seen between experimental challenges and natural colonisation in cattle which may 
be relevant to other bacteria challenge studies. As discussed this may be due to the nature of 
the challenge (i.e. large oral bolus of bacteria) but also the conditions which the calves were 
kept in and the very limited number of animals in the experimental challenges. These factors 
need to be considered when planning future experiments especially if only marginal changes 
in immune responses are expected.  
An implication of the findings from the OVA immune response chapter is that it is unlikely 
that STEC O157 infections in cattle are likely to be affecting their ability to respond to 
concurrent vaccinations. Any systemic effect on immune response by STEC O157 
colonisation seems to be minor. Interestingly our wild type strain did not have an active 
Stx2a A subunit and actually in this study having an active A subunit did not appear to be an 
advantage to the bacteria. Strains which do not produce Stx, where the Stx is inactivated due 
to insertion sequences are isolated in the field again suggesting that Stx may be 




challenge studies is that we do not know how stable the insertion sequence is within the 
PT21/28 Stx2a+Stx2c+ strain at this stage and what other insertion sequences could be 
inserting into the bacteria genome and affecting the strains ability to produce toxin, attach, 
survive etc. within the host animal during these experiments. Long read sequencing 
performed by the group on PT21/28 Stxa+Stx2c+ bacteria recovered from challenged calves 
in this study, has identified large chromosomal inversions in the genomes of the challenge 
strains recovered from shedding animals, suggesting the bacterial genome of the challenge 
strain is not stable in vivo. Whether these inversions were present in the bacterial innocula or 
occurred within the host is unclear, as are the implications of these inversions on the 
bacterial phenotype (Fitzgerald et al., in preparation). 
If the original hypothesis for the OVA immunisation chapter was correct, then STEC O157-
mediated suppression of host immune responses to concurrent vaccination could have been 
used to encourage the farming industry to use STEC O157 vaccinations. At the moment 
there is little incentive for farmers to vaccinate their cattle because STEC O157 does not 
cause clinical disease in cattle. STEC O157 vaccination would still be advantageous, 
reducing STEC O157 shedding levels in cattle has been predicted to reduce the burden of 
disease within the human population5,15. Future work needs to concentrate on developing an 
effective STEC O157 control method in cattle, with a vaccination seeming the most likely to 
be effective. A STEC O157 vaccine needs to be cheap, easy to deliver, reliable and able to 
protect against multiple strains and serotypes. The toxoid vaccination used in chapter 2 of 
this thesis, is showing some promising results and using this in combination with other 
subunit antigens may be an interesting option. Also future work to determine the prevalence 
of STEC O157 in other different host species that may contribute to the STEC O157 
infections in the human population is important and thus evaluating the use of any future 
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Table 15: Test results for the fixed effects of the linear mixed models used to analyse 
changes in gene expression at the terminal rectum for calves challenged with PT21/28 
Stx2c+ or unchallenged controls (treatment groups). 
Gene Fixed Effect Number DF Den DF F-value p-value 
CCL21 Log10 (Expression pre-challenge) 1 6 5.387 0.053 
CCL21 Treatment 1 6 0.390 0.552 
CCL21 Day Post Challenge (DPC) 1 7 0.096 0.766 
CCL21 Treatment*DPC 1 7 0.676 0.435 
CCR7 Log10 (Expression pre-challenge) 1 6 11.215 0.012 
CCR7 Treatment 1 6 1.902 0.210 
CCR7 Day Post Challenge (DPC) 1 7 0.014 0.910 
CCR7 Treatment*DPC 1 7 0.807 0.395 
CD19 Log10 (Expression pre-challenge) 1 6 5.860 0.046 
CD19 Treatment 1 6 0.555 0.481 
CD19 Day Post Challenge (DPC) 1 7 0.007 0.937 
CD19 Treatment*DPC 1 7 1.774 0.220 
CD22 Log10 (Expression pre-challenge) 1 6 4.876 0.063 
CD22 Treatment 1 6 0.005 0.946 
CD22 Day Post Challenge (DPC) 1 7 0.045 0.838 
CD22 Treatment*DPC 1 7 3.401 0.108 
CD80 Log10 (Expression pre-challenge) 1 6 26.810 0.001 




Table 15 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
CD80 Day Post Challenge (DPC) 1 7 38.206 0.000 
CD80 Treatment*DPC 1 7 0.011 0.920 
CD86 Log10 (Expression pre-challenge) 1 6 7.883 0.026 
CD86 Treatment 1 6 0.552 0.482 
CD86 Day Post Challenge (DPC) 1 7 5.253 0.051 
CD86 Treatment*DPC 1 7 0.766 0.407 
CXCL13 Log10 (Expression pre-challenge) 1 6 5.343 0.054 
CXCL13 Treatment 1 6 2.176 0.184 
CXCL13 Day Post Challenge (DPC) 1 7 0.122 0.736 
CXCL13 Treatment*DPC 1 7 2.840 0.130 
IL2RA Log10 (Expression pre-challenge) 1 6 9.768 0.017 
IL2RA Treatment 1 6 2.004 0.200 
IL2RA Day Post Challenge (DPC) 1 7 2.274 0.170 
IL2RA Treatment*DPC 1 7 3.430 0.101 
LTB Log10 (Expression pre-challenge) 1 6 36.405 0.001 
LTB Treatment 1 6 1.258 0.299 
LTB Day Post Challenge (DPC) 1 7 2.716 0.138 
LTB Treatment*DPC 1 7 0.464 0.515 
MS4A1 Log10 (Expression pre-challenge) 1 6 5.928 0.045 





Table 15 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
MS4A1 Day Post Challenge (DPC) 1 7 0.670 0.437 
MS4A1 Treatment*DPC 1 7 1.502 0.255 
POU2AF1 Log10 (Expression pre-challenge) 1 6 7.784 0.027 
POU2AF1 Treatment 1 6 0.770 0.409 
POU2AF1 Day Post Challenge (DPC) 1 7 0.425 0.533 
POU2AF1 Treatment*DPC 1 7 1.650 0.235 
SH2D1A Log10 (Expression pre-challenge) 1 6 5.550 0.051 
SH2D1A Treatment 1 6 0.301 0.600 
SH2D1A Day Post Challenge (DPC) 1 7 0.119 0.739 
SH2D1A Treatment*DPC 1 7 2.982 0.123 
Table 16: Test results for the fixed effects of the linear mixed models used to analyse 
changes in gene expression at the terminal rectum for calves challenged with PT32 
Stx2c+ or unchallenged controls (treatment groups). 
Gene Fixed Effect Number DF Den DF F-value p-value 
CCL21 Log10 (Expression pre-challenge) 1 6 1.847 0.223 
CCL21 Treatment 1 6 0.506 0.504 
CCL21 Day Post Challenge (DPC) 1 7 3.3878 0.090 
CCL21 Treatment*DPC 1 7 0.599 0.464 
CCR7 Log10 (Expression pre-challenge) 1 6 5.270 0.062 
CCR7 Treatment 1 6 0.191 0.678 





Table 16 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
CCR7 Treatment*DPC 1 7 0.084 0.780 
CD19 Log10 (Expression pre-challenge) 1 6 0.025 0.880 
CD19 Treatment 1 6 0.004 0.950 
CD19 Day Post Challenge (DPC) 1 7 3.653 0.098 
CD19 Treatment*DPC 1 7 0.243 0.637 
CD22 Log10 (Expression pre-challenge) 1 6 1.207 0.314 
CD22 Treatment 1 6 1.480 0.270 
CD22 Day Post Challenge (DPC) 1 7 2.792 0.139 
CD22 Treatment*DPC 1 7 0.032 0.863 
CD80 Log10 (Expression pre-challenge) 1 6 0.681 0.441 
CD80 Treatment 1 6 2.549 0.162 
CD80 Day Post Challenge (DPC) 1 7 17.524 0.004 
CD80 Treatment*DPC 1 7 0.056 0.820 
CD86 Log10 (Expression pre-challenge) 1 6 0.383 0.559 
CD86 Treatment 1 6 0.080 0.786 
CD86 Day Post Challenge (DPC) 1 7 32.601 0.001 
CD86 Treatment*DPC 1 7 0.299 0.601 
CXCL13 Log10 (Expression pre-challenge) 1 6 2.747 0.149 
CXCL13 Treatment 1 6 0.327 0.588 





Table 16 continued 
Gene Fixed Effect Number DF Den DF F-value p- value 
CXCL13 Treatment*DPC 1 7 0.624 0.456 
IL2RA Log10 (Expression pre-challenge) 1 6 2.754 0.148 
IL2RA Treatment 1 6 3.282 0.120 
IL2RA Day Post Challenge (DPC) 1 7 9.570 0.018 
IL2RA Treatment*DPC 1 7 1.006 0.349 
LTB Log10 (Expression pre-challenge) 1 6 0.257 0.603 
LTB Treatment 1 6 0.301 0.603 
LTB Day Post Challenge (DPC) 1 7 11.961 0.011 
LTB Treatment*DPC 1 7 0.014 0.911 
MS4A1 Log10 (Expression pre-challenge) 1 6 4.467 0.079 
MS4A1 Treatment 1 6 0.608 0.465 
MS4A1 Day Post Challenge (DPC) 1 7 7.109 0.032 
MS4A1 Treatment*DPC 1 7 0.229 0.647 
POU2AF1 Log10 (Expression pre-challenge) 1 6 1.772 0.232 
POU2AF1 Treatment 1 6 0.201 0.669 
POU2AF1 Day Post Challenge (DPC) 1 7 2.182 0.183 
POU2AF1 Treatment*DPC 1 7 0.146 0.714 
SH2D1A Log10 (Expression pre-challenge) 1 6 1.909 0.216 
SH2D1A Treatment 1 6 0.009 0.928 





Table 16 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
SH2D1A Treatment*DPC 1 7 0.285 0.610 
Table 17: Test results for the fixed effects of the linear mixed models used to analyse 
changes in gene expression at the terminal rectum for calves challenged with PT21/28 
Stx2a+Stx2c+ or unchallenged controls (treatment groups). 
Gene Fixed Effect Number DF Den DF F-value p-value 
CCL21 Log10 (Expression pre-challenge) 1 6 12.222 0.007 
CCL21 Treatment 1 6 0.062 0.809 
CCL21 Day Post Challenge (DPC) 1 7 1.954 0.192 
CCL21 Treatment*DPC 1 7 0.003 0.957 
CCR7 Log10 (Expression pre-challenge) 1 6 18.033 0.002 
CCR7 Treatment 1 6 0.036 0.854 
CCR7 Day Post Challenge (DPC) 1 7 1.808 0.209 
CCR7 Treatment*DPC 1 7 2.535 0.142 
CD19 Log10 (Expression pre-challenge) 1 6 36.219 0.000 
CD19 Treatment 1 6 0.121 0.736 
CD19 Day Post Challenge (DPC) 1 7 1.304 0.280 
CD19 Treatment*DPC 1 7 3.324 0.098 
CD22 Log10 (Expression pre-challenge) 1 6 29.850 0.000 
CD22 Treatment 1 6 0.309 0.592 
CD22 Day Post Challenge (DPC) 1 7 0.104 0.754 





Table 17 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
CD80 Log10 (Expression pre-challenge) 1 6 37.862 0.000 
CD80 Treatment 1 6 0.118 0.739 
CD80 Day Post Challenge (DPC) 1 7 59.697 0.000 
CD80 Treatment*DPC 1 7 1.917 0.196 
CD86 Log10 (Expression pre-challenge) 1 6 57.167 0.000 
CD86 Treatment 1 6 0.056 0.819 
CD86 Day Post Challenge (DPC) 1 7 11.161 0.008 
CD86 Treatment*DPC 1 7 2.753 0.128 
CXCL13 Log10 (Expression pre-challenge) 1 6 19.239 0.002 
CXCL13 Treatment 1 6 0.90 0.771 
CXCL13 Day Post Challenge (DPC) 1 7 0.983 0.345 
CXCL13 Treatment*DPC 1 7 2.958 0.116 
IL2RA Log10 (Expression pre-challenge) 1 6 11.549 0.008 
IL2RA Treatment 1 6 0.191 0.673 
IL2RA Day Post Challenge (DPC) 1 7 4.254 0.066 
IL2RA Treatment*DPC 1 7 7.733 0.019 
LTB Log10 (Expression pre-challenge) 1 6 32.064 0.000 
LTB Treatment 1 6 0.306 0.594 
LTB Day Post Challenge (DPC) 1 7 6.810 0.026 





Table 17 continued 
Gene Fixed Effect Number DF Den DF F-value p-value 
MS4A1 Log10 (Expression pre-challenge) 1 6 16.010 0.003 
MS4A1 Treatment 1 6 0.014 0.907 
MS4A1 Day Post Challenge (DPC) 1 7 0.000 0.986 
MS4A1 Treatment*DPC 1 7 1.236 0.292 
POU2AF1 Log10 (Expression pre-challenge) 1 6 32.251 0.000 
POU2AF1 Treatment 1 6 2.451 0.152 
POU2AF1 Day Post Challenge (DPC) 1 7 1.317 0.278 
POU2AF1 Treatment*DPC 1 7 0.002 0.936 
SH2D1A Log10 (Expression pre-challenge) 1 6 43.512 0.000 
SH2D1A Treatment 1 6 0.951 0.355 
SH2D1A Day Post Challenge (DPC) 1 7 0.421 0.531 






Table 18: Predicted group means (fold change in log10 scale) and 95 % Confidence 
intervals (CIs) from the linear mixed models used to analyse changes in gene expression 
at the terminal rectum. 




95 % CIs 
Lower        Upper 
CCL21 PT21/28 Stx2c+ challenged 7 -0.302 -1.185 0.582 
CCL21 PT21/28 Stx2c+ controls 7 -0.383 -1.516 0.751 
CCL21 PT32 Stx2c+ challenged 7 1.352 0.635 2.068 
CCL21 PT32 Stx2c+ controls 7 1.372 0.337 2.406 
CCL21 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.213 -0.725 1.151 
CCL21 PT21/28 Stx2a+Stx2c+ controls 7 0.093 -0.896 1.081 
CCL21 PT21/28 Stx2c+ challenged 26 -0.745 -1.629 0.139 
CCL21 PT21/28 Stx2c+ controls 26 -0.068 -1.201 1.066 
CCL21 PT32 Stx2c+ challenged 26 0.808 0.092 1.525 
CCL21 PT32 Stx2c+ controls 26 0.201 -0.833 1.235 
CCL21 PT21/28 Stx2a+Stx2c+ 
challenged 
26 -0.248 -1.186 0.690 
CCL21 PT21/28 Stx2a+Stx2c+ controls 26 -0.407 -1.395 0.582 
CCR7 PT21/28 Stx2c+ challenged 7 -0.170 -0.958 0.619 
CCR7 PT21/28 Stx2c+ controls 7 0.049 -0.964 1.063 
CCR7 PT32 Stx2c+ challenged 7 1.120 0.416 1.983 
CCR7 PT32 Stx2c+ controls 7 1.542 0.358 2.725 
CCR7 PT21/28 Stx2a+Stx2c+ 
challenged 




Table 18 continued 




95 % CIs 
Lower        Upper 
CCR7 PT21/28 Stx2a+Stx2c+ controls 7 0.877 0.053 1.702 
CCR7 PT21/28 Stx2c+ challenged 26 -0.419 -1.207 0.370 
CCR7 PT21/28 Stx2c+ controls 26 0.540 -0.474 1.554 
CCR7 PT32 Stx2c+ challenged 26 0.574 -0.210 1.357 
CCR7 PT32 Stx2c+ controls 26 0.658 -0.525 1.842 
CCR7 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.264 -0.490 1.018 
CCR7 PT21/28 Stx2a+Stx2c+ controls 26 -0.191 -1.015 0.634 
CD19 PT21/28 Stx2c+ challenged 7 -0.442 -1.202 0.319 
CD19 PT21/28 Stx2c+ controls 7 -0.670 -1.610 0.269 
CD19 PT32 Stx2c+ challenged 7 0.923 0.282 1.563 
CD19 PT32 Stx2c+ controls 7 1.126 0.197 2.055 
CD19 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.023 -0.605 0.651 
CD19 PT21/28 Stx2a+Stx2c+ controls 7 0.708 -0.002 1.418 
CD19 PT21/28 Stx2c+ challenged 26 -0.828 -1.588 -0.068 
CD19 PT21/28 Stx2c+ controls 26 -0.013 -0.952 0.926 
CD19 PT32 Stx2c+ challenged 26 0.388 -0.253 1.029 





Table 18 continued 




95 % CIs 
Lower        Upper 
CD19 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.146 -0.482 0.774 
CD19 PT21/28 Stx2a+Stx2c+ controls 26 -0.312 -1.022 0.397 
CD22 PT21/28 Stx2c+ challenged 7 -0.242 -1.097 0.613 
CD22 PT21/28 Stx2c+ controls 7 -0.962 -2.000 0.076 
CD22 PT32 Stx2c+ challenged 7 1.053 0.182 1.923 
CD22 PT32 Stx2c+ controls 7 1.765 0.502 3.028 
CD22 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.051 -0.738 0.841 
CD22 PT21/28 Stx2a+Stx2c+ controls 7 1.025 0.130 1.920 
CD22 PT21/28 Stx2c+ challenged 26 -0.753 -1.608 0.101 
CD22 PT21/28 Stx2c+ controls 26 0.250 -1.038 1.539 
CD22 PT32 Stx2c+ challenged 26 0.346 -0.524 1.217 
CD22 PT32 Stx2c+ controls 26 0.886 -0.377 2.150 
CD22 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.550 -0.239 1.340 
CD22 PT21/28 Stx2a+Stx2c+ controls 26 0.025 -0.870 0.920 
CD80 PT21/28 Stx2c+ challenged 7 0.436 0.052 0.819 






Table 18 continued 




95 % CIs 
Lower        Upper 
CD80 PT32 Stx2c+ challenged 7 0.591 0.098 1.084 
CD80 PT32 Stx2c+ controls 7 0.150 -0.538 0.837 
CD80 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.451 0.209 0.694 
CD80 PT21/28 Stx2a+Stx2c+ controls 7 0.653 0.381 0.924 
CD80 PT21/28 Stx2c+ challenged 26 -0.714 -1.098 -0.331 
CD80 PT21/28 Stx2c+ controls 26 -0.921 -1.366 -0.475 
CD80 PT32 Stx2c+ challenged 26 -0.302 -0.795 0.191 
CD80 PT32 Stx2c+ controls 26 -0.855 -1.543 -0.167 
CD80 PT21/28 Stx2a+Stx2c+ 
challenged 
26 -0.259 -0.502 -0.016 
CD80 PT21/28 Stx2a+Stx2c+ controls 26 -0.362 -0.633 -0.091 
CD86 PT21/28 Stx2c+ challenged 7 0.124 -0.212 0.460 
CD86 PT21/28 Stx2c+ controls 7 -0.157 -0.561 0.246 
CD86 PT32 Stx2c+ challenged 7 0.667 0.332 1.002 
CD86 PT32 Stx2c+ controls 7 0.714 0.245 1.183 
CD86 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.343 0.066 0.619 
CD86 PT21/28 Stx2a+Stx2c+ controls 7 0.540 0.223 0.856 





Table 18 continued 




95 % CIs 
Lower        Upper 
CD86 PT21/28 Stx2c+ controls 26 -0.364 -0.767 0.040 
CD86 PT32 Stx2c+ challenged 26 -0.271 -0.606 0.064 
CD86 PT32 Stx2c+ controls 26 -0.428 -0.897 0.041 
CD86 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.076 -0.201 0.352 
CD86 PT21/28 Stx2a+Stx2c+ controls 26 -0.191 -0.507 0.126 
CXCL13 PT21/28 Stx2c+ challenged 7 -0.414 -1.287 0.459 
CXCL13 PT21/28 Stx2c+ controls 7 -0.466 -1.605 0.673 
CXCL13 PT32 Stx2c+ challenged 7 0.881 0.210 1.553 
CXCL13 PT32 Stx2c+ controls 7 0.963 0.012 1.916 
CXCL13 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.309 -0.483 1.101 
CXCL13 PT21/28 Stx2a+Stx2c+ controls 7 1.009 0.133 1.878 
CXCL13 PT21/28 Stx2c+ challenged 26 -1.188 -2.061 -0.315 
CXCL13 PT21/28 Stx2c+ controls 26 0.303 -0.836 1.442 
CXCL13 PT32 Stx2c+ challenged 26 0.853 0.181 1.525 
CXCL13 PT32 Stx2c+ controls 26 0.335 -0.617 1.287 
CXCL13 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.458 -0.335 1.250 





Table 18 continued 




95 % CIs 
Lower        Upper 
IL2RA PT21/28 Stx2c+ challenged 7 -0.795 -1.522 -0.067 
IL2RA PT21/28 Stx2c+ controls 7 -0.910 -1.878 0.058 
IL2RA PT32 Stx2c+ challenged 7 0.441 -0.739 1.620 
IL2RA PT32 Stx2c+ controls 7 0.982 -0.689 2.654 
IL2RA PT21/28 Stx2a+Stx2c+ 
challenged 
7 -1.793 -2.987 -0.600 
IL2RA PT21/28 Stx2a+Stx2c+ controls 7 0.056 -1.480 1.591 
IL2RA PT21/28 Stx2c+ challenged 26 -0.796 -1.524 -0.069 
IL2RA PT21/28 Stx2c+ controls 26 0.501 -0.467 1.469 
IL2RA PT32 Stx2c+ challenged 26 -1.953 -3.132 -0.773 
IL2RA PT32 Stx2c+ controls 26 -0.072 -1.744 1.600 
IL2RA PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.602 -0.591 1.795 
IL2RA PT21/28 Stx2a+Stx2c+ controls 26 -0.611 -2.146 0.925 
LTB PT21/28 Stx2c+ challenged 7 -0.342 -0.634 -0.050 
LTB PT21/28 Stx2c+ controls 7 -0.271 -0.640 0.097 
LTB PT32 Stx2c+ challenged 7 0.863 0.312 1.413 
LTB PT32 Stx2c+ controls 7 0.655 -0.125 1.435 
LTB PT21/28 Stx2a+Stx2c+ 
challenged 





Table 18 continued 




95 % CIs 
Lower        Upper 
LTB PT21/28 Stx2a+Stx2c+ controls 7 0.425 -0.043 0.808 
LTB PT21/28 Stx2c+ challenged 26 -0.671 -0.963 -0.379 
LTB PT21/28 Stx2c+ controls 26 -0.393 -0.762 -0.024 
LTB PT32 Stx2c+ challenged 26 -0.177 -0.727 0.373 
LTB PT32 Stx2c+ controls 26 -0.312 -1.092 0.468 
LTB PT21/28 Stx2a+Stx2c+ 
challenged 
26 -0.140 -0.473 0.193 
LTB PT21/28 Stx2a+Stx2c+ controls 26 -0.247 -0.629 0.136 
MS4A1 PT21/28 Stx2c+ challenged 7 -0.586 -1.545 0.373 
MS4A1 PT21/28 Stx2c+ controls 7 -0.340 -1.566 0.887 
MS4A1 PT32 Stx2c+ challenged 7 0.631 -0.029 1.291 
MS4A1 PT32 Stx2c+ controls 7 0.744 -0.192 1.680 
MS4A1 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.387 -0.387 1.161 
MS4A1 PT21/28 Stx2a+Stx2c+ controls 7 0.812 -0.046 1.671 
MS4A1 PT21/28 Stx2c+ challenged 26 -0.676 -1.634 0.283 
MS4A1 PT21/28 Stx2c+ controls 26 0.796 -0.430 2.023 
MS4A1 PT32 Stx2c+ challenged 26 -0.427 -1.087 0.233 





Table 18 continued 




95 % CIs 
Lower        Upper 
MS4A1 PT21/28 Stx2a+Stx2c+ 
challenged 
26 0.704 -0.070 1.478 
MS4A1 PT21/28 Stx2a+Stx2c+ controls 26 0.384 -0.475 1.243 
POU2AF1 PT21/28 Stx2c+ challenged 7 -0.202 -0.773 0.370 
POU2AF1 PT21/28 Stx2c+ controls 7 -0.321 -1.031 0.390 
POU2AF1 PT32 Stx2c+ challenged 7 0.552 -0.121 1.225 
POU2AF1 PT32 Stx2c+ controls 7 0.578 -0.376 1.532 
POU2AF1 PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.521 -0.380 1.422 
POU2AF1 PT21/28 Stx2a+Stx2c+ controls 7 1.252 0.222 2.282 
POU2AF1 PT21/28 Stx2c+ challenged 26 -0.317 -0.889 0.254 
POU2AF1 PT21/28 Stx2c+ controls 26 0.328 -0.383 1.039 
POU2AF1 PT32 Stx2c+ challenged 26 -0.076 -0.749 0.597 
POU2AF1 PT32 Stx2c+ controls 26 0.241 0.713 1.195 
POU2AF1 PT21/28 Stx2a+Stx2c+ 
challenged 
26 1.048 0.147 1.949 
POU2AF1 PT21/28 Stx2a+Stx2c+ controls 26 1.737 0.706 2.767 
SH2D1A PT21/28 Stx2c+ challenged 7 0.059 -0.483 0.601 
SH2D1A PT21/28 Stx2c+ controls 7 -0.251 -0.965 0.464 





Table 18 continued 




95 % CIs 
Lower        Upper 
SH2D1A PT32 Stx2c+ controls 7 0.238 -0.673 1.149 
SH2D1A PT21/28 Stx2a+Stx2c+ 
challenged 
7 0.187 -0.529 0.903 
SH2D1A PT21/28 Stx2a+Stx2c+ controls 7 0.335 -0.458 1.129 
SH2D1A PT21/28 Stx2c+ challenged 26 -0.427 -0.967 0.115 
SH2D1A PT21/28 Stx2c+ controls 26 0.239 -0.476 0.954 
SH2D1A PT32 Stx2c+ challenged 26 -0.251 -0.902 0.400 
SH2D1A PT32 Stx2c+ controls 26 -0.091 -1.002 0.821 
SH2D1A PT21/28 Stx2a+Stx2c+ 
challenged 
26 -0.213 -0.929 0.504 







Figure 60: Predicted mean log10 fold change (relative to pre challenge) in transcripts 
for each of the 12 genes of interest, at 7 and 26 days post challenge (DPC) from the 
linear mixed model. Calves were orally challenged with PT21/28 Stx2c+ (challenged) or 
unchallenged controls (control) and rectal biopsies taken pre challenge (-3 days), 7 days 
and 26 days post challenge. RT-qPCR was used to determine transcript numbers for 
the specific immune genes, using a plasmid standard and normalisation to two 
housekeeping genes. Black circles represent the predicted mean log10 fold change 
(relative to pre challenged) for each group 7 days post challenge and black squares 26 
days post challenge from the linear mixed model. The red error bars are 95 % 






Figure 61: Predicted mean log10 fold change (relative to pre challenge) in transcripts 
for each of the 12 genes of interest, at 7 and 26 days post challenge (DPC) from the 
linear mixed model. Calves were orally challenged with PT32 Stx2c+ (challenged) or 
unchallenged controls (control) and rectal biopsies taken pre challenge (-3 days), 7 days 
and 26 days post challenge. RT-qPCR was used to determine transcript numbers for 
the specific immune genes, using a plasmid standard and normalisation to two 
housekeeping genes. Black circles represent the predicted mean log10 fold change 
(relative to pre challenged) for each group 7 days post challenge and black squares 26 
days post challenge from the linear mixed model. The red error bars are 95 % 






Figure 62: Predicted mean log10 fold change (relative to pre challenge) in transcripts 
for each of the 12 genes of interest, at 7 and 26 days post challenge (DPC) from the 
linear mixed model. Calves were orally challenged with PT21/28 Stx2a+Stx2c+ 
(challenged) or unchallenged controls (control) and rectal biopsies taken pre challenge 
(-3 days), 7 days and 26 days post challenge. RT-qPCR was used to determine 
transcript numbers for the specific immune genes, using a plasmid standard and 
normalisation to two housekeeping genes. Black circles represent the predicted mean 
log10 fold change (relative to pre challenge) for each group 7 days post challenge and 
black squares 26 days post challenge from the linear mixed model. The red error bars 
are 95 % confidence intervals from the linear mixed model.  
 
